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ABSTRACT

Plasminogen activator inhibitor type 2 (PAI-2) is one of the inhibitors of
the plasminogen activation cascade mediated by urokinase (uPA) which is
overexpressed on the surface of metastatic cancer cells. The plasminogen
activation cascade is the generator of plasmin proteolytic activity on the cell
surface which is required under normal physiological conditions and is largely
exploited during cancer invasion and metastasis. The overall aim of this thesis
was mainly to characterise the inhibition of cell-surface uPA by exogenously
added PAI-2 and the elucidation of the fate of uPA:PAI-2 complexes once formed
on the cell surface. PAI-2 was directly confirmed as a potent and rapid inhibitor
of cell-surface uPA and specifically targets this antigen. PAI-2 internalised
rapidly in a uPA-dependent manner after complex formation with cell-surface
receptor (uPAR)-bound uPA. Internalised PAI-2 localised in endosomes/
lysosomes where it was presumably degraded. While the majority of
uPAR/uPA:PAI-2 complexes formed on the cell surface were internalised, cellsurface uPA appeared to be replenished and uPAR was recycled to the cell
surface. These findings were significant as they provide new information
regarding cell-surface regulation of the plasminogen activation system as well as
a biological rationale for the use of PAI-2 as a delivery vehicle of cytotoxins for
anti-uPA therapeutic strategies.
To extend the analyses of PAI-2 binding to cells and its subsequent fate,
breast cancer cells were genetically modified to provide material for this study.
Modulation of uPA-receptor (uPAR) expression was found to induce changes in
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components of the plasminogen activation cascade on the cell-surface.
Upregulation of cell-surface uPAR on non-invasive, low uPAR/uPA-expressing
T-47D breast cancer cells caused a concomitant increase in cell-surface uPA.
This caused an increase in PAI-2 binding capacity to cells, thus directly
confirming uPA-specificity of PAI-2. In addition, uPAR upregulation induced an
increase in the lysine-dependent binding of plasminogen to the surface of these
cells. Although cell-surface uPA was not confidently excluded as receptor for
plasminogen binding on uPAR-modulated cells, the increase in plasminogen
binding on these cells is ultimately due to increase in cell-surface plasminogen
receptors. Finally, upregulation of uPAR also affected cell morphology and all
together the data confirmed that uPAR/uPA-upregulation is associated with
adoption of a metastatic genotype/phenotype. These results support other
interests in our laboratory directed towards concluding whether uPA may act as
a plasminogen receptor via an active-site independent epitope and elucidating
plasminogen receptors which may be modulated due to modulation of
uPAR/uPA expression.
Finally, this thesis aimed at optimising the preparation of PAI-2 as a
uPA-targeting vehicle for cancer radiotherapy and radioimaging applications.
PAI-2 was modified by the addition of the metal chelator cDTPA; the product
was

characterised

and

radiolabelling

with

a

radioisotope

suitable

for

radiotherapy was optimised. These results allowed the development of standard
operating procedures for use in pre-clinical and potentially clinical studies.
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RT
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SDS
SDS-PAGE
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SPD
suPAR
TA
TAT
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Instant thin layer chromatography strips
Janus kinase/signal transducers and activators of
transcription
Luria Broth
Low-density lipoprotein receptor family
Low molecular weight uPA
Macrophage colony stimulating factor
Mean fluorescence intensity
Myosin light chain kinase
Metalloproteinases
messenger RNA
Membrane-type metalloproteinases
3-(4,5–dimethylthiazol–2-yl)-5-(3carboxymethoxyphenyl)–2-(4-sulfophenyl)-2Htetrazolium/phenazine methosulfate
Optical density
Plasminogen activator inhibitors Type-1
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Phosphate buffered saline
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Pseudomonas exotoxin
Propidium iodide
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Plasminogen
Plasmin
Proteinase nexin-1
Proenzyme form of uPA
Receptor associated protein
Reactive centre loop
Reactive centre peptide bond
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Room temperature
Sarcoma kinase
Single chain tPA
Single-chain uPA
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SDS-polyacrylamide gel electrophoresis
Standard error of the mean
Serine protease inhibitor
Serine proteinase domain
Soluble form of uPAR
Tranexamic acid
Targeted alpha (radiation) therapy
Two-chain tPA
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TGF-α
TNF

Transforming growth factor-α
Tumour necrosis factor

LB
LDLR
LMW-uPA
M-CSF
MFI
MLCK
MMPs
mRNA
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tPA
uPA
uPAR
VLDLR

Tissue-type plasminogen activator
Urokinase-type plasminogen activator
Urokinase (uPA) receptor
Very low-density lipoprotein receptor

UNITS USED
mole
fmole
MW
kDa
g
kg
mg

mole (6.022 x 1023 particles): amount
femto (10-15) mole
Molecular weight: mass of 1 mole (g/mole)
kilo Dalton: unit of molecular weight ≡ 1000 g/mol
gram
kilo (103) gram
milli (10-3) gram

µg
ng
l
ml

micro (10-6) gram
nano (10-9) gram
litre: volume
milli (10-3) litre

µl
M
mM
µM
nM
pM
% v/v
% w/v
m
cm
mm

micro (10-6) litre
Molar: concentration mole/litre
milli (10-3) Molar
micro (10-6) Molar
nano (10-9) Molar
pico (10-12) Molar: unit of concentration
concentration expressed as percentage volume ratio
concentration expressed as percentage weight/volume
ratio
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µm
nm
h
min
sec
kb
Kd
oC
MeV and keV
rpm
xg
Ci
mCi

micro (10-6) meter
nano (10-9) meter
hour
minutes
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kilo (103) base pairs: DNA length sequence length
Binding affinity or dissociation constant
degrees Celsius: units of temperature
Mega (106) and kilo (103) electron volts: Energy
rounds per minutes: rotation
gravity force of rotation
Curies: unit of radioactivity
milli (10-3) Curies

µCi
cpm

micro (10-6) Curies
counts per minute: radioactivity
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Chapter 1: UROKINASE PLASMINOGEN ACTIVATION
PATHWAY: CLINICAL RELEVANCE AND THERAPEUTIC
TARGETS FOR CANCER METASTASIS AND INVASION

1.1. INTRODUCTION
The term “tumour” describes the abnormal uncontrolled proliferation of
cells leading to a mass of cells that have no physiological function. Despite its
common use, the term cancer only refers to an advanced stage of tumour
progression where tumour cells have gained the ability to invade nearby tissues
or spread throughout the body. This process, called metastasis, occurs when
cells detach from the original (primary) tumour site and travel through the
circulatory systems (lymphatic or bloodstream) to other parts of the body,
causing new secondary tumours called metastatic foci. Cancer claims the lives
of millions world wide. In Australia, cancer accounted for 30 % of male deaths
and 25 % of female deaths in year 2000 (Cancer in Australia 2000, 2003)
whereas it accounted for 24 % of male and 22 % of female deaths in the US in
year 2001 (Arias et al., 2003). The leading cause of cancer-related mortality,
even after extensive treatment regimes, is the inability to control the spread of
malignant tumours (Woodhouse et al., 1997). Ongoing research is required to
further understand tumour growth, progression and metastasis to allow the
development of preventative measures and therapies in order to limit the spread
of this disease in humans.
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The plasminogen activation system generates plasmin proteolytic activity
which is a key player in tumour progression and cancer invasion and
metastasis. Proteolysis of the circulatory zymogen plasminogen by these specific
plasminogen activators produces the serine protease plasmin. Plasmin has a
broad specificity and is capable of degrading fibrin as well as other extracellular
matrix (ECM) components, in addition to the activation of other proteinases and
growth factors (for general reviews see Danø et al., 1985; Mignatti and Rifkin,
1993; Andreasen et al., 1997). There are two types of mammalian plasminogen
activators: the urokinase-type plasminogen activator (uPA) and the tissue-type
plasminogen activator (tPA). While tPA has high affinity for binding to fibrin,
uPA binds to the urokinase-type plasminogen activator receptor (uPAR), a cell
membrane-anchored protein which focuses plasminogen activation activity at
the cell surface. The two main inhibitors of these activators are plasminogen
activator inhibitors type-1 and 2 (PAI-1 and PAI-2), whereas plasmin is inhibited
by α2-anti-plasmin (α2AP). This chapter reviews the components of the
plasminogen activation system that leads to proteolysis (Figure 1), their
interactions with other intracellular/extracellular components and roles in
cancer metastasis. The main focus of this review is the urokinase plasminogen
activation pathway of the plasminogen activation system as targeting cellsurface uPA by its inhibitor PAI-2 holds a potential for development of uPAbased cancer therapy strategies.
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Tissue-type
plasminogen activator
(tPA)

Urokinase-type
plasminogen activator
(uPA)
Cellular uPA
receptor (uPAR)

Fibrin in the
ECM

_

Plasminogen activator
inhibitor type 1 and type 2
(PAI-1 and PAI-2)

+
Plasminogen (Plg)

Plasmin (Pln)

α2-anti-plasmin
(α2-AP)

_
ECM degradation and
activation of other
proteolytic enzyme

Figure 1: Components of the plasminogen activation system that lead to
increased proteolysis

1.2. CAUSES OF CANCER
Multiple factors lead to the transformation of normal cells into tumour
cells, including inherited predisposing genes and environmental factors such as
ultraviolet light, ionising radiation and tumour-inducing chemicals (chemical
carcinogens, e.g. asbestos and talc) (Alberts et al., 2002). Lifestyle and dietary
habits such as tobacco smoking, consumption of alcohol, obesity, stress and
infection by certain viruses have also been related to generation of tumour cells
(Alberts et al., 2002). It is not the place here to review the factors leading to or
associated with tumour onset. However, it is important to state that despite the
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variety of causes, the generation of tumour cells requires cumulative genetic
mutations (mutagenesis) to alter the biology of normal cells. Indeed, a
correlation between tumour-cell generation and mutagenesis is clear for three
classes of tumour-causing agents; chemical carcinogens, ionising radiation and
viruses (Alberts et al., 2002). Furthermore, these genetic mutations must be
passed onto progeny in order to maintain the acquired tumour phenotype. In
agreement, molecular evidence suggests that tumour cells from one tumour
type are usually clones descendants from a single abnormal cell (Alberts et al.,
2002). The progeny of the first abnormal tumour cell must undergo further mutations
to obtain characteristics that are required for tumour progression such as high
rate of proliferation (Alberts et al., 2002).
Cell proliferation in general is controlled by mechanisms that determine
whether the cell passes to another round of cell-division cycle, be directed to
differentiate and cease proliferation or undergo programmed cell death
(apoptosis). Thus, two routes are available in order to acquire the uncontrolled
proliferative characteristic of tumour cells (see review by McCormick, 1999;
Alberts et al., 2002). The first route is by hyper-activating proliferation
stimulatory genes (proto-oncogenes) to produce mutant genes (oncogenes)
(reviewed by Bertram, 2001). The second route involves the inactivation of
proliferation inhibitory genes (tumour suppressor genes) (reviewed by Bertram,
2001).
Oncogenesis (activation of proto-oncogenes or deactivation of tumour
suppressor genes) is a multistep mutational process where each new mutational
step leads to a clonal expansion of cells bearing the new mutation. This clonal
expansion is required in order to develop the cancerous (malignant) phenotype
of

transformed

tumour

cells

(McCormick,

1999).

Complications

in

understanding cancer biology arise from the randomness of the genetic
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mutations induced by the variable factors and the subsequent clonal expansion
required for the establishment of cancerous cells. Nevertheless, all cancers can
be expected to involve disruption of the normal restraint on cell proliferation
and cell death (Alberts et al., 2002). Furthermore, despite the randomness of the
mutation process and the variability of causes leading to cancer, a relatively
predictable set of genes may be expected to mutate for the acquisition of the
malignant phenotype (Evans, 1991; McCormick, 1999; Bertram, 2001). Cancer
metastasis appears to be accounted for by deregulation of expression of socalled

“metastasis

genes”

(Weber

and

Ashkar,

2000)

which

aid

the

immobilisation of tumour cells from the primary tumour cell mass to invade
throughout the body. These genes include those that encode proteolysis factors
(e.g. serine proteases, metallo-proteases and cathepsins), angiogenic factors (e.g.
vascular endothelial growth factor) and factors related to cell adhesion and
migration (Mignatti and Rifkin, 1993; Andreasen et al., 1997; Murphy et al.,
2000; Weber and Ashkar, 2000; Chapman and Wei, 2001).

1.3. GENERAL MECHANISMS OF INVASION
The general steps for metastasis are similar for cells derived from all solid
tumours (Woodhouse et al., 1997). This involves the detachment of invasive
tumour cells from the primary tumour site, invasion through surrounding
tissue and invasion into blood/lymph vessels (Figure 2). These cells migrate
through the circulatory system to a distance locus. Adhesion of the migrating
tumour cells to a tissue is the first step for the establishment of a new tumour
site where invasion of the new hosting tissue via proteolysis and proliferation is
induced to form a new tumour cell mass (Andreasen et al., 1997; Woodhouse et
al., 1997; Wang, 2001).
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B

A

C

D

Figure 2: Schematic representation of the general mechanism of tumour-cell
invasion and metastasis
Tumour cells proliferate to form the primary tumour mass (A), this may encourage the
growth of new blood vessels (angiogenesis) that will nourish the tumour (B). Cancerous
cells may detach from the primary tumour mass and invade through tissue barriers and
blood/lymph-vessel wall to enter the blood/lymph circulatory systems (C). These
migrating malignant cells may adhere to capillary walls of blood vessels or lymph nodes
in a distant tissue (D) then proliferate and invade through the tissue leading to the
formation of new tumour sites (metastates).

At the cellular level, tumour cell invasion requires local proteolysis at the
leading edge of the cells to clear the ECM in front of its path (Figure 3 – A and
B). For the cell to move into the area of lysis, the leading edge must attach
(adhere) to the ECM, thus proteolysis at the leading edge is stopped (Figure 3 B and C). Proteolysis then occurs at the rear end to detach the cell (Figure 3 – C
and D) and forward-movement results as intracellular contractions occur in the
direction of the leading edge (Figure 3 – D and E) (Woodhouse et al., 1997).
Taken together, invasion is best defined as a process of networked and
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regulated events of proteolysis/adhesion (detachment/attachment) coupled with
contractions

of

the

intracellular

filaments

(cytoskeleton)

mimicking

pseudopodial movement (Liotta et al., 1991; Condeelis, 1993; Stossel, 1993).

B

A

C

E

D
Cytoskeleton
ECM

Figure 3: Tumour cell invasion through the extracellular matrix
Migrating tumour cells adhere to the ECM of a selected tissue (A) and proteolysis at the
leading front of the cell breaks the ‘front’ attachments and clears the ECM in front of
the cell (B). Proteolysis at this side of the cell is stopped and the leading front adheres
deeply into the cleared ECM (C). Proteolysis at the latter end of the cell breaks the ‘back’
attachments (D) and forward (into the ECM) movement occurs as a result of
intracellular cytoskeletal rearrangements (E).

Proteolytic processes, coupled with invasion and adhesion, are also
necessary for normal physiological functions in the body, including normal
blood vessel maintenance, angiogenesis, clot formation and dissolution, tissue
growth, tissue remodelling (morphogenesis), embryogenesis and ovulation
(Woodhouse et al., 1997; Wang, 2001). It is important to note here that there
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are no qualitative differences between tumour cells and normal cells with
respect to the basic processes of cell detachment, migration, invasion and the
formation of colonies at distant sites. However, the moment and the place of the
expression of these characters by tumour cells are incompatible with normal
cellular activities (see reviews by Werb et al., 1990; Liotta et al., 1991; van Roy
and Mareel, 1992; Andreasen et al., 1997).
Tumour cell invasion into the surrounding ECM is facilitated by a variety
of cell surface-associated proteolytic enzymes. The ECM degrading proteinases
can

be

divided

into

three

major

classes:

metalloproteinases

(MMPs:

Collagenases, gelatinases and stromelysins), cysteine proteinases (cathepsins B
and L, and the aspartyl protease cathepsin D) and serine proteinases (reviewed
by Danø et al., 1985; Liotta et al., 1991; Mignatti and Rifkin, 1993; Andreasen et
al., 1997; Schmitt et al., 2000; Wang, 2001). New classes of proteinases include
the transmembrane serine protease matriptase (Wu, 2003) and membrane-type
metalloproteinases (MT-MMPs) (Zucker et al., 2003). The remainder of this
thesis focuses on the plasminogen activation system, a cascade of serine
proteases. This system, which plays an important role under normal
physiological conditions such as tissue remodelling, ovulation and wound
healing, has been described as a central pathway exploited by a variety of
cancer-related processes (Andreasen et al., 1997; Schmitt et al., 2000).

1.4. PLASMINOGEN

ACTIVATION SYSTEM:
THEIR INTERACTIONS

MAIN

COMPONENTS AND

1.4.A. PLASMINOGEN/PLASMIN
Plasminogen is the single-chain glycoprotein, zymogen form of plasmin
with an activity that is at least several hundred-fold lower than that of plasmin.
Plasminogen is produced mainly in the liver and its concentration in the blood
plasma is approximately 2 µM, but about 40 % of plasminogen is localised
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extravascularly (see reviews by Collen, 1980; Danø et al., 1985; Saksela and
Rifkin, 1988; Mignatti and Rifkin, 1993). Plasminogen is 709 amino acids long
with a molecular weight of 92 kDa (Wiman, 1973, 1977; Sottrup-Jensen et al.,
1978). This zymogen can be observed in several isoforms; the native mature
circulatory form is called glu-plasminogen for the glutamic acid at the amino
terminus (Wallèn and Wiman, 1975). This form can be converted to the lysplasminogen form by cleavages at Arg67-Met68, Lys76-Lys77 and Lys77-Val78 by
plasmin (Wallèn and Wiman, 1972; Collen and DeMaeyer, 1975; Lijnen and
Collen, 1982). The conversion from glu-plasminogen to lys-plasminogen induces
large conformational changes (Violand et al., 1978) resulting in increased rate of
conversion from lys-plasminogen to plasmin compared to conversion of gluplasminogen to plasmin (Claeys and Vermylen, 1974).
Plasminogen is cleaved by plasminogen activators at the Arg560–Val561
bond resulting in plasmin (~ 90 kDa), consisting of A and B chains linked by
two disulfide bridges (reviews by Andreasen et al., 1997; Ranson and
Andronicos, 2003). The C-terminal B-chain contains the serine proteinase
domain responsible for the catalytic activity of the active site which comprises
the amino acids His602, Asp645 and Ser740 (Sottrup-Jensen et al., 1978). The Nterminal A-chain contains 5 kringle domains which are triple loop structures
that can bind to lysine (Sottrup-Jensen et al., 1978) or lysine analogues such as
ε-amino caproic acid (EACA: Markus et al., 1978) and tranexamic acid (Markus
et

al.,

1979).

The

kringle

domains

also

allow

the

binding

of

plasminogen/plasmin to lysine residues available on the cell surface or to
components of the ECM. Candidate plasminogen/plasmin cellular receptors
include tetranectin, α-enolase, actin and cytokeratin 8 (see reviews by Félez, 1998;
Ranson and Andronicos, 2003). Binding to receptors significantly enhances the
rate of plasminogen activation (Andronicos and Ranson, 2001). Plasmin has
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broad substrate specificity and is able to degrade many ECM proteins, such as
fibronectin,

vitronectin,

fibrin

and

activate

zymogen

forms

of

several

metalloproteinases (reviews by Andreasen et al., 1997; Ranson and Andronicos,
2003). Plasmin is also responsible for the release of latent growth/angiogenic
factors from the ECM (Bass and Ellis, 2002; Rakic et al., 2003).

1.4.B. PLASMINOGEN ACTIVATORS
1.4.B.1. UROKINASE-TYPE PLASMINOGEN ACTIVATOR
Urokinase-type plasminogen activator (uPA) is synthesised as a singlechain, 411-amino acids-long glycoprotein in the proenzyme form (pro-uPA or scuPA), with a molecular weight of ~ 50 kDa (Gunzler et al., 1982a; Gunzler et al.,
1982b). uPA was initially found in human urine, then in human blood, seminal
fluids as well as many cancer tissues (Danø et al., 1985). The human blood
plasma concentration of uPA is around 20 pM and mostly complexed with PAI-1
while the remaining fraction is in the zymogen form (see review by Andreasen et
al., 1997). uPA is produced by several cell types in vitro including hepatocytes
(Busso et al., 1994), monocytes, granulocytes and lymphocytes (Carpén et al.,
1986). Pro- or sc-uPA is several hundred-fold less active than uPA (reviews by
Andreasen et al., 1997; Schmitt et al., 2000). uPA (also called two chain uPA [tcuPA] or high molecular weight [HMW] uPA) consists of two polypeptide chains
which are linked by a disulfide bridge. Conversion of pro-uPA to uPA occurs by
cleavage of the peptide bond Lys158–Ile159 (reviewed in Andreasen et al., 1997)
(Figure 4). The conversion of pro-uPA to uPA can be catalysed by plasmin (see
review by Danø et al., 1985). Other proteinases also have been reported to
catalyse this activation, at least in vitro (reviews by Andreasen et al., 1997;
Schmitt et al., 2000): e.g. plasma kallikrein and blood coagulation factor XIIa
(Ichinose et al., 1986), two trypsin-like proteinases purified from human ovarian
tumours (Koivunen et al., 1989), T cell–associated serine proteinase (Brunner et
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al., 1990), cathepsin B (Kobayashi et al., 1991), cathepsin L (Goretzki et al.,
1992), nerve growth factor-γ (Wolf et al., 1993), human mast cell tryptase (Stack
and Johnson, 1994), prostate-specific antigen (Yoshida et al., 1995) and
matriptase (Lee et al., 2000). As shown in Figure 4, alternative proteolysis at
positions preceding the disulfide bridge gives rise to low molecular weight uPA
(LMW-uPA). Low-molecular weight uPA occurring in urine arises by cleavage
between Lys135 and Lys136 by unknown proteases and generates a 33 kDa
molecule that can not bind to its receptor but is still active (Steffens et al.,
1982). The matrix metalloproteinase Pump-1 cleaves the Glu143–Leu144 bond to
produce another form of low molecular weight (32 kDa) uPA (Marcotte et al.,
1992).

GFD

NH 2

Kringle

SPD

COOH

ATF

SPD
S

S

S
K

S
2

1

SPD

K

G
uPA (HMW-uPA)
~ 55 kDa

G
pro-uPA
~ 50 kDa

K
G
LMW-uPA
~ 30 kDa

Figure 4: Structure and activation of pro-uPA
The top panel shows a cartoon representation of pro-uPA as a single-chain polypeptide.
The domains from the amino-terminus to the carboxyl-terminus include: (i) growth
factor-like domain (GFD; G for short), (ii) kringle domain (K) and (iii) the serine
proteinase domain (SPD). The amino-terminal fragment (ATF) in the GFD is 16 amino
acids long (residues 14 – 30). The bottom panel describes (1) the proteolysis of pro-uPA
which leads to the formation of two-chain, disulfide-linked, high molecular weight active
uPA. (2) Proteolysis of pro-uPA at positions NH3-terminal to the disulfide bridge (S-S)
produces low molecular weight uPA.
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The two polypeptide chains of active uPA are called the A- and B-chains.
The N-terminal A-chain is 158 amino acids long (24 kDa) and contains a kringle
domain (Gunzler et al., 1982b) and a growth factor-like domain (GFD) which is
homologous to epidermal growth factor (EGF) and transforming growth factor-α
(TGF-α) (Gunzler et al., 1982b). The A-chain of uPA contains a 16 amino acid
residues-domain (residues 14 – 30) within the GFD, termed the amino terminal
fragment (ATF), which is required for binding of uPA to uPAR (Appella and Blasi,
1987; Appella et al., 1987). The C-terminal B-chain is 253 amino acids long (30
kDa) and contains the serine proteinase domain (SPD) with the active-site
catalytic triad composed of His204, Asp255 and Ser356 (Strassburger et al., 1983;
Verde et al., 1984).
uPA has a restricted substrate specificity with plasminogen being the
main substrate (reviews by Danø et al., 1985; Saksela and Rifkin, 1988;
Mignatti and Rifkin, 1993). However, uPA is also able to catalyse the activation
of hepatocyte growth factor/scatter factor (HGF/SF) (Naldini et al., 1992; Mars
et al., 1993) and the latent from of membrane type 1 matrix metalloprotease
(Kazes et al., 1998), as well as directly cleave uPAR (Høyer-Hansen et al., 1992)
and fibronectin (Quigley et al., 1987; Gold et al., 1989).

1.4.B.2. TISSUE-TYPE PLASMINOGEN ACTIVATOR
Tissue-type plasminogen activator (tPA) is a 70 kDa glycoprotein
containing 527 amino acids (Rijken, 1995) and, like uPA, is secreted as a single
chain zymogen (sc-tPA) (Pennica et al., 1983; Fisher et al., 1985). tPA was
originally identified in tissue extracts and later found in human uterus, plasma
and conditioned cell culture fluids (Gerard et al., 1986; Lill, 1987). The
concentration of tPA in human plasma is 5 – 10 ng/ml (van Hinsbergh et al.,
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1991; Lijnen and Collen, 1995; Rijken, 1995). tPA is also synthesised by other
cell types in vitro such as mast cells (Sillaber et al., 1999).
Cleavage of the Arg275-Ile276 bond is required for the generation of the
active two-chain tPA which consists of A- and B-chains held together by a
disulfide bridge. The N-terminal A-chain contains the active site of tPA
(Hoylaerts et al., 1982), which also contains a classical serine protease catalytic
triad (His322, Asp371 and Ser478) (Pennica et al., 1983). The C-terminal B-chain
contains a fibrin binding domain (also called terminal finger domain, residues
6-43) (Holvoet et al., 1986), growth factor-like domain (residues 44-91), kringle 2
between residues 91-173 and kringle 1 between residues 180-261 (Rijken,
1995). The ability of tPA to bind to fibrin is primarily attributed to the second
kringle and partly to the finger domain (van Zonneveld et al., 1986b, 1986a;
Verheijen et al., 1986). Fibrin binding is required for acquiring fully active tPA
(Hoylaerts et al., 1982) and the A-chain is necessary for this stimulation (Rijken
and Groeneveld, 1986).
1.4.B.3. UPA VERSUS TPA
Although both catalyse the production of plasmin, uPA and tPA are
independent gene products with distinctive structural and functional properties
as their protein and complement DNA (cDNA) sequences are quite different
(Pennica et al., 1983). They only share 40 % homology at the amino acid level
(Degen et al., 1986).
In contrast to pro-uPA that has little or no activity, pro-tPA has
amidolytic activity, binds to fibrin (Higgins and Vehar, 1987), can activate
plasminogen in the presence of fibrin and is inhibited with plasminogen
activator inhibitors (Bachmann and Kruithof, 1984; Danø et al., 1985; Hekman
and Loskutoff, 1987). In vivo, uPA operates as a fibrin-independent, cellular
receptor-bound activator, whereas tPA functions as a fibrin-dependent
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circulatory (blood) activation enzyme (review by Chapman, 1997) though it can
bind to Annexin-II on endothelial cells (Kim and Hajjar, 2002).
As discussed earlier (Section 1.3), proteolytic activity on the cell-surface
(pericellular proteolysis) plays a vital role in cancer metastasis. uPA binds to its
cellular receptor whereas plasma uPA is usually complexed and inhibited by
PAI-1. Thus, this plasminogen activator primarily functions on the cell surface
and is a central molecule for the activation of plasmin-dependent pericellular
proteolysis. The rest of this review addresses the urokinase-type plasminogen
activation pathway; however, it is appreciated that tPA may have significant
functions in certain cancer types such as melanoma (Bizik et al., 1996; de Vries
et al., 1996).

1.4.C. UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR
Specific and high-affinity binding of uPA was first described and detected
in human blood monocytes (Vassalli et al., 1985) and the lymphoma cell line
U937 (Stoppelli et al., 1985). Nielsen et al. (1988) purified and characterised the
membrane protein responsible for this binding from U937 cells, designated as
uPAR. The binding of uPA to its cell-surface receptor, in vitro (Ellis et al., 1991)
and in vivo (Quax et al., 1991b), significantly increases (at least 20-fold) the rate
of its catalytic activity towards plasminogen. This indicates that uPAR plays an
important role in localising uPA activity on the cell surface and is a key player in
directing uPA-mediated pericellular proteolysis.
1.4.C.1. GENE STRUCTURE
uPAR cDNA (1.4 kilo base pairs [kb]) was cloned from the human
lymphoma cell line U937 (Roldan et al., 1990) and the gene mapped to
chromosome 19q13.2 (Webb et al., 1994). uPAR cDNA was also cloned from
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murine (Kristensen et al., 1991) and bovine (Krätzschmar et al., 1993) sources.
The amino acid sequences from these cDNAs are similar to the sequence of the
three domains of the human uPAR (see structure in Section 1.4.C.2.). The
interspecies conservation at the amino acid level of individual repeats in the
domains is more than 60 % (Ploug and Ellis, 1994).
1.4.C.2. PROTEIN STRUCTURE
uPAR is a 55 - 60 kDa cysteine-rich glycoprotein attached to the plasma
membrane via a covalent linkage of its C-terminus to a glycosyl phosphatidyl
inositol (GPI) anchor (Nielsen et al., 1988). The GPI anchor is added during
posttranslational processing involving C-terminal truncation of the primary
translation product (Ploug et al., 1991a; Ploug et al., 1991b; Møller et al., 1992).
The nascent uPAR is translated as a 313 amino acid peptide and preceded by a
21 amino acid signal peptide. The mature uPAR protein is highly glycosylated
and decreases to 35 kDa upon deglycosylation; consistent with the fact that its
amino acid sequence contains 3 potential glycosylation sites (Behrendt et al.,
1990; Roldan et al., 1990).
uPAR consists of three homologous cysteine-rich repeats of about 90
amino acids each (3 domains, Figure 5). The consensus motif of each domain is
characterised by a unique pattern of cysteine residues common to other
proteins of the Ly6 superfamily (Ploug and Ellis, 1994). Stable receptor
fragments can be produced by limited proteolysis (Behrendt et al., 1991; Ploug
et al., 1993; Behrendt et al., 1996), which is consistent with the presence of the
three domains. The disulfide bridge pattern of the N-terminal domain 1 was
determined and found to be similar to that of α-neurotoxins from snake venoms
(Ploug et al., 1993; Ohkura et al., 1994). On this basis, Ploug and Ellis (1994)
proposed a model for the 3-dimensional structure of uPAR domains (Figure 5).
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Figure 5: The structure of urokinase receptor, uPAR
The primary sequence of human uPAR polypeptide is shown as encircled amino acids in
the single letter code and disulphide-bonded cysteine residues are joined by a black bar
(Ploug and Ellis, 1994). The three domains (D1, D2 and D3) are marked according to
Ploug and Ellis (1994) and to date the crystal structure of uPAR has not been resolved.
The uPA-binding residues (7-residue-long Ω loop) are shown; NH2 and COOH represent
the amino- and carboxyl- termini, respectively. Inset: schematic representation of the
GPI-anchored uPAR where the GPI anchorage is added during posttranslational
processing.

1.4.C.3. UPA/UPAR BINDING
The binding affinity (dissociation constant, Kd) for the uPA/uPAR
interaction varies between 0.1 – 1 nM depending on cell type and assay
conditions (e.g. Nykjær et al., 1994). Pro-uPA and uPA bind to uPAR with similar
affinity (Cubellis et al., 1986) via their ATF (residues 14 – 30) (Stoppelli et al.,
1985; Appella and Blasi, 1987; Appella et al., 1987). The uPA-binding residues
of uPAR are located at one side of a 7-residue-long loop (Ω loop, see Figure 5) in
domain 1 (Behrendt et al., 1991; Ploug et al., 1995; Magdolen et al., 1996). Two
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sub-regions within domain 1 of uPAR are critical for uPA recognition (Pöllänen,
1993) and residue 57 in uPAR is specifically involved in binding (Ploug et al.,
1995). The other two domains (2 and 3: residues 88-283) do not have detectable
uPA binding activity, however inter-domain interactions contribute critically to
the binding as the affinity of uPA to isolated domain 1 is approximately 1500fold lower than that to the intact receptor (Ploug and Ellis, 1994; Behrendt et
al., 1996).
Bound uPA can cleave uPAR after Arg83 and Arg89 in the linker region
between domains 1 and 2 and lead to the release of the uPA binding region
(Høyer-Hansen et al., 1992; Høyer-Hansen et al., 1997b). GPI-uPAR has a much
higher susceptibility to uPA-mediated cleavage than soluble forms of uPAR that
lack the GPI moiety (Høyer-Hansen et al., 2001). Furthermore, uPA-mediated
cleavage of GPI-uPAR is accelerated on the cell surface and the specific receptor
binding of active uPA is required for the high-efficiency cleavage (Høyer-Hansen
et al., 1997b). This form of cleaved uPAR has been identified on several cell lines
of neoplastic origin (Høyer-Hansen et al., 1992; Solberg et al., 1994; HøyerHansen et al., 1997b; Ragno et al., 1998) and in extracts of experimental
tumours (Solberg et al., 1994). Since domain 1 of uPAR contains the binding
site for uPA and, as discussed later (Sections 1.5 and 1.6), intact uPAR is
required for uPAR/vitronectin-mediated adhesion, the release of domain 1 of
uPAR by uPA-mediated cleavage is thus likely to affect both pericellular
proteolysis and adhesion (Wei et al., 1994; Kanse et al., 1996; Høyer-Hansen et
al., 1997a; Høyer-Hansen et al., 1997b). Høyer-Hansen et al. (1997a) postulated
that the cleavage and release of domain 1 of uPAR represents an in vivo
regulatory step. Domain 1-deleted uPAR was detected in vivo in uPA/uPARoverexpressing transgenic mice and was related to keratinocyte differentiation
and lowered pericellular proteolytic activity (Zhou et al., 2000).
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1.4.C.4. SOLUBLE UPAR
A soluble form of uPAR (suPAR) has been identified in the plasma of
healthy individuals (Rønne et al., 1995) and the level of suPAR is elevated in
patients with some types of cancers (see Section 1.7.). Soluble uPAR (suPAR)
may be generated by alternative splicing of the uPAR messenger (m)RNA (Pyke et
al., 1993). suPAR functions as a chemoattractant after cleavage between
domains 1 and 2 by any of a number of proteinases, including uPA, plasmin or
chymotrypsin (Resnati et al., 1996). Currently, the role of suPAR in modulating
cancer progression is thought to ensue by either scavenging uPA or alternatively
regulating cell signaling (Resnati et al., 1996; Fazioli et al., 1997; Aguirre Ghiso
et al., 1999b; Degryse et al., 1999; Nguyen et al., 2000; Jo et al., 2003).

1.4.D. SERINE PROTEASE INHIBITORS
In general, proteinase inhibitors represent more than 10 % of total
protein in human plasma of which the majority regulate serine proteases
(reviewed by Travis et al., 1990). The serine protease inhibitor (serpin)
superfamily includes non-inhibitory serpins and inhibitors of various serine
proteases. They are single chain proteins containing conserved domain
structure with 80 % of their amino acids organised in secondary elements
including 7 – 9 α-helices (lettered A - I) and β-sheets A, B and C (see reviews by
Travis et al., 1990; Gettins et al., 1992; Potempa et al., 1994; Stein and Carrell,
1995; Whisstock et al., 1998; Silverman et al., 2001). The most important
feature of inhibitory serpins is the presence of a reactive centre loop (RCL)
exposed on the surface of the protein which is essential for the inhibitory
mechanism of these inhibitors.
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1.4.D.1. INHIBITORY MECHANISM OF SERPINS
Serpins are mechanism-based enzyme inhibitors (also called suicide
inhibitors) since they irreversibly inhibit their target proteinase by forming a
covalent bond with the proteinase. According to Silverman (1996), this class of
inhibitors is characterised by their ability to bind to the enzyme where the
enzyme acts on the inhibitor as a substrate. Both the enzyme and the inhibitor
are then trapped in an inactivated state due to the formation of a covalent bond
between the inhibitor and the enzyme. Sufficient evidence indicates that the
mechanism of action of serpins on their target proteinases involves such events
(see reviews by Travis et al., 1990; Gettins et al., 1992; Potempa et al., 1994;
Stein and Carrell, 1995; Whisstock et al., 1998; Silverman et al., 2001). The
events of this mechanism is described below and illustrated in Figures 6 and 7.
The amino acid sequence of the RCL is the most variable region among
serpins and minor changes within this loop greatly affects the inhibitor
specificity (Travis et al., 1990). Serpins have a single reactive site in the RCL
loop and the amino acids in this region are numbered as …P3-P2-P1-P1`-P2`-P3`…-COOH, where the reactive site is the bond between P1 and P1` (review by
Gettins et al., 1992). This specific bond in the RCL of the serpin (called the
reactive centre peptide bond, RCPB) provides a pseudo-substrate for the target
proteinase and, as described next, the enzyme is trapped in an inactive form
(Andreasen et al., 1997). The serpin initially forms a non-covalent Michaelis-like
(reversible) complex with the target proteinase by the interaction of the RCL of
the serpin with the active site of the enzyme (Figure 6 – A and B). The serine
residue in the active-site of the proteinase attacks the P1-P1` bond (RCPB) of the
serpin and this bond is cleaved then a covalent linkage is formed between the
serine residue and the backbone carbonyl of the P1 residue of the serpin. The
RCL starts to insert into β-sheets A of the serpin and upon complete loop
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insertion the proteinase/serpin undergo conformational changes, Figure 6 – C,
where the active site of the enzyme is distorted and the serpin is in high
conformational-stability state (reviewed by Silverman et al., 2001). The net
result of the conformational rearrangements is the kinetic trapping of the acyl
intermediate complex between the serpin and its target (Lawrence et al., 1995;
Wilczynska et al., 1995). This rearrangement, also called the stressed (S) to
relaxed (R) transition (Whisstock et al., 1998), is essential for efficient inhibition
and formation of the stable final complex. The N-terminal portion of the RCL is
critical for the inhibition mechanism (Chaillan-Huntington et al., 1997) and
variation in the length of this portion of the RCL markedly reduces the efficiency
of inhibition and the stability of the final complex (Zhou et al., 2001).

B
A

C

Figure 6: Inhibitory mechanism of serpins and associated conformational changes
The active serpin (A) in the S state (native) interacts with the active site of the proteinase via the serpin’s RCL (shown in red) to form the initial
Michaelis-like complex (B). The proteinase cleaves the P1-P1` bond in the RCL of the serpin and a covalent bond is formed between the carbonyl group of
the P1 residue and the serine residue of the enzyme. This acyl-enzyme intermediate is trapped in a kinetically stable state (R state, C) by conformational
changes in the serpin structure where the RCL inserts as a β-sheet (shown in red) between the β-sheets A of the serpin (shown in yellow). The
coordinates of the structures shown are available from Protein Data Bank (PDB: http://www.rcsb.org/pdb) and represent: (A) native α1-antitrypsin
(α1AT, PDB entry 1QLP), (B) Michaelis-like complex between Serpin 1 and trypsin (PDB entry 1I99) and (C) covalent complex between α1AT and trypsin
(PDB entry 1EZX). The structures were modelled using Swiss-PdbViewer (Deep View v 3.6: Guex and Peitsch, 1997) available from
(http://www.expasy.org/spdbv).
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The pathway discussed above describes the complete inhibition of the
target proteinase and the formation of covalently-bound, sodium dodecyl
sulphate

(SDS)-stable

1:1

stoichiometric

serpin:proteinase

complex.

Nevertheless, some evidence suggests that in some cases, due to unusual
stabilisation of the initial Michaelis-like complex, progression of the reaction is
blocked and the inhibition of the enzyme by the serpin is reversible (Travis et
al., 1990; Potempa et al., 1994; Silverman et al., 2001). Furthermore,
experimental data also show that, in some cases, the serpin acts in a noninhibitory pathway, where the active proteinase cleaves the serpin and the
inactive serpin is released before loop insertion occurs (Silverman et al., 2001).
This results in release of active proteinase and inactivated serpin where the
proteinase reacted on the serpin as a substrate. In summary, as shown in
Figure 7, the current model for serpin mechanism of action describes an initial
reversible interaction between the serpin (I) and the proteinase (P) to form a
short-lived Michaelis-like complex (IP). The carbonyl group of P1 residue of the
serpin is attacked by the active-site serine residue of the protease. The P1-P1`
bond is cleaved and through a tetrahedral transition state the reaction proceeds
to produce the acyl-enzyme intermediate complex (IP*). The serpin then
undergoes the dramatic conformational change and loop insertion to produce
the stable inhibited serpin/proteinase complex (IPcpx). If loop insertion is not
rapid enough to compete with de-acylation, then the reaction proceeds to
produced cleaved inactivated serpin (I*) and active enzyme (E) mimicking the
normal pathway for the serine protease acting on its substrate.
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Figure 7: Inhibitory pathway of serpin
Inhibitory serpins (I) interact with the target proteinase (P) and form the initial
reversible, short lived Michaelis-like complex (IP). The association/dissociation rates of
this complex are described by kon and koff, respectively. The acyl-enzyme intermediate
complex (IP*) is formed at a rate of k2 through a tetrahedral transition state after the
cleavage of the P1-P1` of the serpin by the active-site serine residue of the proteinase.
The serpin then undergoes dramatic conformational change and loop insertion to
produce the stable inhibited serpin/proteinase complex (IPcpx) at a rate of k4.
Alternatively, the reaction proceeds to produced cleaved inactivated serpin (I*) (i.e. deacylation) and active enzyme (E) at a rate of k3 mimicking the normal pathway for the
serine protease acting on its substrate. The final fate of the acyl-enzyme intermediate
complex (IP*) depends on whether the rate of loop insertion (k4) can compete with the
rate of de-acylation (k3). The Figure was modified from Zhou et al. (2001).

Loop insertion is not only essential for the inhibitory mechanism of
serpins, but also plays a role in serpin biology. For example, some serpins may
adopt an alternative conformation compared to that of the native form (active ‘S’
state, Figure 6 - A) where the RCL is inserted into β-sheets A as in the cleaved
form. This latent form of serpins, Figure 8 – A, is inactive and requires specific
interaction to produce the active form which can interact with target proteinase
and produce the cleaved (‘R’ state, Figure 8 – B) (reviewed by Whisstock et al.,
1998; Silverman et al., 2001). Another consequence of serpins’ conformational
elasticity is the formation of dimers, which are commonly observed under
certain conditions and explained by loop insertion from one serpin molecule into
the β-sheets A of another (Silverman et al., 2001).

A

B

Figure 8: Conformations of serpins
Serpins adopt three conformational states. The native ‘S’ state where the serpin is active and the RCL is exposed for reaction with target proteinase (see
Figure 6 – A), (A) the latent conformation where the RCL (shown in red) inserts in the β-sheets A (shown in yellow) and (B) the ‘R’ state where the P1-P1`
bond is cleaved (by proteinase) and the RCL is inserted into the β-sheets A. The latent conformation resembles the ‘R’ cleaved state; however it can be
converted to the active native state under certain conditions since bond cleavage has not occurred. The structures were modelled using SwissPdbViewer from the coordinate files of A: latent anti-thrombin III (PDB entry 2ANT) and B: cleaved α1-antitrypsin (PDB entry 7API).
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The serpin superfamily includes various members from different
organisms. Only the function and biology of serpins related to the urokinaseplasminogen activation pathway will be reviewed here. For a list of other serpins
and their targets see reviews by Potempa et al. (1994), Whisstock et al. (1998)
and Silverman et al. (2001). PAI-1, PAI-2 and

α2AP

belong to the serpin

superfamily and while PAI-1 and PAI-2 target both uPA and tPA,

α2AP

is the

primary inhibitor of plasmin. Two other serpins, proteinase nexin-1 (PN-1) and
protein C inhibitor (PCI), also inhibit uPA and tPA at physiologically relevant
rates, though they are not specific and react more slowly with these proteinases
than PAI-1 and PAI-2 (Sprengers and Kluft, 1987; España et al., 1993a; España
et al., 1993b). The crystal structures of both PAI-1 (Nar et al., 2000) and PAI-2
(Jankova et al., 2001; Saunders et al., 2001) confirm that these act as classic
serpins and form SDS-stable 1:1 stoichiometric complexes with the catalytic site
on their target protease. Since one of the aims of this thesis relates to targeting
the urokinase-type plasminogen activation pathway as a potential anti-cancer
strategy, the following sections only address the two main inhibitors of uPA/tPA
activities, PAI-1 and PAI-2.
1.4.D.2. PAI-1
PAI-1 was first described in conditioned media of human endothelial cells
(Loskutoff and Edgington, 1977) and later detected in a wide variety of cell types
(see review by Kruithof, 1988). PAI-1 level in plasma is variable but is
approximately 20 ng/ml (Kruithof et al., 1987). It is a single chain glycoprotein
with 379 amino acids (~ 52 kDa) and an isoelectric point (pI) of 4.5 – 5.0
(Erickson et al., 1984; Andreasen et al., 1986a). The active site is located at
Arg346-Met347 (Andreasen et al., 1986b; Ny et al., 1986; Sanzo et al., 1987) and
the sequence contains an amino terminal signal peptide (21 – 23 amino acids)
that is cleaved in the mature protein (Andreasen et al., 1986b; Ginsburg et al.,
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1986; Ny et al., 1986; Pannekoek et al., 1986; Wun and Kretzmer, 1987). PAI-1
is highly sensitive to oxidation (Baker et al., 1990b), relatively unstable and
rapidly converts into the latent conformation at 37oC (Levin and Santell, 1987;
Mimuro et al., 1987; Reilly et al., 1990). This latent form can be re-activated by
denaturation (Hekman and Loskutoff, 1985) and heat (Katagiri et al., 1988).
Interaction of active PAI-1 with the matrix protein vitronectin stabilises PAI-1 in
this active form and reduces the formation of latent PAI-1 (see Section 1.5.A.2.
for more details).
PAI-1 efficiently inhibits tPA and uPA (Erickson et al., 1984; Colucci et
al., 1986) with similar second order rate constants for both targets;
approximately 2 x 107 M-1s-1 (Declerck et al., 1988; Thorsen et al., 1988). In the
presence of vitronectin, the second order rate constant of PAI-1 towards uPA is
lowered to 7.9 x 106 M-1s-1 (Ellis et al., 1990) and by 35 % towards tPA (Declerck
et al., 1988). PAI-1 is a less efficient inhibitor of pro-tPA (5.5 x 106 M-1s-1)
compared to tPA (Thorsen et al., 1988) and inhibition of tPA is lowered when tPA
is bound to fibrin (Kruithof et al., 1984). Similarly, the second order constant
towards uPA is lowered when uPA is bound to cell-surface uPAR (4.5 x 106 M-1s-)
(Ellis et al., 1990).
1.4.D.3. PAI-2
PAI-2 inhibitory activity was first described in partially purified extracts
from human placenta (Kawano et al., 1970). Pure PAI-2 was later prepared from
placenta and human monocyte/macrophage lineages (see reviews by Dear and
Medcalf, 1995; Kruithof et al., 1995). PAI-2 exists in two forms; a nonglycosylated form with a molecular weight of 47 kDa and pI of 5.0 (Kruithof et
al., 1986) and a 60 kDa glycosylated form with pI of 4.4 (Kruithof et al., 1986;
Genton et al., 1987; Wohlwend et al., 1987b). These two forms also have distinct
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cellular localisation; the 47 kDa PAI-2 being intracellular and the 60 kDa PAI-2
being secreted (Genton et al., 1987; Wohlwend et al., 1987a, 1987b).
PAI-2 is an efficient inhibitor of uPA (second order rate constant of 106
M-1s-1) and tPA (2 x 105 M-1s-1) (Kruithof et al., 1986; Thorsen et al., 1988; Mikus
et al., 1993). The second order rate constant for PAI-2 inhibition of pro-tPA is
much lower than that of tPA (103 M-1s-1) (Åstedt et al., 1985; Kruithof et al.,
1986) and fibrin bound tPA appears to be protected from inhibition by PAI-2
(Leung et al., 1987). As in the case of PAI-1, the second order rate constant for
the inhibition of cell-surface uPAR-bound uPA by PAI-2 is lower than that of
soluble uPA (Ellis et al., 1990). All together, PAI-2 may be accepted to function
primarily as an inhibitor of uPA and only has a minor role in controlling tPAmediated fibrinolysis. This serpin would preferentially target the urokinase
plasminogen activation pathway on the cell surface, thus an expanded review of
the structure/function of PAI-2 is described below.
1.4.D.3.I. PAI-2 GENE STRUCTURE AND EXPRESSION
PAI-2 gene is 16.5 kb long and consists of 8 exons and 7 introns located
on chromosome 18q21-23 (Webb et al., 1987; Webb et al., 1994). Three other
ov-serpins (see Section 1.4.D.3.II.); squamous cell carcinoma antigen (SCCA-1
and SCCA-2) genes and the maspin gene, are located 300 kb centromeric from
the PAI-2 gene (Schneider et al., 1995). In addition, the bcl-2 proto-oncogene,
regulator of apoptosis (Vaux et al., 1994), lays 600 kb centromeric to the PAI-2
gene suggesting a role for PAI-2 in apoptosis (Silverman et al., 1991; Schneider
et al., 1995).
PAI-2, in both forms, is 415 amino acids long encoded by a single mRNA
of approximately 2.0 kb length (see reviews by Dear and Medcalf, 1995; Kruithof
et al., 1995). The transcription initiation site for PAI-2 gene resides between 22
to 25 base pairs (bp) downstream of a consensuses TATAAAA sequence
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(Kruithof and Cousin, 1988; Ye et al., 1989; Samia et al., 1990) and the
promoter region contains two alu repeat sequences, 1390 - 1100 and 870 - 580
(Kruithof and Cousin, 1988). Two closely spaced activator protein (AP)-1 like
elements (at -116 to -97) and a cyclic adenosine monophosphate (cAMP)
response element (CRE)-like element (-189 to -182) in the PAI-2 promoter are
essential for basal gene transcription and for phorbol ester-mediated induction
of PAI-2 expression (Cousin et al., 1991). Retinoic acid receptor/glucocorticoid
element (at -1659 to -1620) mediates the retinoic acid response of the PAI-2
gene (Schuster et al., 1994). The region around -1150, homologous to dioxin
response element, may mediate the response of PAI-2 gene to the toxin dioxin
(Sutter et al., 1991). The sequences at -3.4 and at -4.1 kb in PAI-2 promoter
bind a protein with a similar size to that of an interferon-gamma activated DNA
binding element (Antalis et al., 1993). As suggested by the structure and
characteristics of the promoter of PAI-2, various agents affect the expression of
PAI-2 gene. These agents are summarised in Figure 9. For more details refer to
reviews by Bachmann (1995), Dear and Medcalf (1995) and Kruithof et al.
(1995).
1.4.D.3.II. PAI-2 BIOCHEMISTRY
The polypeptide chain of PAI-2 has three potential N-glycosylation sites
(Asn75, Asn115 and Asn339), which all appear occupied in the glycosylated form of
PAI-2 (Ye et al., 1988), and the reactive centre (P1-P1`) maps to Arg380-Thr381
bond (Kiso et al., 1988). There are two common variants of PAI-2 which differ at
three amino acid positions; Asn120, Asn404 and Ser413 for Type A compared to
Asp120, Lys404 and Cys413 for Type B (Ye et al., 1987; Ye et al., 1989). The extra
cysteine in Type B PAI-2 may mediate dimerisation (Mikus et al., 1993) and the
formation of disulfide bridges with other proteins as that described with
vitronectin in human placenta (Wun and Reich, 1987; Radtke et al., 1990).
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Figure 9: Regulation of PAI-2 gene expression
Agents that affect PAI-2 gene expression are classified in the groups shown in balloons.
Shaded balloons indicate suppressors of PAI-2 gene expression while the remaining
(clear) are activators of PAI-2 gene expression (modified from Dear and Medcalf, 1995).
These agents have been shown experimentally to modulate PAI-2 expression in several
different cell lines. Abbreviations: EGF: epidermal growth factor, M-CSF: macrophage
colony stimulating factor, GM-CSF: granulocyte-macrophage colony stimulating factor,
TNF: tumour necrosis factor, IL-1 and IL-2: interleukin-1 and -2.

PAI-2 does not have a cleavable signal peptide (Ye et al., 1988; von Heijne
et al., 1991) as the case in ovalbumin (a non-inhibitory serpin). In fact, evidence
suggests that PAI-2 belongs to a subfamily of serpins called ov-serpins, which
includes ovalbumin, chicken gene Y and other serpins (reviewed by Bachmann,
1995; Silverman et al., 2001). Members of this subfamily show additional amino
acid sequence homology compared to other serpins, lack N-terminal and Cterminal extensions, often contain a non-conserved loop between their C and D
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helices (C-D interhelical region) and lack a cleavable signal peptide (Bachmann,
1995). As many other ov-serpins, PAI-2 is mainly found intracellularly in almost
all cell types studied (Genton et al., 1987; Wohlwend et al., 1987b; Medcalf et
al., 1988a; Medcalf et al., 1988b; Belin et al., 1989). However, extracellular
traces of PAI-2 under normal conditions were reported and under certain
conditions secreted PAI-2 may represent a significant part of total PAI-2,
indicating that cellular targeting of synthesised PAI-2 may be modulated (Ye et
al., 1988; Quax et al., 1990). The differential translocation of the two forms of
PAI-2, which are encoded by a single mRNA species, may be explained by the
presence

of

two

internal

hydrophobic

signal

regions.

Increasing

the

hydrophobicity of these regions, which are homologous to an internal
hydrophobic

signal

region

in

ovalbumin,

enhances

the

extracellular

translocation of PAI-2 (von Heijne et al., 1991; Belin, 1993). These regions may
explain the secretion of PAI-2 to the endoplasmic reticulum (ER)-Golgi
apparatus pathway, however other evidence suggests that secretion of PAI-2 by
monocytes occurs via ER-Golgi-independent and vesicle-independent pathway
(Ritchie and Booth, 1998). To date, the exact mechanism of PAI-2 secretion is
unknown.
1.4.D.3.III. FUNCTIONS OF PAI-2
The principal known target proteinases of PAI-2 are uPA and tPA. This is
intriguing considering that PAI-2 is mainly localised intracellularly and its
secretory pathway is poorly understood. Thus, the physiological role of PAI-2
has been a subject for research. PAI-2 levels in plasma are normally below
detection limits, however, intracellular (47 kDa form) and extracellular PAI-2 (60
kDa form) seem to play physiological roles under certain conditions such as
pregnancy, cancer, inflammation, diseases and in apoptosis (Dear and Medcalf,
1995; Kruithof et al., 1995).
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During pregnancy, plasma concentrations of PAI-2 increase from below
detection limits to a maximum of 250 ng/ml at term (Kruithof et al., 1987;
Lecander and Åstedt, 1987; Wright et al., 1988; Koh et al., 1992; Stegnar et al.,
1993; Halligan et al., 1994). Changes in PAI-2 concentration have been shown
to occur in cases of pre-eclampsia and intrauterine growth retardation,
indicating a role of PAI-2 in securing hemostasis during pregnancy (reviewed by
Dear and Medcalf, 1995; Kruithof et al., 1995; Åstedt et al., 1998). This role may
be related to regulation of uPA activity since PAI-2 cleaved at the reactive centre
is observed in placental extracts (Kiso et al., 1991). PAI-2 levels are modulated
during cancer and as discussed in later sections (see Section 1.7); elevated
PAI-2 levels appear to be a marker of low metastatic activity and good prognosis
in a few cancer models. Induction of PAI-2 expression by inflammatory
mediators (e.g. phorbol esters) and down-regulation by anti-inflammatory
agents (e.g. dexamethasone) suggest a role for PAI-2 in inflammation (Dear and
Medcalf, 1995; Kruithof et al., 1995). The precise role of the predominant
intracellular form of PAI-2 is still not clearly elucidated. PAI-2 seems to play a
role in keratinocytes differentiation (Lavker et al., 1998; Risse et al., 1998;
Williams et al., 1999; Risse et al., 2000), prevention of apoptosis (Kumar and
Baglioni, 1991; Jensen et al., 1994; Dickinson et al., 1998; Jensen et al., 1999)
and protection against viral or bacterial infections (Gan et al., 1995; Antalis et
al., 1998; Shafren et al., 1999). Recently, a novel intracellular role of PAI-2 as a
retinoblastoma protein (Rb)-binding protein was reported (Darnell et al., 2003).
Rb is a ubiquitous regulator of transcription involved in activities such as cell
cycle control, apoptosis, differentiation and tumour suppression (Harbour and
Dean, 2000b, 2000a). Binding of PAI-2, via its unique C-D interhelical region, to
Rb in the nucleus inhibits the turnover of Rb which leads to increase of Rb
protein levels and activity (Darnell et al., 2003). These recent results provide
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further insights to the mechanism by which intracellular PAI-2 may mediated
its effects, however, further work is still required to elucidate the complete roles
of intracellular PAI-2.

1.5. THE

UROKINASE PLASMINOGEN ACTIVATION PATHWAY:
PROTEOLYTIC FUNCTIONS

NON-

Members of the urokinase-plasminogen activation pathway of the
plasminogen activation system are associated with other molecules present on
the cell surface and/or the ECM, which appear to expand the functions of this
pathway further than just generating proteolytic activity on the cell surface.
This section addresses these other molecules which associate with this
pathway.

1.5.A. VITRONECTIN
Vitronectin is a 78 kDa glycoprotein that contains a somatomedin B
domain, an integrin-binding RGD (single-letter amino acid code) sequence, a
collagen-binding region and two hemopexin-like domains (reviewed by FeldingHabermann and Cheresh, 1993; Hess et al., 1995). This glycoprotein is
primarily a circulatory plasma protein (plasma concentration of 4 µM) and it is
deposited extravascularly in the ECM during injury and repair (Dvorak et al.,
1995; Hess et al., 1995). Plasma vitronectin is in the closed form (native, Figure
10), while the extended form is believed to be the one deposited in the ECM
(Hess et al., 1995). Cell-surface receptors of the integrin family (see Section
1.5.B.), especially those containing αv chain (e.g. αvβ1, αvβ3, αvβ5), bind to the
RGD sequence of vitronectin (Felding-Habermann and Cheresh, 1993; Schnapp
et al., 1995). Interestingly, evidence suggests important functional binding
between vitronectin and components of the urokinase plasminogen activation
system.
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Figure 10: Vitronectin structure
The structures of native (right) closed vitronectin and the active extended vitronectin
(left) are shown (modified from Andreasen et al., 1997). Abbreviations: Somatomedin B
domain (SomB), integrin-binding Arginine-Glycine-Aspartic acid sequence (RGD),
collagen-binding region connecting segment (Con.S) and two hemopexin-like domains
(HPI and HPII).

1.5.A.1. UPAR/VITRONECTIN INTERACTION
uPAR is a high affinity receptor for the matrix (extended) form of
vitronectin (Wei et al., 1994; Kanse et al., 1996). The vitronectin-binding site on
uPAR is within domains 2 and 3 (Wei et al., 1994) while the uPAR-binding
residues on vitronectin are located at the amino-terminal somatomedin B
domain (Deng et al., 1996; Waltz et al., 1997). Vitronectin-uPAR binding is not
blocked by RGD peptides, distinguishing this interaction from the known
integrin–vitronectin interactions (Preissner et al., 1988). Intact uPAR is required
for efficient vitronectin binding (Høyer-Hansen et al., 1997a) and this binding is
enhanced by the presence of uPA on uPAR (Wei et al., 1994). This enhancement
of the adhesion of uPAR to vitronectin is independent of the proteolytic activity
of uPA (Chang et al., 1998; Sidenius et al., 2002).
1.5.A.2. PAI-1/VITRONECTIN INTERACTION
PAI-1 in its native form binds to vitronectin and this binding stabilises
PAI-1 in active conformation (Reilly et al., 1992), thus protecting PAI-1 from
converting into its latent form. The amino terminus of vitronectin (Somatomedin
B domain) is involved in the PAI-1/vitronectin interaction and the binding site
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for PAI-1 overlaps with those of uPAR and integrins (Seiffert and Loskutoff,
1991; Royle et al., 2001). This is in agreement with data indicating that active
PAI-1 blocks uPAR/vitronectin interaction (Deng et al., 1996; Kanse et al., 1996;
Waltz et al., 1997; Loskutoff et al., 1999) and competition between PAI-1 and
integrins for binding to vitronectin (Stefansson and Lawrence, 1996; Kjøller et
al., 1997).
The quantity of ECM-deposited PAI-1 correlates strongly with the
availability of ECM-associated vitronectin (Mimuro et al., 1987; Declerck et al.,
1988; Mimuro and Loskutoff, 1989a, 1989b). Furthermore, the distribution of
PAI-1 in the extracellular space is almost the same as that of vitronectin
(Barnes et al., 1983; Hayman et al., 1983; Neyfakh et al., 1983). Thus,
vitronectin appears to function as a ‘carpet’ for presenting active PAI-1 in the
ECM. The vitronectin-PAI-1 complex dissociates simultaneously with the
appearance of the inactive enzyme–PAI-1 product upon the reaction of
vitronectin-associated PAI-1 with uPA or tPA (Declerck et al., 1988; Salonen et
al., 1989; Hess et al., 1995; Deng et al., 1996). The significance and
consequences of these interactions are discussed later (Section 1.6.).
1.5.A.3. UPA/VITRONECTIN INTERACTION
Moser et al. (1995) showed a concentration-dependent reversible binding
of uPA to vitronectin in vitro (Kd approximately 97 nM). This binding involves the
hemopexin domain fragment of vitronectin and the N-terminal fragment of uPA.
PAI-1 does not compete with uPA for binding to vitronectin, suggesting that
both molecules may co-localise on vitronectin (Moser et al., 1995). To date,
functional consequences of uPA binding to vitronectin or co-localisation of uPA
and PAI-1 on vitronectin have not been demonstrated in vivo.
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1.5.B. INTEGRINS
Integrins are heterodimeric transmembrane glycoprotein receptors
composed of distinct α and β subunits, which bind to ECM proteins such as
vitronectin, collagens, fibrin, laminin and fibronectin (Hynes, 1992; Chapman,
1997). These receptors mediate adhesion of cells to the ECM via RGD moiety as
well as non-RGD dependent interactions with intracellular signalling proteins
and cytoskeletal elements (Hemler, 1998). Integrins undergo reversible
activation upon binding to their ligands. This activation is characterised by
conformational changes in the extracellular domains, reorganisation of
intracytoplasmic connections (actin-cytoskeleton) and redistribution of integrins
on the cell surface (Diamond and Springer, 1994; Yednock et al., 1995).
A comprehensive study on the association of integrins with uPAR found
that β1 integrins and uPAR co-localise with close proximity (7 nm) at focal
contacts between carcinoma cells and fibronectin, laminin or vitronectin
matrices (Xue et al., 1997). On the other hand, uPAR and β3 integrins co-localise
only when cells attach to vitronectin. Furthermore, uPAR co-localises with α5
integrins on cells attached to fibronectin, with α5 and αv integrins on cells
attached to vitronectin and with α3 and α6 integrins on cells attached to laminin
(Xue et al., 1997). The formation of complexes between uPAR and β1 integrins
alters the phenotype (not the expression) of these integrins, thus affecting
integrin functions (Wei et al., 1996; Wei et al., 2001). uPAR also interacts with
the β2 integrin CD11b/CD18 (termed Mac-1) (Sitrin et al., 1996) and the
interaction of β2 integrins with uPAR is essentially identical to that of β1
integrins and uPAR (Wei et al., 1996). uPAR-dependent adhesion to immobilised
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vitronectin is enhanced by uPAR-integrin-calveolin* multimeric complexes on
the cell membranes (Wei et al., 1996; Chapman, 1997) and uPA/uPAR
complexes are concentrated at these multimeric complexes (Stahl and Mueller,
1995).
The association of uPAR with various members of the integrin family and
its ability to induce their activation indicate additional functions for the
plasminogen activation pathway. As discussed in Section 1.6., uPAR may
modulate integrin functions to focus proteolysis at specified sites and utilise the
intracellular domains of integrins for signal transduction.

1.5.C. LOW-DENSITY LIPOPROTEIN RECEPTOR (LDLR) FAMILY
Currently, there are more than six known mammalian members of the
low-density lipoprotein receptor family of endocytosis (LDL receptors), which
mediate the endocytosis of various types of ligands (Nykjær and Willnow, 2002;
Strickland et al., 2002). Specifically, the α2-macroglobulin receptor/low density
lipoprotein receptor-related protein (α2MR/LRP), the epithelial glycoprotein 330
(megalin, gp330) and the very low-density lipoprotein receptor (VLDLR) of the
LDLR family are known to mediate the endocytosis of components of the
plasminogen activation system (reviewed by Andreasen et al., 1994; Andreasen
et al., 1997; Strickland et al., 2002).
Cell-surface uPAR-bound uPA/PAI-1 complex is rapidly internalised and
degraded in lysosomes in a process mediated by α2MR/LRP (Cubellis et al.,
1990; Jensen et al., 1990; Nykjær and Willnow, 2002), gp330 (Moestrup et al.,
1993) and VLDLR (Argraves et al., 1995; Heegaard et al., 1995). Similarly, PAI-1
mediates binding of tPA to α2MR/LRP (Owensby et al., 1989; Owensby et al.,

* Caveolae are plasma membrane structures that contain calveolin; a protein associated
with intracellular signalling pathways and cytoskeletal elements.
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1991; Bu et al., 1993; Grobmyer et al., 1993) and gp330 (Willnow et al., 1992)
and these complexes are internalised and degraded. The uPA/PN-1 complex and
the uPA/PCI complex are also endocytosed by α2MR/LRP and VLDLR (Conese et
al., 1994). The endocytosis of uPA:PAI-2 complexes was only recently illustrated
by definitive evidence (see Chapter 4, Al-Ejeh et al., 2004). The internalisation of
uPA:PAI-2 complexes is mediated in part by members of the LDLR family;
however, other mediators seem to play a role in this internalisation (see Chapter
4 for more details).

1.5.D. INTERACTION WITH SIGNALLING MOLECULES
Studies indicate that uPAR transmits intracellular signals despite the
lack of transmembrane structure in this extracellularly GPI-anchored receptor.
The expression of uPAR and its ability to bind uPA are required for such
signalling (Resnati et al., 1996) and uPA-mediated signalling is independent of
its proteolytic activity (Sidenius et al., 2002; Liu et al., 2003). To date, molecular
adaptors that may mediate uPAR signalling include integrins, calveolin and Gprotein-coupled receptor (GPCR) (reviewed by Ossowski and Aguirre-Ghiso,
2000; Blasi and Carmeliet, 2002). Other less defined signal mediators have been
proposed to mediate uPAR signalling such as α2MR/LRP and mannose-6phosphate/insulin-like growth factor II receptor (Blasi and Carmeliet, 2002).
The uPA-uPAR/mediator association have been shown to modulate
several signalling pathways. It is beyond the scope of this thesis to discuss the
growing evidence of the signalling role of uPA/uPAR complexes (For more details
see reviews by Conese and Blasi, 1995; Andreasen et al., 1997; Chapman, 1997;
Dear and Medcalf, 1998; Konakova et al., 1998; Preissner et al., 2000; Blasi and
Carmeliet, 2002). In brief, however, signalling pathways which are linked to
uPA/uPAR

include

cytosolic

kinase

pathways

(tyrosine

kinases,
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serine/threonine kinases and protein kinase C), focal adhesion kinase (FAK)
pathway, extracellular signal-regulated kinase/mitogen-activated protein kinase
(ERK/MAPK) pathway, intracellular calcium mobilisation, Src (sarcoma) family
kinases, Janus kinase/signal transducers and activators of transcription
(JAK/STAT) in addition to cytoskeletal elements such as vinculin and actin.
These signalling pathways regulate the proteolytic as well as the non-proteolytic
functions of the urokinase plasminogen pathway such as cellular adhesion,
chemotaxis, proliferation, differentiation and LDLR-mediated endocytosis (see
Section 1.6.). For example, FAK and ERK/MAPK signalling pathways are
activated while the p38 MAPK pathway is down-regulated due to interaction
between integrin and uPAR (Liu et al., 2002), thus affecting epidermal growth
factor-receptor-dependent proliferation. Gradients of uPA, pro-uPA or the ATF of
uPA display a chemotactic effect on cells which express uPAR (Resnati et al.,
1996) and a GPCR member is implied in transduction of signals for cytoskeletal
adjustment required for this chemotactic activity (Fazioli et al., 1997; Degryse et
al., 1999; Nguyen et al., 2000; Resnati et al., 2002).

1.6. UROKINASE

PLASMINOGEN ACTIVATION PATHWAY:

THE

OVERALL

PICTURE
The components of the urokinase-plasminogen activation pathway and
their interactions which result in the generation and control of plasmin on the
cell surface were introduced. However, studies indicate that the urokinase
plasminogen activation pathway is more than just a provider of proteolytic
activity required for ECM degradation. These studies improve the understanding
of

the

role

of

this

pathway

in

cell

migration

which

emerges

from

characterisation of cross-talk between components of this pathway and other
cellular components (e.g. integrins and signalling mediators) as well as
components in the microenvironment (e.g. ECM components such as
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vitronectin). Given these biochemical and physical interactions, the overall
organisation and functions of the urokinase plasminogen activation pathway is
discussed in this section.

1.6.A. LOCALISED PROTEOLYSIS
Localisation

studies

describe

the

accumulation

of

uPAR

and

pro-uPA/uPA [pro/uPA for abbreviation] at focal adhesion sites (cell-tosubstratum) and cell-to-cell contact sites (Pöllänen et al., 1987; Glass et al.,
1988; Hébert and Baker, 1988; Takahashi et al., 1990; Del Rosso et al., 1992;
Jensen and Wheelock, 1992; Bastholm et al., 1994a; Bastholm et al., 1994b;
Reinartz et al., 1995; Sitrin et al., 1996). Integrins also accumulate at these sites
and their cytoplasmic domains interact with intracellular filaments (see reviews
by Clark and Brugge, 1995). The accumulation of pro/uPA:uPAR at focalcontacts occurs on specific ECM substrates, e.g. vitronectin (Ciambrone and
McKeown-Longo, 1990; Nusrat and Chapman, 1991; Waltz and Chapman,
1994; Wei et al., 1994; Wei et al., 1996). In vivo, only uPAR occupied with
pro/uPA, but not unbound uPAR, accumulates at these specific sites on the cell
surface (Myöhänen et al., 1993). The accumulation of pro/uPA:uPAR complexes
at focal adhesion sites (see Figure 11) may be explained by uPAR/vitronectin
and/or uPAR/integrin interactions described earlier (Section 1.5.).
During cell migration, uPAR polarises to the leading edge of the cell in
vitro (Estreicher et al., 1990; Okada et al., 1995) and in vivo (Del Vecchio et al.,
1993). Similarly, uPA also accumulates at the leading edge of cells (Pöllänen et
al., 1987). The localisation of uPA/uPAR at focal adhesion sites and leading
edges of migrating cells indicate the role of uPAR-bound uPA during phases of
cell migration, invasion and tissue remodelling (Danø et al., 1985; Saksela and
Rifkin, 1988; Gold et al., 1989). This role is convincingly related to the
generation of plasmin on the cell surface since uPA-mediated plasminogen
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activation occurs much faster in the presence of cells than their absence, both
in vitro (Ellis et al., 1991) and in vivo (Quax et al., 1991b). The co-localisation of
plasminogen with uPA at cell surfaces provides a mechanism for accelerated
plasminogen activation by cells (Andronicos and Ranson, 2001). This is because
binding leads to an activation susceptible conformation of glu-plasminogen; an
important requirement for efficient generation of cell-surface plasmin (reviewed
by Ranson and Andronicos, 2003). Plasmin generation on the cell surface is also
dependant on binding of uPA to uPAR, since blocking uPAR/uPA binding
inhibits it (Stephens et al., 1989; Ellis et al., 1991; Rønne et al., 1991) and
accelerated cell-surface plasmin generation is not observed in uPAR-deficient
mice (Bugge et al., 1995). Thus, cell-surface-associated plasmin generated by
uPAR-bound uPA confers plasmin-dependent degradation of ECM (Bergman et
al., 1986; Cajot et al., 1989; Schlechte et al., 1989; Cohen et al., 1991; Quax et
al., 1991a; Quax et al., 1991b; Reiter et al., 1993). Conclusively, the correlation
between plasmin-dependent proteolysis and uPA/uPAR binding in addition to
the directed distribution of uPAR-bound uPA at focal adhesion sites on the cell
surface indicate the conception of localised pericellular proteolysis at the
invading fronts of migrating cells (see Figure 11).
Plasmin bound to the cell surface is protected from inhibition by its
efficient inhibitory serpin, α2AP (Stephens et al., 1989; Plow and Miles, 1990;
Ellis et al., 1991; Duval-Jobe and Parmely, 1994; Falcone et al., 1994). Thus,
control of plasmin activity on the cell-surface appears to be controlled by the
level of plasmin generation rather than the activity of the generated plasmin.
PAI-1 and PAI-2 can react with uPAR-bound uPA on the cell surface (Cubellis et
al., 1989; Pöllänen et al., 1990). Although the reaction on the cell-surface may
be slower than in fluid phase (Ellis et al., 1990), PAI-1 (Cajot et al., 1990;
Shirasuna et al., 1993), PAI-2 (Laug et al., 1993) and PN-1 (Bergman et al.,
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1986) inhibit plasmin-dependent ECM degradation initiated by uPAR-bound
uPA.
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Figure 11: The urokinase plasminogen activation pathway on the cell surface
Accelerated plasmin generation on the cell-surface requires the co-localisation of
receptor-bound plasminogen (plg) and binding of pro/uPA to uPAR. Interactions
between uPAR with vitronectin and integrins and the interaction between vitronectin
and integrins account for the accumulation of uPA/uPAR complexes at sites of focal
adhesion. The accumulation of uPAR-bound pro/uPA at focal adhesion sites also leads
to localised plasmin-dependent pericellular proteolysis at these sites. The generation of
plasmin on the cell-surface allows the plasmin-mediated functions indicated in the
Figure and discussed elsewhere in this review. Plasminogen activator inhibitors (PAIs)
inhibit the uPA catalytic activity and thus control cell-surface plasminogen generation.
uPAR/uPA:PAIs complexes are internalised by LDLRs. Intracellular signals which are
mediated by various signal transduction adaptors may be initiated due to uPA/uPAR
binding or during the internalisation of uPAR/uPA:PAIs. Note: Plasmin generated on the
cell-surface remains bound to the cell-surface; this is not shown in the Figure for clearer
presentation.

As discussed earlier (Section 1.5.C.), serpin/uPA complexes are
endocytosed readily after complex formation, thus clearing the cell surface of
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inhibited uPA. Endocytosis of uPAR-bound uPA/serpin complexes is much
faster than that of fluid-phase complexes (Olson et al., 1992; Conese et al.,
1994). Furthermore, the affinity of α2MR/LRP to uPA:PAI-1 complex is
approximately 100-fold higher than the affinities for un-complexed components
(Nykjær et al., 1994). This indicates preferential clearance of complexes when
bound to cell-surface uPAR and suggests another control-point of the urokinase
plasminogen activation pathway on the cell surface. However, in the case of PAI1, both uPAR and the α2MR/LRP are recycled to the cell surface (Nykjaer et al.,
1997). This recycling in addition to the binding properties of PAI-1 and uPAR to
vitronectin, which have not been demonstrated for PAI-2, suggests that PAI-1
may play as a switch molecule in the process of cell migration.

1.6.B. FUNCTIONAL DUALITY
Cell invasion through the ECM (see Section 1.3.) involves interplay of
proteolytic and adhesive functions (detachment/attachment) at the leading and
posterior ends of the cell. uPAR-bound uPA, which generates plasmin, is
localised at focal adhesion sites, polarises to the leading edge of the cell and
leads to degradation of the ECM in front of the cell. This proteolytic activity is
inhibited when uPAR-bound uPA encounters active PAI-1 embedded on
vitronectin. uPA:PAI-1 complexes are endocytosed and uPAR along with the
endocytosis receptor are recycled back to the cell surface where uPAR may be
able to bind to integrins and/or PAI-1-free vitronectin. Alternatively, the
interaction of PAI-1 with vitronectin may also suppress integrin/vitronectinmediated adhesion independent of its serpin activity (Kjøller et al., 1997), thus
modulating cellular adhesion. In the case of internalisation of uPA:PAI-1
complex, binding of uPA to recycled uPAR may initiate another round of
proteolysis and result in further ECM degradation and decrease in attachment.
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This scenario implicates proteolytic/adhesive interplay through multiple
interactions between uPA, uPAR, vitronectin, integrin and PAI-1. Similar
proteolytic activity followed by detachment/attachment events at the posterior
end of the cell may collectively lead to the migration and invasion of the cell
through the ECM.
Recent evidence indicates that PAI-1 can activate signalling systems and
stimulate cell migration during chemotaxis, chemokinesis and wound healing
assays (Degryse et al., 2004). These effects of PAI-1 are blocked when α2MR/LRP
is blocked by antibodies or antagonist, suggesting that α2MR/LRP mediates the
signalling activation and affects of PAI-1 in these assays (Degryse et al., 2004).
These findings along with other growing evidence (Deng et al., 1996; Chapman,
1997; Brooks et al., 2000), suggest that uPA and PAI-1 co-operate in the
migratory process by facilitating attachment to and subsequent detachment
from vitronectin in the extracellular matrix. Association of uPAR with
integrins/vitronectin also links uPAR with intracellular signalling/cytoskeletal
elements (Porter and Hogg, 1998; Chen et al., 2001; Kjøller and Hall, 2001) and
facilitates cell migration and invasion (Yebra et al., 1996; Carriero et al., 1999;
Yebra et al., 1999; Khatib et al., 2001; Prifti et al., 2002). Furthermore, these
interactions even modulate the expression of uPAR/uPA/PAI-1 (Hapke et al.,
2001a; Hapke et al., 2001b) and plasminogen receptors (Kim et al., 1996). This
dynamic organisation and interplay/cross-talk of plasminogen activation
pathway components and other microenvironmental factors need intracellular
signalling to orchestrate the organisation of the events (see Section 1.5.D.). As
discussed in the previous section (Section 1.5.), signalling and other nonproteolytic interactions of the urokinase plasminogen activation pathway
provide further evidence for the critical involvement of this pathway in tumour
cell invasion and metastasis.
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1.7. UROKINASE

PLASMINOGEN ACTIVATION PATHWAY:

REGULATION

AND CANCER
Plasmin generation on the cell surface requires the presence of uPAR,
uPA, plasminogen and plasminogen receptors. PAI-1 and PAI-2 are required for
controlling uPA-mediated plasminogen activation. Thus, the first level of control
of this pathway is the synthesis of these components, which can be regulated by
a wide variety of factors including hormones, phorbol esters, growth factors,
retinoids and cytokines (reviewed by Danø et al., 1985; Saksela and Rifkin,
1988; Andreasen et al., 1990; Blasi et al., 1990; Besser et al., 1996). The control
of expression of these components occurs at both transcriptional and
posttranscriptional levels (Vassalli et al., 1991). In brief, under normal
physiological conditions, complex regulation of plasminogen activators and PAIs
synthesis allows this system to be precisely controlled in time and space and in
a manner that depends upon hormones and growth factor balance and other
microenvironmental conditions.
In cancer, the precise regulation of the plasminogen activation system
appears to be lost or modified. Early studies provided evidence for the particular
involvement of uPA in the invasive and metastatic properties of malignant
tumours. These include the close correlation between oncogene transformation
and high increase in uPA synthesis (Unkeless et al., 1973; Unkeless et al.,
1974), the immunohistochemical localisation of uPA in invading areas of
tumours (Skriver et al., 1984; Grøndahl-Hansen et al., 1991) and the inhibition
of cellular invasion and metastasis by anti-catalytic antibodies to uPA in model
systems (Ossowski and Reich, 1983; Mignatti et al., 1986; Hearing et al., 1988;
Ossowski, 1988; Reich et al., 1988). During the last two decades, an
overwhelming number of reports implicate the important role of the
plasminogen activation pathway in cancer invasion and metastasis in vitro and
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in vivo. In the space of this thesis, it is impossible to review all the available data
to date which describe the effect of the different components of this pathway on
cancer invasion and metastasis (for detailed reviews refer to Duffy et al., 1999;
Murphy and Gavrilovic, 1999; Andreasen et al., 2000; Dunbar et al., 2000;
Choong and Nadesapillai, 2003; Ranson and Andronicos, 2003; Reuning et al.,
2003a; Reuning et al., 2003b; Rosenberg, 2003; Sidenius and Blasi, 2003). In
summary, in vitro evidence for the role of urokinase plasminogen activation
pathway in cancer metastasis and invasion include: (1) correlation between
metastatic and invasive potential of cancer cells and the expression of uPA,
uPAR and plasminogen binding; (2) retardation of cancer cell migration and
invasion by inhibiting the enzymatic activity of uPA or binding of uPA to uPAR;
(3) increased migration and invasion when cells are transfected with uPAR or
uPA cDNAs whereas migration decreased when uPAR- or uPA-overexpressing
cancer cells are transfected with anti-sense cDNAs and (4) inhibition of invasion
and metastasis when invasive cancer cells are treated with PAI-2 or transfected
with PAI-2 cDNA. In vivo evidence for the role of this pathway in cancer invasion
and metastasis include: (1) correlation between increased uPAR, uPA and PAI-1
expression and plasmin generation with cancer metastasis in animal models; (2)
inhibition of metastatic cancers in animal models when treated with anti-uPA
antibodies or when pre-transfected with uPA anti-sense oligonucleotides; (3)
decreased metastasis in animal models treated with uPA/uPAR binding
antagonists and (4) suppression of tumour growth and invasion in animal
models inoculated with PAI-2 or with invasive cancer cells transfected with PAI2 cDNA.
The established role of the urokinase plasminogen activation pathway in
cancer metastasis and invasion initiated the interest in evaluating its clinical
significance in cancer patients. Early studies established that the level of uPA in
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malignant tumours is significantly higher than that in the corresponding
normal or benign tumours of the same tissue (for reviews see Duffy, 1993a;
Duffy, 1996). A considerable number of studies have since evaluated the
prognostic significance of uPA, uPAR, PAI-1 and PAI-2 in a wide variety of
human cancers. Table I summarises the outcome of such studies undertaken
between 1999 to date. For extensive reviews of studies prior to 1999 concerning
this topic refer to Andreasen et al. (1997), Schmitt et al. (1997), Brunner et al.
(1999), Duffy et al. (1999), Look and Foekens (1999) and Mazar et al. (1999).
uPA and/or PAI-1, as evident in earlier reviews and Table I, appear to be
the most common and best clinical and prognostic factors of the urokinase
plasminogen activation pathways in many cancers including breast, prostate
and colorectal cancers. In fact, the prognostic value of uPA/PAI-1 in axillary
node-negative

breast

cancer

patients

was

recently

validated

through

randomised controlled trials (RCTs). RCTs ensure low risk of incorporating
false-positive or false-negative results, thus uPA/PAI-1 were justified as strong
prognostic markers in breast cancer patients by Level 1 of evidence (LOE-1
which is highest level of evidence) (Duffy, 2004). Assay of uPA and PAI-1 may
therefore help identify high risk node-negative breast cancer patients who would
benefit from adjuvant chemotherapy (Duffy, 2004).

Table I: Clinical significance of components of the plasminogen activation pathway in human cancers
Antigen
Cancer

Multiple myeloma

uPA

● Marker of deeper myometrial
invasion (Gerstein et al., 2003)
(EI)

● Urinary uPA has prognostic ability
(Shariat et al., 2003a)
(ELISA and EI)

Bladder cancer

Pancreatic cancer

Prostate cancer

● Serum uPA level is an
independent predictor of poor
outcome (Shariat et al., 2003b)
(ELISA)
● Potential prognostic indicator
(Harvey et al., 2003)
(IHC and ISH)

● Serum levels alone or with uPAR
could be predictor of progression
and prognosis (Miyake et al., 1999a;
Miyake et al., 1999b)
(ELISA)

PAI-1

uPAR

PAI-2

● Soluble uPAR in plasma predicts
extra-bone marrow involvement and
poor prognosis (Rigolin et al., 2003)
(IF)
● High levels of soluble uPAR
independent factor predicting worse
prognosis (Bene et al., 2004)
(VA)

● uPAR has prognostic ability
(Shariat et al., 2003a)
(ELISA and EI)

● uPAR overexpression correlates
with poorer survival (Harvey et al.,
2003)
(IHC and ISH)
● Serum levels alone or with uPA
could be predictor of progression
and prognosis (Miyake et al., 1999a;
Miyake et al., 1999b)
(ELISA)
● Serum levels of soluble uPAR is a
possible diagnostic marker for early
detection (McCabe et al., 2000)
(ELISA)

Table continues …
EI: enzyme immunoassays; IFA: Immunofluorescent assays (e.g. flow cytometry); ELISA: enzyme-linked immunosorbent assay; IHC: immunohistochemistry; ISH: in situ
hybridization; EA: enzymatic assay; NB: northern blots; RT-PCR: reverse transcription-PCR; IRA: Immuonoradioactivity assay; VA: Various Assays (generally a review article)

Antigen
Cancer

Ovarian cancer

Melanoma

Gastric cancer

uPA

PAI-1

● Strong prognostic relevance
(Konecny et al., 2001)
(ELISA)

● Plasma levels correlate with
presence of malignancy and higher
stage of disease (Ho et al., 1999)
(ELISA)
● Statistically independent strong
prognostic factor (Kuhn et al., 1999)
(ELISA)
● Predictor for overall survival
(Tecimer et al., 2000)
(ELISA)
● Strong prognostic relevance
(Konecny et al., 2001)
(ELISA)

● Provides significant additional
prognostic information (Stabuc et al.,
2003)
(ELISA)

● Provides significant additional
prognostic information (Stabuc et al.,
2003)
(ELISA)

● uPA enzymatic activity is a
prognostic factor (Okusa et al.,
1999)
(EA and IHC)
● Associated with a poor outcome
(Kaneko et al., 2003)
(IHC)

uPAR

● Correlated with tumour size,
depth, lymph node involvement,
differentiation and vascular invasion
(Kaneko et al., 2003)
(IHC)

● Correlated with tumour size,
depth, lymph node involvement,
differentiation and vascular invasion
(Kaneko et al., 2003)
(IHC)

Hepatocellular
carcinoma

● Increased and related to
invasiveness, metastasis and poor
prognosis (Zheng et al., 2000)
(IHC and NB)

● Contributes to the invasion,
metastasis and prognosis (Zheng et
al., 2000)
(IHC and NB)

● Increased and related to
invasiveness, metastasis and poor
prognosis (Zheng et al., 2000)
(IHC and NB)

Colon cancer

● Increase in tumour and serum
levels is associated with a worse
prognosis (Berger, 2002)
(VA)

● Increase in tumour and serum
levels is associated with a worse
prognosis (Berger, 2002)
(VA)

● Increase in tumour and serum
levels is associated with a worse
prognosis (Berger, 2002)
(VA)

PAI-2

Table continues …
EI: enzyme immunoassays; IFA: Immunofluorescent assays (e.g. flow cytometry); ELISA: enzyme-linked immunosorbent assay; IHC: immunohistochemistry; ISH: in situ
hybridization; EA: enzymatic assay; NB: northern blots; RT-PCR: reverse transcription-PCR; IRA: Immuonoradioactivity assay; VA: Various Assays (generally a review article)

Antigen
Cancer

uPA

PAI-1

uPAR

PAI-2

Colorectal cancer

● Combined analysis of uPA and
PAI-1 is a useful prognostic factor
(Fujii et al., 1999)
(IHC and RT-PCR)
● Major prognostic impact
(Herszenyi et al., 1999)
(ELISA)
● Independent prognostic factors
(Yang et al., 2000)
(IHC)
● Marker of late stages of this
cancer (Papadopoulou et al., 2002)
(ELISA and IHC)

● PAI-1 level over uPAR or uPARbound uPA associate with tumour
progression (Abe et al., 1999)
(ELISA)
● Combined analysis of uPA and
PAI-1 is a useful prognostic factor
(Fujii et al., 1999)
(IHC and RT-PCR)
● Major prognostic impact
(Herszenyi et al., 1999)
(ELISA)
● Marker of later stages
(Papadopoulou et al., 2002)
(ELISA and IHC)
● PAI-1 genotype may be a useful
prognostic marker (Loktionov et al.,
2003)
(Genotyping)

● Higher expression related to poor
prognosis (Abe et al., 1999)
(ELISA)
● Plasma level of soluble uPAR
independently predict survival
(Stephens et al., 1999)
(ELISA)
● Independent prognostic factors
(Yang et al., 2000)
(IHC)
● Soluble uPAR has an independent
prognostic information in rectal
cancer patients and high values
associate with shorter survival
(Fernebro et al., 2001)
(ELISA)

Endometrial
cancer

● Elevated levels correlate with
unfavourable prognosis (Taponeco
et al., 2001; Tecimer et al., 2001)
(ELISA and IHC)
● High level correlates with unfavourable prognosis (Gerstein et
al., 2003)
(EI)

● Elevated levels appear correlated
with unfavourable prognosis
(Taponeco et al., 2001; Tecimer et
al., 2001)
(ELISA and IHC)

● Useful prognostic marker for
biologically aggressive forms
(Memarzadeh et al., 2002)
(IHC)

● High tumour tissue concentration
independent marker for shorter
progression-free survival
(Nordengren et al., 2002)
(ELISA)

● Parameter for prediction of
prognosis (Sakakibara et al., 2004)
(RT-PCR)

● Elevated levels of soluble uPAR in
plasma, but not significantly
correlated to metastasis or
recurrence (Schmidt and Hoppe,
1999)
(ELISA)

● Expression of PAI-2 in fibroblasts
surrounding these carcinomas is
protective (Shiomi et al., 2000)
(IHC and ISH)

Squamous cell
carcinoma

● Predictive of poor survival
(Shiomi et al., 2000)
(IHC and ISH)
● Tumour and serum levels
potentially predict survival
probability (Strojan et al., 2000)
(ELISA and IRA)

Table continues …
EI: enzyme immunoassays; IFA: Immunofluorescent assays (e.g. flow cytometry); ELISA: enzyme-linked immunosorbent assay; IHC: immunohistochemistry; ISH: in situ
hybridization; EA: enzymatic assay; NB: northern blots; RT-PCR: reverse transcription-PCR; IRA: Immuonoradioactivity assay; VA: Various Assays (generally a review article)

Antigen
Cancer

Breast cancer

uPA

PAI-1

uPAR

● Prognostic role (de Witte et al.,
1999b)
(ELISA)
● Independent predictive factors of
poor overall survival and relapsefree survival (Foekens et al., 2000)
(ELISA)
● Clinical relevance and prognosis is
best when combined with PAI-1
(Harbeck et al., 2002a; Harbeck et
al., 2002b)
(ELISA)
● High cytosolic levels correlate
significantly with shorter diseasefree survival (Levicar et al., 2002)
(ELISA)
● Independent prognostic value in
primary breast cancer (Look et al.,
2002; Luqmani et al., 2002)
(VA)
● Cytosolic levels at diagnosis may
be predictive of early relapse in
primary cancer (Dazzi et al., 2003)
(ELISA)
● Prognostic marker validated by
level-1-evidence for node-negative
patients (Qin et al., 2003a;
Thomssen et al., 2003; Duffy, 2004)
(VA and ELISA for Qin et al.)

● Prognostic role (de Witte et al.,
1999a; de Witte et al., 1999b)
(ELISA)
● Tumour-associated levels as
independent prognostic information
in a follow-up period of ~10 years
(Harbeck et al., 1999a; Harbeck et
al., 1999b; Harbeck et al., 2000)
(EI and ELISA)
● Independent predictive factors of a
poor overall survival and relapsefree survival (Foekens et al., 2000)
● Patients with low levels of PAI-1
have better disease-free survival
(Borstnar et al., 2002)
(ELISA)
● Clinical relevance and prognosis is
best when combined with uPA
(Harbeck et al., 2002a; Harbeck et
al., 2002b)
● High cytosolic levels correlate
significantly with shorter diseasefree survival (Levicar et al., 2002)
● Independent prognostic value in
primary cancer (Cufer et al., 2002;
Look et al., 2002; Luqmani et al.,
2002)
● Independent prognostic marker for
recurrence-free survival in primary
cancer (Hansen et al., 2003)
(IHC and ELISA)
● Prognostic marker validated by
level-1-evidence for axillary nodenegative patients (Qin et al., 2003a;
Qin et al., 2003b; Thomssen et al.,
2003; Duffy, 2004)
(VA and ELISA for Qin et al.)

● Elevated levels of cytosolic uPAR
is an independent predictors of poor
overall survival and relapse-free
survival (de Witte et al., 2001)
(ELISA)
● Increased uPAR mRNA in primary
cancer may be a predictor of poor
overall survival (Pacheco et al.,
2001)
(NB)
● High level of age-dependent
soluble uPAR in serum
independently associate with poor
outcome (Riisbro et al., 2002)
(ELISA)
● uPAR provides useful information
for cancer diagnosis and prognosis
(Qin et al., 2003a)
(ELISA)

PAI-2

● Intermediate and low levels show
poor overall survival and relapsefree survival (Foekens et al., 2000)
(ELISA)
● Patients with high levels of PAI-2
have better disease-free survival
(Borstnar et al., 2002)
(ELISA)

EI: enzyme immunoassays; IFA: Immunofluorescent assays (e.g. flow cytometry); ELISA: enzyme-linked immunosorbent assay; IHC: immunohistochemistry; ISH: in situ
hybridization; EA: enzymatic assay; NB: northern blots; RT-PCR: reverse transcription-PCR; IRA: Immuonoradioactivity assay; VA: Various Assays (generally a review article)

53

1.8. UROKINASE

PLASMINOGEN ACTIVATION PATHWAY AND CANCER

THERAPY
The identification of strong tumour cell markers, especially to identify
metastatic cells, is one of the main directives of cancer research. Since the
leading cause of cancer-related mortality is the inability to control the spread of
malignant tumours (Woodhouse et al., 1997), characterisation of strong
tumour/malignancy markers is vital for therapeutic targeting purposes. It is
beyond the scope of this thesis to review the efforts and the success of studies
endeavouring to identify such markers (see review by Dubowchik and Walker,
1999). As discussed in the previous section (Section 1.7.), uPA appears be a
strong marker of cancer progression and metastasis and is currently validated
by LEO-1 as a clinical and prognostic marker in breast cancer (Duffy, 2004) and
may be validated for other human cancers in the near future. Modulation of
uPA expression and the use of antagonist of the uPA/uPAR binding have shown
success in regulating cancer metastasis and invasion (Crowley et al., 1993;
Achbarou et al., 1994; Wilhelm et al., 1995; Min et al., 1996; Shapiro et al.,
1996). The therapeutic potential of modulating gene expression in humans is
limited due to the requirement of cancer cell-specific gene delivery methods.
Thus, antagonists of the uPA/uPAR binding or uPA inhibitors, natural (e.g. PAI2) or engineered (see review by Rockway et al., 2002), seem more feasible for
clinical

applications.

Although

such

antagonists/inhibitors

may

be

administered to inhibit tumour growth, migration or differentiation, tactics such
as cytotoxins or toxic radiation for the killing and clearance of tumour cells
present more valuable curative advantages.
Several

biological

and

chemical

agents

with

different

cytotoxic

mechanisms are readily available for the targeted or non-targeted killing of cells.
A particular targeted uPA-based anti-cancer strategy involves the production of
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uPA-toxin conjugates. Examples of such successful strategies include uPAPseudomonas exotoxin (PE) (Rajagopal and Kreitman, 2000), ATF-saporin (plant
ribosome-inactivating protein) (Cavallaro et al., 1993; Fabbrini et al., 1997;
Fabbrini et al., 2000), ATF-Diphtheria toxin (DT) (Vallera et al., 2002;
Rustamzadeh et al., 2003) and PAI-1-(A-chain)Cholera toxin (Jankun, 1992)
conjugates. Another example of uPA-based therapy is a recombinant fusion
protein consisting of anthrax toxin lethal factor and Pseudomonas exotoxin
which is engineered to be only cleaved and internalised by uPA-overexpressing
cells (Liu et al., 2001; Ye et al., 2003).
Alternatively,

new

hopes

for

cancer

therapy

arise

from

recent

characterisation of radionuclides with favourable radiophysical states which are
efficient for cytotoxic targeting. γ-emitting radionuclides are widely used for
radioimaging; however, γ rays do not contribute significantly to therapeutic
efficacy (Chatal and Hoefnagel, 1999). Isotopes emitting β particles are more
often used for therapy (e.g.

131Iodine, 90Yttrium, 186Rhenium,

and

67Copper)

and

are characterised by low linear energy transfer released over a relatively long
distance, resulting in inefficient local killing of target cells coupled with toxicity
to distant normal tissues (Waldmann, 1991; Bender et al., 1992; O'Donoghue et
al., 1995; Griffiths et al., 1999). On the other hand, α-emitting radionuclides
release high-energy emissions (6 - 9 Mega electron volts [MeV]; ten times as
great as β- or γ-emitters) over a short distance (40 to 80 µm) (Waldmann, 1991;
Behr et al., 1998; Behr et al., 1999; Chatal and Hoefnagel, 1999; Griffiths et al.,
1999). Thus, using α-emitters, much greater fraction of the total energy is
deposited in the targeted cells and very few nuclear hits are required to kill
these cells (Lloyd et al., 1979; Kassis et al., 1986). Monoclonal antibodies
conjugated to metal chelators, such as cDTPA or its derivates, and labelled with
α–emitting radionuclides (e.g.

213Bismuth

and

211Astatine)

are starting to show
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promise in radio-immunotherapy. In preclinical studies, McDevitt et al. (2000)
and Nikula et al. (1999) have proven the efficacy of

213Bismuth-labelled

monoclonal antibodies for radio-immunotherapy of prostate cancer and
leukaemia and are conducting a phase I trial for end stage leukaemia (Jurcic et
al., 2002).

213Bismuth-labelled

antibody has been validated for radio-

immunotherapy of multiple myeloma (bone marrow cancer) (Couturier et al.,
1999).

211Astatine-labelled

antibodies have been used clinically in a phase I trial

to treat malignant gliomas in humans (Zalutsky and Vaidyanathan, 2000).
There are many other examples of the use of DTPA or its derivatives for
chelating metals to agents used for imaging or targeting α-radiation to tumours
(targeted alpha therapy, TAT) (Merlo et al., 1997; Boerman et al., 1999; GruazGuyon et al., 2001; Gulec et al., 2001; McDevitt et al., 2001; Wen et al., 2001).

1.9. RATIONALE AND OBJECTIVES
Given the functional duality (proteolytic and non-proteolytic functions) of
the urokinase plasminogen activation pathway, it is not surprising that this
pathway is critical in processes of cancer invasion and metastasis. Growing
evidence suggest that uPA and PAI-1 co-operate in the migratory process by
facilitating attachment to and subsequent detachment from vitronectin in the
extracellular matrix (Deng et al., 1996; Chapman, 1997; Brooks et al., 2000;
Degryse et al., 2004). In agreement, high levels of uPA and/or PAI-1 have shown
a prognostic significance in many types of cancers (see Section 1.7.). This
invites the clinical use of uPA as a target for therapeutic strategies against
cancer. The low level of PAI-2 in metastatic cancers together with the good
prognosis in cancer patients with high PAI-2 expression indicate the possible
use of PAI-2 for the development of uPA-based targeted therapies. Exogenous
PAI-2 (either as a free molecule or coupled to radionuclides) localises within
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uPA-expressing colon carcinoma xenografts (Hang et al., 1998) and significantly
reduces tumour growth and metastases with no evidence of toxicity (Shinkfield
et al., 1992; Åstedt et al., 1995; Evans and Lin, 1995; Li et al., 2002; Allen et al.,
2003). Thus, despite the presence of PAI-1 in malignant tumours, it is apparent
that uPA is accessible to exogenously administered PAI-2 within several tumour
types in vivo. PAI-2 can specifically access and inhibit uPA while sparing
thrombosis as suggested by the low second order inhibition rate constant
towards tPA and that fibrin-bound tPA is protected from PAI-2 inhibition
(Kruithof et al., 1995). Furthermore, unlike PAI-1 which is subject to oxidation
(Baker et al., 1990b), stable cytotoxin-PAI-2 conjugates may be easily achieved
in vitro (Ranson et al., 2002).
The primary aim of this thesis was to provide further biological rationale
for

the

preliminary success

PAI-2 linked to

213Bismuth

of

the

anti-uPA

targeted

therapy

using

reported by Li et al. (2002), Ranson et al. (2002) and

Allen et al. (2003). This involved the direct in vitro determination of the
inhibition kinetics of cell-surface uPA by PAI-2 on invasive and non-invasive
breast cancer cells. The controversial fate of uPAR-bound uPA:PAI-2 complexes
was also addressed as a part of these studies. An additional aim was to
modulate uPAR-expression in breast cancer cells to assess the role of
uPAR/uPA in the acquisition of metastatic phenotype and extend the analyses
of PAI-2 binding to cells. Lastly, this thesis also aimed to optimising the protocol
used for the preparation of PAI- 2-213Bismuth (α-PAI-2). This involved the
development of standard operating procedures for the conjugation of PAI-2 to
cDTPA and radiolabelling of the conjugate with 213Bismuth for radiotherapy.
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Chapter 2: MATERIALS AND GENERAL CELL AND PROTEIN
ANALYSIS METHODS

2.1. MATERIALS
Lipofectamine™ 2000, pcDNA3 plasmid, RPMI-1640 powder and T7promoter primer were purchased from Invitrogen® Life Technologies, NSW,
Australia. Foetal calf serum (FCS) was obtained from ThermoTrace®, VIC,
Australia. Acetonitrile (100 %), ammonium persulfate, ammonium bicarbonate
(NH4HCO3),

ampicillin,

bovine

serum

albumin

(BSA

fraction

V),

β-

mercaptoethanol, Brilliant Blue R250, bromophenol blue, chloroform, dimethyl
sulfoxide (DMSO), ethidium bromide, ethyldiaminetriacetic acid (EDTA), Hank’s
and phenol red-free Hank’s balanced salt powders, HEPES, hydroiodic acid (HI),
insulin, lysozyme, nitric acid (HNO3), paraformaldehyde, pH strips (pH range 0 14), phenol: chloroform, potassium phosphate (KH2PO4), propidium iodide,
rabbit anti mouse IgG monoclonal antibody (IgG) conjugated to Cy3 or FITC,
sodium monophosphate (Na2HPO4), TEMED, tranexamic acid (TA), Tris-HCl,
trypsin-EDTA, urea and xylene cyanol were purchased from Sigma-Aldrich®,
MO, USA. The colorimetric substrate for uPA Spectrozyme®-UK and mouse
monocolonal antibodies raised against human A-chain uPA (#3921), B-chain
uPA (#394), PAI-2 and uPAR (#3934) were all obtained from American
Diagnostica Inc. (ADI), CT, USA. Another mouse monoclonal antibody raised
against human uPAR (MAB807) was purchased from R&D Systems Inc., MN, USA.
Rabbit anti-human uPAR polyclonal antibody was provided by David Croucher
(School of Biological Sciences, University of Wollongong, Australia). Mouse
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isotype control subclass IgG1 antibody was from Silenus, Sydney, NSW,
Australia. Boric acid, calcium chloride (CaCl2), gelatine powder, glucose, glycine,
magnesium chloride (MgCl2), magnesium sulphate (MgSO4), potassium acetate,
potassium chloride (KCl), sodium acetate, sodium chloride (NaCl) and sodium
dodecyl sulphate (SDS) were obtained from BDH Chemicals Australia Pty. Ltd.,
VIC, Australia. Absolute alcohol, citric acid, isopropanol, glacial acetic acid,
hydrochloric acid (HCl), methanol and sodium hydroxide tablets (NaOH) were
purchased from Ajax Chemicals, NSW, Australia. Agar, bactotryptone, trypton
and yeast extract were obtained from Oxoid Australia Pty Ltd, VIC, Australia.
Hind III, Not I, Pst I and Xho I restriction enzymes and their compatible 10 x
buffers were purchased from Roche Applied Science, IN, USA. The Cy5 monoreactive dye pack, PD-10 columns (Sephadex G-25 columns), T4 DNA ligase and
10 x ligation buffer were from Amersham Biosciences, Uppsala, Sweden.
Qiagen® plasmid midi-prep kit and Superfect® transfection reagent were
purchased from Qiagen Pty Ltd, VIC, Australia. BigDyeTM terminator mix v2.0
was obtained from Applied Biosystems, CA, USA and PAGE-PLUSTM purchased
from Amresco Inc., OH, USA. AG® 501-X8 resin, BioRad® DC protein
concentration assay kit, broad range unstained and prestained markers and
precision plus unstained marker were from BioRad Laboratories Inc., CA, USA.
Prestained protein ladder marker (10 – 160 kDa) was obtained from Fermentas
Inc., MD, USA. Agarose, glycerol and polyacrylamide were purchased from
Progen

Industries

Limited,

QLD,

Australia.

Human

recombinant

PAI-2

(molecular weight 47 kDa) and Actisolv uPA were provided by PAI-2 Pty Ltd,
Sydney, Australia. Iodo-beads were purchased from Pierce Chem. Co., IL, USA.
Iodine-125 (125I) was obtained from PerkinElmerTM, MA, USA. Actinium-225
(225Ac) and prepacked columns containing resin (AG® 50W-X4) were purchased
from the Oak Ridge National Laboratory, United States Department of Energy,
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USA. Whatman #1 filter paper was purchased from Whatman International Ltd.,
Kent, UK. Cyclic anhydride diethylenetriaminepentacetic acid (cDTPA) was
purchased from MP Biomedicals Inc., formerly ICN Biomedicals, CA, USA. GluPlasminogen was purified from human plasma and conjugated to FITC and Cy5
as described earlier (Andronicos et al., 1997). uPA and the goat anti-human uPA
polyclonal antibody were obtained from Chemicon® International, CA, USA.
LysoTracker® Yellow DND-68 and transferrin-Alexa488 were purchased from
Molecular Probes, Inc., OR, USA. Lambda (λ) DNA and the CellTitre 96®
AQueous Non-Radioactive Cell Proliferation Assay were obtained from Promega®
Corporation, WI, USA. Instant thin layer chromatography (ITLC-SG) strips were
purchased from Gelman Science, MI, USA. The 0.22 µm sterile filter units and
the 30 kDa cut-off microconcentrators were obtained from Millipore, MA, USA.
Gamma (γ) counter tubes were purchased from Sarstedt®, NSW, Australia.
AtomLab 200 dose calibrator was purchased from Pinestar Technology Inc., PA,
USA.

2.2. GENERAL METHODS†
2.2.A. TISSUE CULTURE AND ANALYSIS
2.2.A.1. CELL LINES
The human breast cancer cell lines - MDA-MB-231, T-47D and MCF-7
(American Type Culture Collection, ATCC®, VA, USA) - were routinely cultured
at 37oC in a Heracell incubator (Kendro® Laboratory Products, Langenselbold,
Germany) in atmospheric air containing humidified 5 % CO2. Cells were grown
in culture media [10.4 g/l of RPMI-1640 and 2 g/l sodium bicarbonate; solution
was adjusted to pH 7.2 and filter-sterilised using 0.22 µm sterile filters units].

† All buffers and solutions in this thesis are described in alphabetical order in Appendix
4 (Section 7.4.)
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Culture media was supplemented with 5 % (v/v) foetal calf serum (FCS) and
T-47D cells were also supplemented with 0.26 units/ml insulin. Cells were
routinely passaged at confluency using Trypsin-EDTA. The MDA-MB-231 cell
line has been shown previously to display a metastatic phenotype (high uPA,
uPAR and plasminogen binding and activation capacity) and metastasise in
nude mouse models (Andronicos et al., 1997; Ranson et al., 1998; Li et al.,
2002). The T-47D and MCF-7 cells display a non-metastatic phenotype (low
uPA, uPAR, plasminogen binding and activation capacity) (Ranson et al., 1998).
All cell experiments were performed using cells cultured for 48 – 72 h
without a change of media. Cells were detached using sterile 1 x phosphate
buffered saline (PBS) containing 5 mM EDTA [PBS: 8 g/l NaCl, 0.2 g/l KCl, 1.44
g/l Na2HPO4, 0.24 g/l KH2PO4; pH adjusted to 7.4; then EDTA was added at 5
mM final concentration]. Detached cells were centrifuged at 652 x g for 3 min at
4oC and cell pellets were washed and resuspended at 1 x 106 cells/ml in ice-cold
binding buffer [Hank’s buffered saline solution: 9.5 g/l Hank’s powder, 1 mM
HEPES and 0.1 % w/v bovine serum albumin (BSA); 1 mM CaCl2 and 1 mM
MgCl2; pH 7.4]. Cell and viability were assessed by trypan blue exclusion and
visualisation in hemocytometer. Unless specified otherwise, all surface pro-uPA
was activated by incubation of cells at 1 x 106 cells/ml for 5 min at room
temperature (RT) with 5 µg/ml plasminogen solution in RPMI-1640, washed
then resuspended at 1 x 106 cells/ml in binding buffer for further
experimentation.
2.2.A.2. FLOW CYTOMETRY
Cell-surface antigens were detected by indirect immunofluorescence
staining as previously described (Ranson et al., 1998). The concentration and
the specificity of the primary and secondary antibodies used are specified in the
Figure legends. Plasminogen binding was detected directly using 50 µg/ml
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plasminogen-FITC conjugate in the absence or presence of 1 mM tranexamic
acid (TA, a lysine analogue) as described by Ranson et al. (1998). Plasminogen
was purified from human plasma and conjugated with FITC as described by
Andronicos et al. (1997). After the direct and indirect staining, cells were
washed and resuspended in PBS containing 1 mM CaCl2 and 1 mM MgCl2 and
the vital fluorescent stain propidium iodide (PI) at 5 µg/ml. Flow data was
acquired using the Becton-Dickinson FACSCalibur™ flow cytometry system (BD
Biosciences, CA, USA) and the instrument calibrated with reference settings for
each cell line. Cell-associated fluorescence was measured by dual-colour flow
cytometry which allows a differentiation between cell-surface and total
fluorescence (Ranson et al., 1998). Briefly, PI positive cells (non-viable) were
excluded from the remaining cells which were intact (PI negative) and hence
indicate cell-surface detection. Flow cytometry data was analysed using WinMDI
v2.8 (Scripps Research Institute, CA, USA) and only viable cell-associated
fluorescence are reported.
2.2.A.3. CONFOCAL MICROSCOPY
Confocal microscopy was used to visualise the distribution and
localisation of cell-surface and internalised antigens. For assays on attached
cells, these cells were cultured for 48 – 72 h on sterile glass-slide cover slips,
washed and blocked for 1 h at room temperature with phenol red-free binding
buffer [prepared as for normal binding buffer however using phenol red-free
Hank’s powder]. Cells were gently washed using ice cold PBS containing 1 mM
CaCl2 and 1 mM MgCl2 before staining. For assays with suspension cells, 48 hcultures were detached with EDTA and washed with ice cold PBS containing 1
mM CaCl2 and 1 mM MgCl2 before staining. Staining assays were performed
using antibodies or fluorochrome-conjugated antigens which are specified for
each assay. Generally, in staining assays involving plasminogen binding, cells
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were first incubated with 50 µg/ml plasminogen-Cy5 [prepared as described by
Andronicos and Ranson (2001)] for 1 h on ice in the absence or presence of 5
mM TA. Cells were then washed 3 x 5 min incubation in ice-cold phenol red-free
binding buffer. For double staining assays, cells were then incubated for 30 min
on ice in 20 µg/ml of primary antibody, washed three times as described earlier
and then incubated for 30 min on ice in 1:50 dilution of secondary antibody
(anti-immunoglobulin antibodies conjugated to FITC or Cy3) in phenol red-free
binding buffer. Cells were washed and cover slips were air-dried and mounted
on glass slide using mounting buffer [1 x PBS containing 1 mM CaCl2 and 1 mM
MgCl2 and 10 % glycerol]. Cells were not fixed prior staining as earlier assays
found cell-fixing (using paraformaldehyde) resulted in disruption of cell-surface
and reduced cell viability (data not shown), thus slides were analysed
immediately.
All confocal laser scanning microscopy images were acquired using a
Leica TCS SP system and the UV 63x1.32 NA oil PLAPO immersion objective
lens (Leica, Heidlberg, Germany). FITC and Cy3 fluorochromes were excited
using the 488 nm and the 583 nm spectral lines of the Argon ion laser,
respectively. Cy5 fluorochrome was excited with the 633 nm spectral line of the
Helium-Neon laser. The emissions of Cy3, FITC and Cy5 were collected at 525540 nm, 545-560 nm, and greater than 650 nm, respectively. Furthermore,
transferrin-Alexa488 and LysoTracker® Yellow DND-68 were excited using the
488 nm spectral line of the Argon ion laser and their emissions were collected at
510-530 and 545-560 nm, respectively. The signal from each of the
fluorchromes used did not leak into the channels used for detection of the other
fluorochromes. All confocal images were analysed and manipulated using the
softwares Volocity (version 2.0.1 Build 85, Improvision Ltd., MA, USA) and
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Confocal Assistant (version 4.02 Build 101, developed by Todd Clark Brelje,
University of Minnesota, MN, USA).
2.2.A.4. CELL PROLIFERATION/CYTOTOXICITY ASSAYS
Cell proliferation was determined using the colorimetric CellTitre 96®
AQueous Non-Radioactive Cell Proliferation Assay (Promega® Corporation, WI,
USA).

This

assay

is

based

on

the

conversion

of

the

substrate

3-(4,5–dimethylthiazol–2-yl)-5-(3-carboxymethoxyphenyl)–2-(4-sulfophenyl)-2Htetrazolium/phenazine methosulfate (MTS/PMS) to a coloured product by
metabolically active cells. The effect of various agents on cell proliferation was
also determined using this assay since cytotoxic or proliferative agents result in
modulation of metabolism.
In order to establish the relationship between cell number and
absorbance of the product produced from the substrate of this assay, increasing
number of cells was transferred in triplicate to 96-wells plate in a final 100 µl of
phenol red-free binding buffer containing 5 % (v/v) FCS. The assay substrate,
MTS/PMS (20 µl), was added to cell solutions in addition to control triplicate
wells containing 100 µl of phenol red-free binding buffer only. The plate was
incubated at 37oC in the humidified 5 % CO2 incubator for 3 h and then the
absorbance at 490 nm was measured using the Spectramax® 250 UV plate
reader (Molecular Devices Corporation, CA, USA). A standard curve for the
relationship between cell number and absorbance was constructed after
blanking all values to the absorbance reading of control wells. Further cell
proliferation assays were performed using the number of cells which falls in the
linear range of the correlation between cell number and the absorbance of the
product from the breakdown of the MTS/PMS substrate.
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2.2.B. PROTEIN ANALYSIS METHODS
2.2.B.1. PROTEIN CONCENTRATION ASSAY
The BioRad® DC protein concentration assay kit was used to determine
the concentration of protein samples against standard BSA solutions. Aliquots
(5 µl) of standard BSA solutions (0 - 1 mg/ml in PBS) and protein samples were
added in duplicates to 96-wells plate. For each well, 25 µl of Reagent A from the
kit was added and then two 100 µl volumes of Reagent B were mixed. The plate
was stored on ice for 5 min for maximal colour development and the absorbance
of all wells was measures at 750 nm using the Spectramax® 250 plate reader.
The concentrations of protein samples were interpolated using the curve
constructed from the standard BSA solutions and their absorbencies.
2.2.B.2. SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)
PAGE, unless otherwise specified, was performed using gels composed of
4 % stacking gel and 12 % resolving gels as per Laemmli (1970). Briefly,
resolving gel [12 % v/v of liquid 40 % acrylamide, 0.1 % w/v sodium dodecyl
sulphate (SDS), 375 mM Tris-HCl pH 8.8, 0.1 % v/v TEMED and 0.05 % w/v
ammonium persulphate (APS)] was poured and set. Stacking gel [4 % v/v of
liquid 40 % acrylamide; 126 mM Tris-HCl pH 6.8; 0.1 % w/v SDS; 0.1 % v/v
TEMED and 0.05 % w/v APS] was poured on top of stacking gel and a comb
was inserted to form wells. Samples for PAGE were prepared in a 20 µl final
volume and 5 µl of 5 x non-reducing sample buffer was added [60 mM Tris-HCl;
2 % w/v SDS; 10 % v/v glycerol; 0.01 % w/v bromophenol blue]. For reducing
conditions 5 µl of 5 x reducing sample buffer [non-reducing sample buffer but
including 5 % w/v 2-β-mercaptoethanol] was added and samples were boiled for
5 min. Electrophoresis was carried out for 1 h at 150 volts against 15 µl of SDS-
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PAGE markers (specified for each gel) using 1 x running buffer [3.03 g/l Tris,
14.4 g/l glycine and 1 g/l SDS]. Gels were stained overnight in Coomassie blue
stain [0.1 % w/v Brilliant Blue R250, 40 % v/v methanol and 10 % v/v glacial
acetic acid]. Gels were destained in destain buffer [40 % methanol and 10%
glacial acetic acid] and documented using the Novex® Gel Document System
(Novel Experimental Technology, CA, USA). Gels were analysed by the software
LabImage® (version 2.62, Labsoft Diagnostics AG, Germany). Standard curves
were constructed for the relationship between the size of bands in the molecular
marker lane and the distance travelled by these bands. The molecular weights
of bands observed on the gel were interpolated from these standard curves.
2.2.B.3. RADIO- AND FLUORO-IMAGING OF SDS-PAGE GELS
The Storm® scanner (Molecular Dynamics, Amersham Biosciences,
Uppsala, Sweden) was used to acquire images of SDS-PAGE gels used to
analyse radiolabelled or fluorochrome-conjugated proteins. In the case of
radiolabelled proteins, the SDS-PAGE gel was exposed to a phosphor screen
(Molecular Dynamics, Amersham Biosciences, Uppsala, Sweden) for 3 h prior to
Coomassie blue staining. The phosphor screen was scanned at 100 micron
resolution

using

the

phosphor

imager

scanner-head.

In

the

case

of

fluorochrome conjugated-proteins (Cy5), the gel was scanned using the red
fluorescence/chemiluminescence scanner-head at 100 micron resolution and
800 volts photomultiplier. Images obtained after scanning were processed with
the associated software (ImageQuantTM, Molecular Dynamics, Amersham
Biosciences, Uppsala, Sweden). SDS-PAGE gels were stained in Coomassie blue
stain solution and destained as described above (Section 2.2.B.2.) then
superimposed on the radio- or fluoro-image of the gels.
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2.2.B.4. CONFIRMATION OF MODIFIED PAI-2 ACTIVITY
The effect of PAI-2 modification on its biological function was determined
by two methods; complex formation with uPA and inhibition of the activity of
uPA. The ability of modified PAI-2 to form SDS-stable complexes with uPA was
compared to unmodified PAI-2 as previously described (Hang et al., 1998;
Ranson et al., 2002). Briefly, modified and unmodified PAI-2 were incubated for
90 min at 37oC with equimolar amount of uPA in a final 20 µl of 1 x PBS, then
fractionated by SDS-PAGE under reducing conditions (see Section 2.2.B.2.).
The activity of modified PAI-2 was investigated by its ability to inhibit
active

uPA

from

acting

on

the

synthetic

colorimetric

uPA

substrate,

Spectrozyme®-UK. Assays were performed in triplicate in 96-wells plate with 150
µl final volume in each well and all solutions were prepared in 0.1 % gelatine
buffer [0.1 g gelatine dissolved in 100 ml of dH2O containing 150 mM NaCl, 20
mM Tris-HCl and adjusted to pH 8.4]. Unmodified and modified PAI-2 or BSA
(negative control) at 2, 1 or 0.1 µg/ml were mixed with 20 IU uPA (100 µl of 200
IU/ml actisolv uPA stock) in a final 150 µl of buffer. Standard curve was
prepared by 1:2 serial dilutions of 20 IU uPA in a final 150 µl of buffer (see
Appendix 3 for example, Section 7.3.). Reactions were incubated at 37oC for 30
min. The Spectrozyme®-UK substrate (50 mM stock in DMSO) was prepared at 2
mM in 0.1 % gelatine buffer and 50 µl aliquots were added to all wells including
a triplicate blank wells (150 µl buffer only). The appearance of coloured product
was assayed kinetically at 37oC for 10 min measuring absorbance at 405 nm
every 15 sec using the Spectramax® plate reader.
2.2.B.5. INSTANT THIN LAYER CHROMATOGRAPHY (ITLC)
Instant thin layer chromatography was generally used for assessing
percentage incorporation of radionuclide by protein or the purity of radiolabelled
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protein from free contaminating radioisotope. Marks were placed 1 cm from
both the bottom and top edges and at the middle of the 1 x 9 cm ITLC-SG strips.
Sample (1 - 2 µl) was applied at the bottom 1 cm-mark and the strip was placed
vertically in a minimal volume of mobile phase (0.1 M citrate pH 5.5, unless
specified otherwise). Chromatography was performed until the solvent reached
the top 1 cm-mark then the strip was cut into two pieces at the middle mark.
The two pieces of each strip were placed in separate gamma counter tubes and
radioactivity was measured. Since protein movement is retarded on these strips,
radionuclide incorporation on the protein or purity was calculated as the
percentage of activity at the bottom section (origin, Ori) over the sum of the
activity at the bottom and top (solvent front, SF) sections.
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Chapter 3: MODULATION OF THE EXPRESSION OF
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR
(UPAR): ASSOCIATED PHENOTYPIC AND FUNCTIONAL
CHARACTERS

3.1. INTRODUCTION
Expression levels of urokinase plasminogen activator (uPA) and its
receptor (uPAR) strongly correlate with a malignant tumour cell phenotype
(Andreasen et al., 1997; Wang, 2001). The role of uPAR as an integral
membrane protein that specifically binds uPA has been long established. More
recently, data suggests that uPA/uPAR may have two complementary
functions; the established role as an activator of the proteolytic cascade on the
surface of cancer cells (reviews by Mignatti and Rifkin, 1993; Andreasen et al.,
1997) and another non-proteolytic role as a component of a signal transducing
assembly and cell adhesion factor (Busso et al., 1994; Chapman, 1997; Fazioli
et al., 1997).
Expression of the various components of the plasminogen activation
system is under regulation by hormones, cytokines and growth factors both
under normal physiological conditions and during cancer. For example, the
cytokines interleukin-2 (IL-2) and interleukin-1β (IL-1β) up-regulate both uPA
and uPAR (Ogura et al., 2001; Al-Atrash et al., 2002). Basic fibroblast growth
factor (bFGF) or transforming growth factor (TGF)-alpha increase invasion
activity and associate with increases in cellular mRNA levels of uPA and uPAR
(Mori et al., 2000). The upregulation of uPA and uPAR by these, and other
factors, is mediated largely by classical mitogenic signalling pathways (Aguirre
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Ghiso et al., 1999a). Evidence suggests that upon experimental oncogenic
transformation or in spontaneous human cancers, mitogenesis and expression
of uPA and uPAR are activated through common signalling complexes and
pathways (Aguirre Ghiso et al., 1999a). Interestingly, several examples of these
mitogenic signalling pathways have been shown to be activated by uPA
binding to uPAR and/or the interaction of uPAR with integrins and/or
vitronectin and mediate the role of uPA/uPAR in cancer invasion and
metastasis. The activation of these pathways have been described by the
interaction of several adaptors such as integrins, calveolin and G-proteincoupled receptor (GPCR) with uPAR (reviewed by Ossowski and Aguirre-Ghiso,
2000; Blasi and Carmeliet, 2002).
The ability to modulate the expression of physiologically important
proteins in cultured mammalian cells after delivering the encoding cDNA or
mRNAs (transfection) have important applications for analysing their in vivo
functions. Utilising these techniques, early in vitro and in vivo studies
investigated the role of uPA/uPAR in cancer invasion and metastasis. For
example, uPAR downregulation via anti-sense transfection techniques delivery of anti-sense cDNA or mRNA - renders many human cancers dormant
(Kook et al., 1994; Mohanam et al., 1997; Yu et al., 1997; Mohan et al., 1999;
Lakka et al., 2001; Liao et al., 2001; Wang et al., 2001). Such studies showed
that, as an activator of the proteolytic cascade, uPA/uPAR enhances local
invasion, intravasation and metastasis formation (for more details and
examples see Andreasen et al., 1997). While these early studies addressed the
end-point result on cancer invasion and metastasis, a growing number of
investigations are interested in understanding the mechanisms underlying the
effects of modulating the expression of uPA/uPAR. For example, evidence
suggests

that

uPAR

downregulation

leads

to

abolishment

of
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uPA/uPAR/integrin(α5β1)–dependent
extracellular

signal-regulated

signal

transduction;

kinase/mitogen-activated

reducing
protein

the

kinase

(ERK/MAPK) pathway activation (Aguirre Ghiso et al., 1999b) or focal adhesion
kinase (FAK) mitogenic signalling (Aguirre Ghiso, 2002) and resulting in
cancer cell dormancy. In contrast, overexpression of uPAR through its
interaction with integrins is responsible for generating a feedback loop where
ERK activity increases and this feeds back by increasing the expression of
uPAR (Aguirre-Ghiso et al., 2001). A similar positive feedback loop is also
activated by the binding of uPA to uPAR that activates ERK signalling which in
turn increases uPAR on the cell surface (Ma et al., 2001). In addition to
activation of ERK proteins, binding of uPA to uPAR activates myosin light
chain kinase (MLCK) thus affecting cell motility (Nguyen et al., 1999). The level
of uPAR occupancy affects cysteine- and metallo-protease expression during
macrophage differentiation (Rao et al., 1995) which is mediated by activation
of FAK and MAPK following the occupancy of uPAR by uPA (Tang et al., 1998).
Given the crosstalk between uPA/uPAR and other cell-surface adaptors (e.g.
integrins), extracellular proteins (e.g. vitronectin) and intracellular signalling
pathways, modulation of uPAR expression is expected to affect various cellsurface markers and cell behaviour including the ability to bind uPA-inhibitors
e.g. PAI-2.

3.1.A. RATIONALE AND AIMS
The aim of this chapter was to modulate the expression of uPAR on
invasive

and

non-invasive

breast

cancer

cell

lines

using

transfection

methodology. This involved the cloning of uPAR cDNA in sense and antisense
orientations into an expression vector and then extensive optimisation of
transfection protocols for the different cell lines used. The transfected cells were
used for PAI-2 binding studies (see Chapter 4) and also provided materials for
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studies concerning the relationship between uPA/uPAR overexpression and
plasminogen binding capacity on cancer cells (Stillfried, G., Al-Ejeh, F. and
Ranson, M., manuscript in preparation).

3.2. METHODS
3.2.A. BIOINFORMATICS TOOLS
The sequence of human uPAR cDNA (ID: X51675 Roldan et al., 1990),
and pBSM13+ were obtained from the National Centre for Biotechnology
Information (NCBI). Sequence alignments were performed using ClustalW®
(version 1.7, Thompson et al., 1994). Restriction enzyme sites on DNA stretches
were detected using the software pDRAW32 (the DNA analysis software version
1.1.61 by AcaClone® software). The software pDRAW32 was also used for
drawing maps of plasmids and genes based on their sequences.

3.2.B. PRODUCTION OF PLASMID CONSTRUCTS AND ANALYSIS
3.2.B.1. AGAROSE GEL ELECTROPHORESIS
Electrophoresis was performed using specified volumes of DNA with DNA
sample buffer [5 x concentration: 30 % glycerol; 0.125 % w/v xylene cyanol,
0.125 % w/v bromophenol blue]. The molecular weight marker, λDNA digested
with Hind III restriction enzyme (lab preparation at 37 ng/µl), was mixed (5 µl)
with 1 µl of 5 x DNA sample buffer. Solutions were loaded onto a set agarose gel
[1.2 % w/v agarose dissolved in 1 x Tris-Borate-EDTA (TBE) buffer].
Electrophoresis was performed at 70 volts for 1 h in 1 x TBE [10 x buffer
prepared at 108 g/l Tris-HCl; 55 g/l boric acid, 40 mM EDTA pH 8.0 and
diluted 1 in 10 for use at 1 x concentration]. Gels were stained in 1 µg/ml
ethidium bromide solution for 30 min, destain in distilled water (dH2O) for 30
min or more (as required) then visualised and documented using the Novex® gel
document system.
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All gels were analysed using Gel-Pro Analyzer™ software (version 3.1,
Media Cybernetics, MD, USA). A standard curve was constructed for the
relationship between the distance travelled and the molecular weight of the
bands in the molecular weight marker lane. The sizes of bands in samples
loaded were interpolated from this standard curve. Similarly, a standard
calibration curve was constructed for the relationship between the amount of
bands in the molecular weight marker and the intensity of their staining. The
amount of DNA in loaded samples was calculated based on these calibration
curves. Spectrophotometry was used to determine the purity of DNA
preparation expressed as the ratio of absorbance at 260 nm (DNA) to the
absorbance at 280 nm (protein) as per Maniatis et al. (1989).
3.2.B.2. RESTRICTION ENZYME DIGESTION
Analytical restriction enzyme digestions were performed using 2 µg of
DNA, 2 µl of the compatible 10 x restriction enzyme buffer and 1 µl restriction
enzyme (approximately 1000 units) diluted with dH2O to final volume of 20 µl
and mixed gently. The reaction was spot-centrifuged and incubated at 37oC for
3 h or overnight prior to agarose gel electrophoresis (Section 3.2.B.1.). For
preparative restriction enzyme digestion, the volumes and amounts were
increased and incubated at 37oC for 24 h.
3.2.B.3. ELECTROELUTION OF DNA FROM AGAROSE
This was performed as described by Maniatis et al. (1989). Briefly, DNA of
interest was separated using agarose gel electrophoresis followed by ethidium
bromide staining (Section 3.2.B.1.). Stained DNA fragments were visualised
using a hand-held ultra-violet lamp and the bands of interest were excised
using a razor blade. One end of a washed dialysis tube (prepared by boiling in 1
mM EDTA (pH 8.0) for 10 min and then washed in water) was sealed and the
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slice of agarose containing the band of interest was transferred into the tube.
Approximately 350 µl of 1 x TBE buffer was added, enough to keep the excised
agarose in constant contact with buffer. The other end of the dialysis tube was
sealed forming a bag. The bag was immersed in 1 x TBE buffer and
electrophoresis was performed. The hand-held ultra-violet light was used to
visualise the movement of the DNA fragments out of the gel piece and
electrophoresis was stopped. The buffer containing the DNA fragments were
collected and phenol/chloroform extractions followed by ethanol precipitation
with 0.3 M sodium acetate (pH 5.5) were performed as described by Maniatis et
al. (1989).
3.2.B.4. CDNA LIGATION
A mixture was prepared in a final 8.5 µl of dH2O containing 50:1 massratio mixture of insert (uPAR cDNA): linearised cloning vector (pcDNA3) and was
incubated at 45oC for 5 min. The DNA mix was cooled on ice and 1 µl of 10 x
ligation buffer and T4 DNA ligase (0.5 µl of 400 U/µl) were added. Reaction was
incubated at room temperature overnight and then frozen for further use.
3.2.B.5. DYE TERMINATOR CYCLE SEQUENCING
DNA strands were sequenced using an automated ABI 377 sequencer
(Applied Biosystems, CA, USA). Cycle sequencing reactions were carried out as
per manufacturer’s instructions (Applied Biosystems, CA, USA) in final 10 µl
volumes containing 3.5 µl of BigDyeTM terminator mix v2.0, 3.2 µM of primer for
the universal promoter T7, 3 % v/v DMSO and 200 - 300 ng of plasmid DNA.
Thermocycling conditions were one cycle at 95°C for 3 min, followed by 28
cycles at 95°C for 15 sec and 3.5 min at 60°C. Reactions were precipitated by
the addition of 2 µl of DNA precipitation buffer (1.5 M sodium acetate pH 8; 250
mM EDTA) and 10 µl of dH2O. Ice-cold 100 % ethanol was added at five-volumes
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of the reactions and the samples incubated on ice for 5 min. These were
centrifuged at 12500 g for 15 min, supernatant discarded and pellets washed
once with ice-cold 70 % ethanol before air-drying. Reactions were resuspended
in 3.5 µl DNA loading buffer and denatured at 90°C for 3 min before plunging
on ice until running sequencing gel. Sequencing gels were prepared in a final 50
ml volume of dH2O containing 1 x TBE buffer, 6 M Urea and 4.8 % PAGEPLUSTM both deionized with AG® 501-X8 resin. Solutions were filtered using
0.22 µm filters and the gel was polymerized with 35 µl TEMED and 350 µl of 10
% APS.
3.2.B.6. REPARATION

OF

UPAR

SENSE

AND

ANTISENSE

EXPRESSION

VECTORS: RATIONALE OF CDNA CLONING

The pcDNA3 plasmid was used as an expression vector as it contains the
high efficiency Human cytomegalovirus immediate-early (CMV) promoter for
high-level expression in a wide range of mammalian cells (Invitrogen® Life
Technologies, NSW, Australia). The uPAR cDNA insert (Roldan et al., 1990) was
provided as pBluescriptM13+/uPAR+ (pBSM13+/uPAR+) by Professor E. Kruithof
(Geneva). The uPAR cDNA was cloned in the sense orientation into the plasmid
pcDNA3 (Figure 12) (Ranson M., unpublished data). This plasmid, designated
pcDNA3/uPAR+, was confirmed to contain the uPAR cDNA in the sense
orientation by restriction enzyme analysis (Figure 12). In order to clone the
cDNA

in

the

antisense

orientation

into

pcDNA3

plasmid

(designated

pcDNA3/uPAR-), uPAR cDNA was released from pBSM13+/uPAR+ plasmid using
Not I and Hind III restriction enzyme digestion and the pcDNA3 plasmid was
linearised using the same restriction enzyme combination (Figure 13). The uPAR
cDNA and linearised pcDNA3 plasmid were purified by electroelution and DNA
extraction/precipitation as described earlier (Section 3.2.B.3.). cDNA was ligated
into the linearised pcDNA3 as described in Section 3.2.B.4. to produce the
pcDNA3/uPAR- plasmid. The presence of the uPAR cDNA in the antisense
orientation was confirmed by restriction enzyme analysis (Figure 13).
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Not I/Xho I

2950 bp

1150 bp

Not I/Xho I
Digestion

Not I/Xho I
Digestion
Ligation

Not I/Xho I
5444 bp

Pst I

4261 bp
2096 bp

1181 bp

268 bp

Figure 12: Confirmation of uPAR cDNA inserted into pcDNA3 in sense direction
The ~ 1150 kb uPAR cDNA was excised from pBSM13+/uPAR+ by restriction with Not I
and Xho I, as confirmed by agarose gel electrophoresis. Excised uPAR cDNA was ligated
with Not I/Xho I digested pcDNA3 mammalian expression vector. The produced plasmid
(pcDNA3/uPAR+, prepared by Ranson M., unpublished data) was confirmed to contain
the uPAR cDNA in the sense orientation by restriction digestion followed by agarose gel
electrophoresis.
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Not I/Hind III

2950 bp

1150 bp

Not I/Hind III
Digestion

Not I/Hind III
Digestion
Ligation

Not I/Hind III

5370 bp

Pst I

4730 bp
1538 bp

1166 bp

268 bp
Figure 13: uPAR cDNA cloning in antisense orientation into pcDNA3 vector
The ~ 1150 kb uPAR cDNA was excised from pBSM13+/uPAR+ by restriction with Not I
and Hind III, as confirmed by agarose gel electrophoresis. The pcDNA3 mammalian
expression vector was also digested with Not I and Hind III. Digested pcDNA3 and uPAR
cDNA were electroeluted from agarose gel then ligated to produce pcDNA3/uPARplasmid which was confirmed to contain the uPAR cDNA in the antisense orientation by
restriction digests followed by agarose gel electrophoresis.
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3.2.B.7. TRANSFORMATION OF COMPETENT ESCHERICHIA COLI
Luria Broth [LB 100 ml: 10 g/l trypton, 5 g/l yeast extract and 10 g/l
NaCl] was inoculated with 2 ml of freshly prepared overnight culture of
Escherichia coli (E. coli). The inoculated medium was incubated at 37oC with
shaking at 180 rpm until the optical density at 600 nm wavelength reached 0.5
(OD600

nm

= 0.5 approximately after 3 h using LB as a blank). Grown bacteria

were centrifuged at 3020 x g for 10 min at 4oC. The pellet was incubated on ice
for 10 min and then resuspended in 50 ml of ice-cold 0.1 M MgCl2. The solution
was centrifuged at 3020 x g for 10 min at 4oC and the pellet was resuspended in
5 ml of ice-cold 0.1 M CaCl2. Solution was divided to 1 ml aliquots and the
competent E. coli was stored 4oC until further use (maximum 7 days storage).
Plasmids constructs (5 µl, ~ 5 µg) were mixed with 100 µl of competent
E. coli cells and incubated on ice for 30 min. Transformation reaction was heatshocked at 42oC for 45 seconds and then placed on ice for 2 min. SOC medium
[900 µl sterile solution containing: 2 % w/v Bactotryptone, 0.5 % w/v yeast
extract; 10 mM NaCl; 2.5 mM KCl; 20 mM MgCl2; 10 mM MgSO4 and 20 mM
Glucose] was added and the reaction was incubated at 37oC with 180 rpm
shaking for 1 h. Aliquots (10, 100 and 890 µl) of the transformation reaction
were spread onto three separate Z-agar plates [sterile 1.5 % w/v agar in LB]
containing 100 µg/ml ampicillin (Amp) antibiotic. Plates were incubated at 37oC
overnight and colonies were randomly selected and screened for the presence of
plasmid containing the uPAR cDNA in the designated orientations. Briefly,
single colonies were used to inoculate separate 3 ml aliquots of LB media
containing 100 µg/ml Amp for plasmid mini-preparations as described by
Maniatis et al. (1989). Isolated plasmids were analysed by restriction enzyme
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mapping to confirm the presence and orientation of uPAR cDNA (Section
3.2.B.2.).
3.2.B.8. PLASMID MIDI-PREPARATION
Colonies containing the pcDNA3 plasmid with the insert uPAR cDNA in
the desired orientations were used to make overnight starting cultures which
were then used to inoculate 50 ml of LB media containing 100 µg/ml Amp. After
overnight incubation at 37oC with constant 180 rpm shaking, samples of the
cells (100 µl) were used to prepare glycerol: cells (7:1 v:v) stocks for storage at –
80oC. The remainder of the bacterial cell culture was centrifuged at 6000 x g for
15 min at 4oC. Plasmid midi-preparations were then performed to extract the
DNA from bacterial cells as per manufacturer’s instructions using the Qiagen®
plasmid midi-prep kit. The DNA pellet produced was resuspended in water, then
chloroform/phenol extractions and ethanol precipitation were performed as
described by Maniatis et al. (1989). The precipitated plasmids were sterilised by
rinsing in 100 % ethanol in a biohazard sterile hood, the final sterile extracted
DNA solution was resuspended in sterile TE buffer [10 mM Tris-HCl, pH 7.4; 1
mM EDTA] and frozen at -20oC until further use. The DNA concentration was
determined specifically for each plasmid preparation from standard curves
constructed from the molecular weight marker for the relationship between the
amount of DNA and intensity of ethidium bromide staining. The absorbance at
260 nm (DNA) and 280 nm (protein) measured for plasmid solutions allowed
measurement of the purity of DNA.
The concentration of plasmid DNA solutions ranged between 0.8 and 1.2
µg/µl and were in the range of pure DNA preparation (A260/A280 = 1.8 - 2) (data
not shown, see Section 7.2 - Appendix 2 for example). Dye terminator cycle
sequencing (Section 3.2.B.5.) of the plasmid constructs using T7 promoter-
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primer confirmed the presence of the uPAR cDNA in the sense (Figure 14) and
antisense (Figure 15) orientations.

GAGCTGnCCTCnCCnACATGGGTnACCCGTCGCTGCTGCCGTTGnnGTTGCCTGnTCnAC 97
|||||| |||| | |||||||| ||||| ||||||||||| || | || ||| || ||
GAGCTGCCCTCG-CGACATGGGTCACCCGCCGCTGCTGCCGCTGCTGCTG-CTGCTCCAC 116
ACTCTGTGTCCCACCCTCTnGGGGCCTGCnGTGTATGCAnTGTAAnACCAACGGnGATTG 157
|| ||| |||||| ||||| ||||||||| ||| ||||| ||||| |||||||| |||||
AC-CTGCGTCCCAGCCTCTTGGGGCCTGCGGTGCATGCAGTGTAAGACCAACGGGGATTG 175
CCTATGCnGGnAGAGnGCGCnCTGGGACAGGACCTCTGTTGGAnCACGATCGnnTCCTCG 217
|| || || |||| |||| ||||||||||||||||| ||| ||||||||
|| |
CC-GTG-TGGAAGAGTGCGCCCTGGGACAGGACCTCTGCAGGACCACGATCGTGCGCTTG 233
TGGGAAGAAGGAGAAnAGCTGGAnnTGGTGGAnAAAATCTGTCCCCACTCATAGAAGACC 277
||||||||||||||| ||||||| ||||||| |||| |||| |||||||| ||||||||
TGGGAAGAAGGAGAAGAGCTGGAGCTGGTGGAGAAAAGCTGTACCCACTCAGAGAAGACC 293
AnCAGGACCCTnAGCTATCGGACTGGnTnTGAAGATCACCACCCTCACCnAGGTTGTGTG 337
| ||||||||| |||||||||||||| | |||||||||||| ||| ||| ||||||||||
AACAGGACCCTGAGCTATCGGACTGGCT-TGAAGATCACCAGCCTTACCGAGGTTGTGTG 352
nGGGTTAGACTTGnGCAACCnCGGCAACTnTGGnCnGGCTGTnACCTATTCTnnnAnCCn 397
|||||||||||| |||||| ||||||| ||| | |||||| ||||||||
| ||
TGGGTTAGACTTGTGCAACCAGGGCAACTCTGGCCGGGCTGTCACCTATTCCCGAAGCCG 412
TTCCCTCCAnTGnATTTCCTGTGGCTCATCATACATGAACTTGTGAnAGGGGTCnGTACC 457
|| |||| | || |||||||||||||||||| |||||| | ||||| ||||| | | |||
TTACCTCGAATGCATTTCCTGTGGCTCATCAGACATGAGC-TGTGAGAGGGGCCGGCACC 471
AnAGCCTTnnAGCGCCGCATCCCCTGAAGAACAAnTGTnTTGnATGTGGTGACCCCACTG 517
| |||| | || |||||| ||||||||||| | ||
|| ||||||||| |||||||
AGAGCC-TGCAGTGCCGCA-GCCCTGAAGAAC-AGTG-CCTGGATGTGGTGA-CCCACTG 526
nATnCnnCAAGGnGAATAAGGGCGnTCAnAGGATGACCCGCCACCTnCGTGGGCTGTTGG 577
|| |
|||| ||| ||||||| || ||||||| ||||||||| ||| ||||| |||
GATCCAGGAAGGTGAAGAAGGGCGTCCAAAGGATGA-CCGCCACCTCCGT-GGCTG-TGG 583
nTACCTTCCCnGCTGnCCGGGCTTTCCAATGGTTTCCAC 616
||||||||| |||| |||||| |||||||||||||||
CTACCTTCCCGGCTGCCCGGGC--TCCAATGGTTTCCAC 620

Figure 14: Alignment of sequence from pcDNA3/uPAR+ and Human uPAR gene
The sequence from the chromatogram produced from the ABI prism cycle sequencer
(black) was exported and aligned with human uPAR gene sequence (red, NCBI accession
#: X51675, Roldan et al., 1990) using the ClustalW® program. Matched pairs are
marked by ( | ) and the sequence shows almost complete homology to the uPAR cDNA
gene when both aligned in the same 5’ Æ 3’ orientation (sense).
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GGCTGGGAGCCGAGGGAAGGGCAAAGGGGTCCCCCGGATCCAGCCAGGGCAGAGAGGGGG 74
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GGCTGGGAGCCGAGGGAAGGGCAAAGGGGTCCCCCGGATCCAGCCAGGGCAGAGAGGGGG 1092
ATTTCAGGTTnAGGTCCAGAGGAGAGTGCCTCCCCACAGTCTGGCAGTCATTACCAnGGT 134
|||||||||| |||||||||||||||||||||||||||||||||||||||||| || |||
ATTTCAGGTTTAGGTCCAGAGGAGAGTGCCTCCCCACAGTCTGGCAGTCATTAGCAGGGT 1032
GATGGTGAGGCTGAnATGGGCAGGGCCAGnCTGAGGAGCAnCCCCACTGCGGTACTGGAC 194
|||||||||||||| |||||||||||||| |||||||||| |||||||||||||||||||
GATGGTGAGGCTGAGATGGGCAGGGCCAGGCTGAGGAGCAGCCCCACTGCGGTACTGGAC 972
ATCCAGGTnTGGGTGGTTACAGCCACTTTTAnTACAGCAGAAGACATnAATGTGGTTCAT 254
|||||||| |||||||||||||||||||||| |||||||| |||||| ||||||||||||
ATCCAGGTCTGGGTGGTTACAGCCACTTTTAGTACAGCAGGAGACATCAATGTGGTTCAT 912
GCTGAAGGCGTCACCCAGGTGGGCATGTTGGCACATTGAGGCGGTTGCACAGCCTCTTAC 314
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GCTGAAGGCGTCACCCAGGTGGGCATGTTGGCACATTGAGGCGGTTGCACAGCCTCTTAC 852
CATATAGCTTTGGTTTTTCGGTTCGTGAGTGCCGGTGGCTACCAGACATTGATTCATGGG 374
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CATATAGCTTTGGTTTTTCGGTTCGTGAGTGCCGGTGGCTACCAGACATTGATTCATGGG 792
GCCTCGGCAGTCAATGAGGAAAGTCTCTTCAGAGGAGCATCCATGGGTGCTGTTCCCCTT 434
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GCCTCGGCAGTCAATGAGGAAAGTCTCTTCAGAGGAGCATCCATGGGTGCTGTTCCCCTT 732
GCAGCTGTAACACTGGCGGCCATTCTGCGGnAGATTTTCAAGCnCCAGGATTGGGCCCTC 494
|||||||||||||||||||||||||||||| |||||||||||| ||||||||||||||||
GCAGCTGTAACACTGGCGGCCATTCTGCGGCAGATTTTCAAGCTCCAGGATTGGGCCCTC 672
GTTGCATTTGGTGGTGTTGCAnCATTTCAnGAAGTGGAAGGTGTCGTTGTTGTGGAAACC 554
||||||||||||||||||||| ||||||| ||||||||||||||||||||||||||||||
GTTGCATTTGGTGGTGTTGCAGCATTTCAGGAAGTGGAAGGTGTCGTTGTTGTGGAAACC 612
ATTGGAGCCCCGGGCAnCCGGGAAGGTAGCCACAGCCACGGAGGTGGCGGTCATTCTTTG 614
|||||||||| ||||| ||||||||||||||||||||||||||||||||||||| |||||
ATTGGAGCCC-GGGCAGCCGGGAAGGTAGCCACAGCCACGGAGGTGGCGGTCATCCTTTG 553
GACGCCCTTTTTCACCTTCCTGGATCCAGTGGGT-ACCACATCCAnGCACTTGTTCTTCA 673
||||||||| |||||||||||||||||||||||| |||||||||| ||||| ||||||||
GACGCCCTTCTTCACCTTCCTGGATCCAGTGGGTCACCACATCCAGGCACT-GTTCTTCA 494
GGGCTTGCnGCGCTGCATGCTCTGnTGCCCCGCCCTCTCACAGCTCATGnnTTGATGAGC 733
||||| || || ||||| |||||| ||||
||||||||||||||||| | |||||||
GGGCT-GCGGCACTGCAGGCTCTGGTGCCGGCCCCTCTCACAGCTCATGTCT-GATGAGC 436
CACACGAAATGCTTTCGAnGTAACCGCTTTCCGGGAATnAGGTGACAGCCC 784
|||| ||||||| ||||| ||||| |||| ||||||| ||||||||||||
CACAGGAAATGCATTCGAGGTAACGGCTT--CGGGAAT-AGGTGACAGCCC 388

Figure 15: Alignment of sequence from pcDNA3/uPAR- and human uPAR gene
The sequence produced from the ABI prism cycle sequencer (black) was aligned with
human uPAR gene sequence (red, NCBI accession #: X51675, Roldan et al., 1990) using
the ClustalW® program. Matched pairs are marked by ( | ) and the sequence shows
almost complete homology to the uPAR cDNA gene when aligned in the opposite
orientation (3’ Æ 5’) (antisense).
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3.2.C. TRANSIENT TRANSFECTION OF CANCER CELLS WITH UPAR CDNA
Transient transfection of mammalian cells was optimised using the
Lipofectamine™ 2000 and Superfect® transfection reagents. The pcDNA3/uPAR
sense (pcDNA3/uPAR+) plasmid was used with MCF-7 and T-47D cell lines and
pcDNA3/uPAR antisense (pcDNA3/uPAR-) plasmid with the MDA-MB-231 cell
line. Transfection was performed as per manufacturer’s instruction as follows.
Cells cultured for 48 h were detached using Trypsin-EDTA and resuspended at
1 x 106 cells/ml in RPMI-1640 containing 5 % FCS. Cells were seeded into 6wells plates containing 2 – 2.5 ml RPMI-1640 containing 5 % FCS in order to
achieve subconfluent culture after overnight incubation at 37oC. After this
incubation complexes between plasmid DNA and reagent for each well were
formed by incubating together in 200 µl RPMI-1640 for 20 min at RT after
which 300 µl of RPMI-1640 containing 5 % FCS was added to the plasmid DNA:
reagent complexes. Control treatments were prepared identically either in the
absence of reagent (plasmid DNA only control), absence of plasmid DNA (reagent
only control) or in the absence of both plasmid DNA and reagent (negative
control). While the manufacturer’s instructions recommend the addition of the
final 500 µl transfection solution directly to the 2 – 2.5 ml cell culture media, it
was found that removal of culture media and incubation of cells only with the
transfection solution overnight then supplementing the cells with 2 ml of
culture media significantly increased the transfection efficiency (data not
shown).
Transfection optimisation in terms of cell-surface uPAR levels as
detected by flow cytometry involved variation in the number of cells, amount of
plasmid DNA, ratio of plasmid DNA to reagent and the time of culturing after
transfection.
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3.3. RESULTS
3.3.A. OPTIMISATION OF TRANSIENT TRANSFECTION OF CANCER CELLS
Initial transfection experiments using the Superfect® reagent in the
absence or presence of pcDNA3/uPAR- showed this reagent to be cytotoxic to all
cell lines used (Figure 16).

Figure 16: Cytotoxic effect of Superfect® reagent and plasmid DNA on
MDA-MB-231 cells
Density plots showing fluorescence of propidium iodide (PI) detected by FL-2 detector on
Y-axis plotted against forwards scatter (FSC) on the X-axis. Cell viability of transfected
cells was assessed in comparison to a gate established for viable population (excluding
PI) of untreated cells (region R1).Cell populations presented were identically treated
during the transfection procedure where an overnight culture of 5 x 105 MDA-MB-231
cells per well in 6-wells plates were seeded overnight then incubated overnight with
transfection solution: (A) in the absence of pcDNA3/uPAR- plasmid and Superfect
reagent, (B) presence of 7.5 µl reagent alone, (C) 1.5 µg DNA with 3 µl Superfect, (D) 1.5
µg DNA with 4.5 µl Superfect or (E) 1.5 µg DNA with 7.5 µl Superfect. Cells were
supplemented with 2 ml of culture media, incubated for further 24 h and viability was
assessed (i.e. 48 h after transfection) by the incorporation of propidium iodide (PI) dye.
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Treatment of cells with the Superfect® reagent alone showed a slight
toxicity in comparison to untreated cells. However, fluorescence due to
incorporation of PI dye significantly increased when cells were transfected using
the same amount of DNA with increasing volumes of the Superfect® reagent
(Figure 16). This observed toxicity due to transfection with the Superfect®
reagent was also seen with the other cell lines (data not shown), thus the
Superfect® reagent was abandoned.
3.3.A.1. TRANSIENT TRANSFECTION OF MDA-MB-231 CELLS
Initial

transfection

experiments

of

MDA-MB-231

cells

with

LipofectamineTM-2000 transfection reagent showed that 24 h after addition of
1 µg pcDNA3/uPAR- plasmid DNA and 2 µl of reagent, uPAR expression
significantly decreased by 30 % in comparison to that with non-transfected
MDA-MB-231 cells (Figure 17 - A, p < 0.05, n = 4). The cell-surface expression
of uPAR on cells transfected using the 1:2 ratio was significantly different from
all other reagent-treated cells (Figure 17 – A, p < 0.05, n = 4). Treatment of cells
with the 1:2 plasmid DNA to reagent ratio displayed the lowest PI incorporation,
indicating lower toxicity compared to the other treatments (data not shown).
Finally, the expression of uPAR on the surface of cells treated with other
plasmid DNA to reagent ratios or reagent alone was not significantly different
from that of control MDA-MB-231 cells (Figure 17 - A, p > 0.05, n = 4). For
further optimisation, the 1:2 pcDNA3/uPAR- plasmid (µg): LipofectamineTM-2000
(µl) ratio was kept constant but the amounts was increased in addition to
increasing the transfection time from 24 h to 48 h. Control MDA-MB-231 cells
assayed at 48 h past transfection (Figure 17 – B) showed higher uPAR
expression compared to cells assayed at 24 h (Figure 17 - A).
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Figure 17: The effect of LipofectamineTM-2000 on MDA-MB-231 cell-transfection
MDA-MB-231 cells (5 x 105 cells/well in 2.5 ml of RPMI-1640 + 5 % FCS) were added to
6-wells plate, incubated overnight and attached cells were washed and treated as
follows. (A) Cells were incubated in transfection solution for 24 h and then assayed by
flow cytometry. Transfection solutions were prepared using 1 µg pcDNA3/uPAR- in the
absence (DNA only control) or presence of different volumes of LipofectamineTM-2000
(LF) reagent. For the reagent control (LF only control), transfection solution was
prepared using 4 µl of LipofectamineTM-2000 in the absence of plasmid DNA. (B) Cells
were incubated in transfection solution for 24 h then supplemented with 2 ml of RPMI1640 + 5 % FCS and incubated for another 24 h then assayed by flow cytometry (i.e. 48
h after transfection). Transfection solutions were prepared using 1 µg pcDNA3/uPAR- in
the absence LipofectamineTM-2000 reagent (DNA only control) or using 1, 1.5, 2 and 2.5
µg of pcDNA3/uPAR- complexed with 2, 3, 4 and 5 µl of LipofectamineTM-2000 reagent,
respectively. uPAR expression was determined using the #3934 antibody (5 µg/ml) and
data shown is the MFI ± SEM (n = 4). In order to measure cell-surface uPAR, only values
from viable cells (excluded PI) were used and the asterisks denote statistically significant
differences between cell-surface uPAR levels in comparison to the DNA control treatment
(p < 0.05, n = 4).
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The expression of uPAR at 48 h on MDA-MB-231 cells transfected at
each of the pcDNA3/uPAR- plasmid concentration was significantly lower from
control cells (p < 0.05, n = 4) (Figure 17 – B). The maximal decrease in uPAR
expression was observed using 1.5 µg pcDNA3/uPAR- plasmid and 3 µl reagent
(62 % decrease compared to control MDA-MB-231 cells; p < 0.05, n = 4). uPAR
expression on cells transfected with 1 µg of pcDNA3/uPAR- plasmid and 2 µl
reagent was higher at 48 h than that at 24 h (compare Figure 17 – A and B).
The decrease in uPAR expression using the 1:2 plasmid DNA (µg) to
LipofectamineTM-2000 (µl) ratio was not associated with significant cell death as
assessed by PI incorporation (Figure 18).

Figure 18: Viability of MDA-MB-231 cells transfected with increasing
pcDNA3/uPAR-: LipofectamineTM-2000 amounts
Cell populations were identically treated during the transfection procedure described
earlier (Figure 17 – B). Cells were either incubated (A) in the absence of plasmid DNA
and LipofectamineTM-2000 (LF) reagent, or with (B) 1.0 µg DNA: 2 µl LF, (C) 1.5 µg DNA:
3 µl LF, (D) 2 µg DNA: 4 µl LF, (E) 2.5 µg DNA: 5 µl LF or (F) reagent (5 µl) alone. Viability
was assessed by the exclusion of PI dye (R1 gate).
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3.3.A.2. TRANSIENT TRANSFECTION OF T-47D CELLS
Adopting the transient transfection procedure optimised for MDA-MB231 cells, uPAR expression in T-47D cells was significantly increased using
different amounts and ratios of pcDNA3/uPAR+ plasmid: LipofectamineTM-2000
reagent compared to cells treated with LipofectamineTM-2000 reagent alone
(Figure 19, p < 0.05, n > 3). Transfection of T-47D cells with 1.5 µg
pcDNA3/uPAR+ and 4.5 µl LipofectamineTM-2000 resulted in 2.0-fold increase in
cell surface uPAR compared to cells treated with LipofectamineTM-2000 alone.
Consistent high transfection efficiency and cell viability were obtained when
5 x 105 of T-47D cells were transfected using 2 µg of pcDNA3/uPAR+ and 6 µl of
LipofectamineTM-2000 reagent (data not shown).
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Figure 19: Transfection of T-47D cells with different amounts of pcDNA3/uPAR+:
LipofectamineTM-2000 complexes
T-47D cells were used to inoculate 6-wells plate at 5 x 105 cells per well in 2 ml of RPMI1640 + 5 % FCS the day before transfection procedure. Cells were transfected according
to optimised protocol using specified pcDNA3/uPAR+ plasmid (µg): of LF reagent (µl). 48
h past transfection, cells were detached and assayed for uPAR expression using the
MAB807 anti-uPAR monoclonal antibody (10 µg/ml). Data shown is the MFI ± SEM (n ≥
3) for cell-surface uPAR detection. Asterisks mark significantly different uPAR levels in
comparison to control treatment (no DNA control, 0 µg DNA: 4.5 µl LF) (p < 0.05, n ≥ 3).
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Given that conditions were optimised in terms of cell-viability and uPAR
expression, mock transfections were also performed using the a 1:3 ratio (2 µg:
6 µl) of pcDNA3 plasmid: LipofectamineTM-2000 reagent for 48 h incubation in
order to determine whether the increase of cell-surface uPAR was specifically
due to the presence of uPAR cDNA expression. As shown in Figure 20 - A,
transfection of T-47D cells with pcDNA3 plasmid did not affect cell-surface
uPAR levels at all. In contrast, transfection of these cells with pcDNA3/uPAR+
plasmid significantly increased cell-surface uPAR compared to both control and
mock-transfected T-47D cells (p < 0.05, n = 3) as detected by flow cytometry
(Figure 20 – A) and confocal microscopy (Figure 20 – B).

3.3.B. THE EFFECT OF UPAR OVEREXPRESSION
The effect of increasing uPAR expression via transfection was investigated
with respect to cell-surface expression of the components of the plasminogen
activation pathway and cell morphology. Flow cytometry and confocal
microscopy techniques (see Section 2.2.A.) were used to compare control and
transfected cells.
3.3.B.1. CELL-SURFACE ANTIGEN CHANGES
The upregulation of uPAR on the surface of T-47D cells was found to be
associated with significantly increased levels of endogenous cell-surface uPA
and increased lysine-dependent binding of plasminogen (Table II). The values
were

obtained

from

five

different

transfection

experiments

independently using different batches of pcDNA3/uPAR+ plasmid.

performed
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Figure 20: Increased cell-surface
uPAR is due transfection with uPAR
cDNA
(A) Cell-surface uPAR level was
determined on DNA only control (2 µg
pcDNA3/uPAR+: 0 µl LF, clear bars),
mock-transfected (2 µg pcDNA3: 6 µl
LF, light grey) and pcDNA3/uPAR+transfected (2 µg pcDNA3/uPAR+: 6 µl
LF, dark grey) T-47D cells using the
MAB807 antibody. Data presented are
the MFI ± SEM (n = 3) and the viability
of cell population in all assays was
higher than 70%. The levels on
pcDNA3/uPAR+-transfected cells were
significantly different compared to both
control and mock-transfected cells
(p < 0.05). (B) Mock-transfected (I and
II)
and
pcDNA3/uPAR+-transfected
(III – VI) T-47D cells were analysed by

confocal microscopy. Mock- and pcDNA3/uPAR+-transfected cells were incubated with polyclonal anti-uPAR
antibody (I - IV, 20 µg/ml). pcDNA3/uPAR+-transfected cells were alternatively incubated with isotype control
(rabbit serum, V and VI, 20 µg/ml). Cells were then incubated with anti-rabbit IgG FITC-conjugated
antibody, washed and analysed by confocal microscopy. Top panels are transmission images of basal
sections and the scale bars represent 10 µm of actual length. Bottom panels are the corresponding fluoroimages. Data shown in (A) and (B) are representative data of at least two independent assays.

89

Table II: The effect of uPAR overexpression on uPA levels and plasminogen
binding on T-47D cells

Experiment
number
1
2
3
4
5

uPAR
Mean
SEM
3.0
0.3
2.2
0.1
1.8
0.3
1.2
0.2
1.6
0.2

uPA
Mean SEM
2.5
0.1
1.9
0.1
1.5
0.2
1.3
0.4
1.3
0.0

Plg
Mean SEM
1.4
0.1
1.8
0.1
1.4
0.5
1.5
0.6
2.4
0.3

T-47D cells were transfected according to the optimised transfection protocol where 5 x
105 cells were seeded in 2 ml of RPMI-1640 + 5 % FCS per well in 6-wells plate,
incubated overnight, washed and incubated for 24 h with transfection solution
containing preformed complexes (20 min at RT) of 2 µg pcDNA3/uPAR+ and 6 µl
LipofectamineTM-2000 in 200 µl RPMI-1640 then 300 µl RPMI-1640 + 5 % FCS was
added. Cells incubated with the 500 µl transfection solution were supplemented with 2
ml or RPMI-1640 + 5 % FCS and incubated for another 24 h before flow cytometry
assays using MAB807 anti-uPAR and #392 anti-uPA antibodies for cell-surface uPAR
and uPA, respectively. Lysine-dependent plasminogen binding was also determined by
flow cytometry using plasminogen-FITC incubated with cells in the absence or presence
of TA. Controls were either no treatment, LipofectamineTM-2000 reagent alone or mocktransfected (2 µg pcDNA3 complexed with 6 µl LipofectamineTM-2000) which showed no
difference in uPAR expression. Values presented are the mean fold-increase of cellsurface parameter on transfected cells compared to control T-47D cells. There was a
significant difference between the levels of each parameter on control and
pcDNA3/uPAR+-transfected T-47D cells in all cases (p < 0.05, n ≥ 3). Values shown were
obtained from viable cells only (excluded PI) and thus represent cell-surface levels.

A linear correlation (r2 = 0.95) described the relationship between the
fold-increase of endogenous cell-surface uPA and the fold-increase of cellsurface uPAR shown in Table II (Figure 21). This indicated that the significant
increase in cell-surface expression of uPAR on T-47D cells was directly
associated with increased uPA levels on the cell-surface. Cell-surface uPA
completely co-localised with cell-surface uPAR on pcDNA3/uPAR+-transfected
T-47D cells (Figure 22), emphasising the role of uPAR to localise uPA on the
cell-surface. Nevertheless, areas of unoccupied uPAR were evident in the
overlays, indicating incomplete occupancy of cell-surface uPAR.
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As suggested in Table II, the increase of lysine-dependent binding of
plasminogen, whilst significant, failed to directly correlate to either the increase
of cell-surface uPAR or the resulting increase of endogenous cell-surface uPA
(data not shown). Mock-transfected T-47D cells did not show any significant
changes in cell-surface uPA and lysine-dependent plasminogen binding in

Fold-increase in cell-surface uPA

comparison to untreated T-47D cells (p < 0.05, n = 3) (data not shown).
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Fold-increase in cell-surface uPAR
Figure 21: Correlation between increased surface uPAR and uPA on transfected
T-47D cells
The fold-increase of cell-surface uPA on transfected T-47D cells compared to control
cells was directly correlated to the fold-increase of cell-surface uPAR. Data points are
the mean of triplicate determination for both control and transfected T-47D cells. Error
bars are the SEM and data were obtained from independent assays performed at
different times. The bold line represents the linear correlation with a regression (r2) of
0.95 and the dotted lines are the 95% confidence interval of the linear correlation.
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I
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Figure 22: Distribution of cell-surface uPA and uPAR on T-47D cells transfected
with uPAR cDNA
Transiently transfected T-47D cells were stained with mouse anti-human B-chain uPA
then goat anti-mouse IgG Cy3-conjugated antibody. Cells were washed and then
incubated with rabbit anti-human uPAR polyclonal antibody (provided by David
Croucher, University of Wollongong) then goat anti-rabbit IgG FITC-conjugated
antibody. There was no leakage between the FITC and Cy3 channels and addition of
secondary antibodies alone did not produce any staining (data not shown). Furthermore,
according to manufacturer’s specifications, the goat anti-mouse IgG Cy3-conjugated and
the goat anti-rabbit IgG FITC conjugated antibodies do not show cross reactivity. Colocalisation of uPAR (green, panel II) and uPA (blue, panel III) is shown in the overlay
and appear in cyan colour (panel IV). The image shown is a representative sample
obtained from basal sections and the scale bar in the transmission image (panel I)
represents 10 µm.

The optimised transfection procedure was utilised to modulate uPAR
expression on MCF-7 cells. This cell line did not resist manipulation as cell
viability was generally low when cells were assayed by flow cytometry (50 – 70 %
viability). This reduced viability was consistently observed with experiments on
both control and transfected MCF-7 cells. Despite this resistance to
manipulation, a small but significant increase in uPAR expression was observed
on transfected MCF-7 cells overexpression which was also associated with small
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but significant increase in cell-surface uPA (Figure 23). However, this was not
accompanied by a significant increase in the lysine-dependent binding of
plasminogen possibly due to the low increase in cell-surface uPAR/uPA on
MCF-7 cells or that the overexpression of uPAR/uPA on T-47D and MCF-7 cells

Mean Fluorescence Intensity

resulted in different effects on the binding of plasminogen to the cell-surface.
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Figure 23: The effect of uPAR overexpression on MCF-7 cells
MCF-7 cells were transfected with pcDNA3/uPAR+ plasmid and cell-surface uPAR
(#3934 antibody), uPA (#392 antibody) and lysine-dependent plasminogen binding were
compared between DNA only control (empty bars) and transfected (grey bars) cells. Data
are the MFI ± SEM (n = 3) and cell viability in all assays ranged between 65 – 75 %. Only
the lysine-dependent plasminogen binding was not significantly different between
control and transfected cells (p > 0.05). Data presented are from one representative
experiment and similar data were observed in other experiments.

3.3.B.2. SPATIAL AND MORPHOLOGICAL CHANGES
Control and T-47D cells transiently transfected with pcDNA3/uPAR+
plasmid were analysed for the localisation of uPAR, uPA and plasminogen
binding on the cell-surface by confocal microscopy. Cell-surface uPA and
plasminogen binding on control T-47D cells was very low (Figure 24 – A)
compared to pcDNA3/uPAR+-transfected T-47D cells (Figure 24 – B and C).
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Plasminogen binding was greatly reduced in the presence of the lysine analogue
TA (Figure 24 – D), indicating that lysine-dependent binding dominated the total
plasminogen binding to transfected cells. Thus, confocal microscopy analysis
emphasised the success of the transfection procedure and showed that
endogenous cell-surface uPA levels and plasminogen binding were increased in
association with overexpression of uPAR on these cells.
Control incubations with antibody isotypes (e.g. Figure 24 – E),
secondary antibodies alone (data not shown) or in the presence of TA (Figure 24
– D) confirmed the lack of signal leakage between the different channels used for
the

detection

of

the

different

fluorochrome-emissions

by

the

confocal

microscope. Therefore, overlays of images were a bona fide evidence of colocalisation not artefacts of staining procedure. uPA and plasminogen binding
had a higher distribution on the cell surface at basal and transverse sections
(Figure 24) compared to the apical surfaces (data not shown) of attached
transfected T-47D cells. Plasminogen binding and uPA displayed a punctuate
distribution and co-localised almost completely on transfected T-47D cells.
Nevertheless, small areas on the cell surface of the transfected cells did not bind
plasminogen although uPA appeared in these areas.
Control T-47D cells displayed a general cuboidal (spherical) shape as
seen in the transmission images in Figure 24. The overexpression of uPAR
affected the morphology of these cells where transfected cells appeared to
display a more elongated (fibroblastic) shape compared to control cells. This was
seen in most transmission images of transfected T-47D cells; however it was
most apparent in the transmission images displayed in Figure 24 – B and C
compared to Figure 24 - A.
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Figure 24: Confocal microscopy of control and T-47D cells transiently transfected with pcDNA3/uPAR+ plasmid
T-47D cells cultured on glass slide cover-slips were transfected as per optimised protocol and subjected to double staining procedure then analysed by
confocal microscopy. Cells in Panels I - IV were incubated with pcDNA3/uPAR+ plasmid only (control T-47D cells) whereas in Panels V - XX were
incubated with pcDNA3/uPAR+: LipofectamineTM-2000 complexes (pcDNA3/uPAR+-transfected T-47D cells). Cells in Panels I – XII were incubated with
plasminogen-Cy5, washed and incubated with anti-B-chain uPA monoclonal antibody (#394, 20 µg/ml) then with anti-mouse IgG FITC-conjugated
antibody. Cells in Panels XIII- XVI were incubated with plasminogen-Cy5 in the presence of TA, washed and incubated with anti-B-chain uPA
monoclonal antibody (#394, 20 µg/ml) then with anti-mouse IgG FITC-conjugated antibody. Cells in panels XVII – XX were incubated with
plasminogen-Cy5 then with mouse isotype IgG1 followed with anti-mouse IgG FITC-conjugated antibody. The lack of signal in XV when cells incubated
with TA compared to VII and XI when cells incubated in the absence of TA indicate that plasminogen binding is completely lysine dependent on these
cells and that the signal from uPA staining (green, VI, X and XIV) did not leak into the plasminogen channel (red, VII, XI and XV). On the other hand,
the lack of signal in XVIII indicates that staining with anti-uPA antibody is specific (no staining seen with isotype) and that the signal from plasminogenCy5 (VII, XI, and XIX) does not leak into the uPA channel (VI, X, and XVIII). Images in I, V, IX, XIII and XVII are transmission images and the scale bars
represent 10 µm of actual length. Overlays of uPA and plasminogen staining are shown in IV, VIII, XII, XVI and XX and co-localisation appears in
orange/yellow. All images shown in Figure were obtained from basal sections of the attached cells (i.e. sections at the site of attachments to the cover
slip) except for Panels IX - XII. Images in Panels IX - XII were obtained from transverse section (i.e. section between the basal [attachment site] and
apical [opposite side] sections of attached cells). Transverse sections were selected where the cells are largest and the membrane is highest in focus.
Images shown in the Figure are representative samples of several assays each performed in replicates (> 3 images per assay).
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3.3.C. COMPARISON BETWEEN T-47D AND MDA-MB-231 CELLS
The previous results showed that the overexpression of uPAR resulted in
increase of uPA and lysine-dependent plasminogen binding on the surface of
T-47D cells (Table II and Figure 24). Taken together, the overexpression of
uPAR/uPA and increased plasminogen binding on T-47D cells appeared to
manifest a more metastatic phenotype (Ranson et al., 1998). To further
characterise the effect of uPAR-overexpression on T-47D cells, these cells were
directly compared to the metastatic MDA-MB-231 cells.
3.3.C.1. CO-LOCALISATION OF UPA AND PLASMINOGEN
The lysine-dependent binding of plasminogen on the surface MDA-MB231 cells was independent from the pattern of uPA distribution at both the
basal (Figure 25) and transverse sections (data not shown). Cell-surface uPA
displayed a punctuate distribution while diffused plasminogen binding was
observed on MDA-MB-231 cells. These patterns were previously reported on this
cell line by Andronicos and Ranson (2001). In comparison to MDA-MB-231
cells,

transiently

uPAR-overexpressing

T-47D

cells

displayed

punctuate

distribution and very high co-localisation of both uPA and plasminogen (Figure
24). Cell-surface uPA and plasminogen binding on MDA-MB-231 cells was more
than 5- to 10-fold higher than that on uPAR-overexpressing T-47D cells. This
indicated that MDA-MB-231 cells still showed a more malignant phenotype,
however, in order to allow spatial comparison, the signals detected in Figure 24
and Figure 25 were normalised to the same level.
3.3.C.2. THE EFFECT OF EXOGENOUS UPA BINDING ON PLASMINOGEN BINDING
Incubation of MDA-MB-231 cells with exogenous uPA showed a
significant increase (1.5-fold) of cell-surface uPA compared to control cells (p <
0.05, n = 3, Figure 26 - A). This indicated that majority, but not all, of cell-
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surface uPAR was occupied with uPA (69 % in the representative Figure 26 - A)
prior to addition of exogenous uPA. The level of uPA and the occupancy of uPAR
on the surface of MDA-MB-231 cells were much higher than control or
transfected T-47D cells. Furthermore, in contrast to T-47D cells (Figure 26 - B),
lysine-dependent binding of plasminogen on MDA-MB-231 cells was not
significantly different before and after incubation with exogenous uPA (p > 0.05,
n = 3, Figure 26 - A).
The incubation of T-47D cells with exogenous uPA showed a significant
increase (2.3-fold) of cell-surface uPA compared to control T-47D cells (p < 0.05,
n = 3, Figure 26 - B). This indicated that only a fraction (44 % in the
representative Figure 26 - B) of cell-surface uPAR was occupied with uPA prior
to addition of exogenous uPA. Lysine-dependent binding of plasminogen also
significantly increased (2.2-fold) on cells incubated with exogenous uPA
compared to control T-47D cells (p < 0.05, n = 3, Figure 26 - B). It should be
noted that uPAR occupancy was not significantly different between transfected
and control T-47D cells, 44 ± 6 % and 36 ± 2 % respectively (p > 0.05 from
experiments repeated 3 times in triplicate, data not shown).
3.3.C.3. EFFECT OF UPA OR UPAR BLOCKING ON PLASMINOGEN BINDING
Lysine-dependent plasminogen binding was not significantly different
between cells blocked with anti-uPA or anti-uPAR antibodies and cells blocked
with isotype antibody (p > 0.05, n = 3 in two identical assays) (data not shown).
This indicated that blocking of uPA or uPAR on transfected T-47D cells did not
specifically affect plasminogen binding. The lysine-dependent binding of
plasminogen to the invasive MDA-MB-231 cells also was not significantly
affected by conditions leading to the blocking of uPA or uPAR (p > 0.05, n = 3 in
two identical assays) (data not shown).
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Figure 25: Distribution of uPA and plasminogen binding on MDA-MB-231 cells
Cells cultured on glass slide cover-slips were subjected to double staining procedure, mounted onto glass slides and analysed immediately by confocal
microscope. Scale bars in all images represent 20 µm and only images from basal sections are presented. Top panel: Cells incubated with
plasminogen-Cy5 followed by indirect immunostaining for uPA using anti-B-chain uPA antibody (#394) then by rabbit anti-mouse IgG FITC conjugated
antibody. Bottom panel: Cells incubated with plasminogen-Cy5 in the presence of 5 mM TA followed by uPA staining. The lack of signal in the
plasminogen channel when cells incubated in the presence of TA indicate that plasminogen binding was lysine-dependent and that signal from uPA
staining did not leak into this channel.
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Figure 26: Effect of exogenous uPA on plasminogen binding to the cell-surface
Cell-surface uPA (using the #394 antibody) and lysine-dependent binding of
plasminogen (using plasminogen-FITC) to (A) MDA-MB-231 cells and (B) T-47D cells
were determined by flow cytometry before and after the incubation of cells with
exogenous uPA (50 nM). Data presented are the MFI ± SEM (n = 3) and cell-viability was
higher than 70 % and 90 % in all assays for T-47D and MDA-MB-231 cells, respectively.
One asterisk denotes significant differences in cell-surface uPA level before and after
incubation with exogenous uPA (p < 0.05). Two asterisks denote significant differences
in the lysine-dependent binding of plasminogen to the cell-surface before and after
incubation with exogenous uPA (p < 0.05).
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3.4. DISCUSSION
A transient transfection procedure was successfully optimised using the
LipofectamineTM-2000 transfection reagent and uPAR cDNA for the modulation
of cell-surface expression of uPAR in breast cancer cell lines. Consistent
significant increases (1.5- to 3-fold) of cell-surface uPAR were observed by
transfection of T-47D cells with pcDNA3/uPAR+ plasmid using LipofectamineTM2000 reagent.
The increase of cell-surface uPAR on T-47D cells was associated with
increased

cell-surface

levels

of

uPA

and

plasminogen

binding.

Mock

transfection, using null pcDNA3 plasmid, confirmed that this increase of cellsurface markers was specifically due to transfection of these cells with the uPAR
cDNA. The increase of cell-surface uPA and plasminogen binding observed may
be due to concurrent increased secretion of uPA and overexpression of
plasminogen receptors with the overexpression of uPAR in T-47D cells. The
direct correlation between the increase of cell-surface uPA and the increase of
cell-surface uPAR on transfected T-47D cells supported this. Kariko et al.
(1993) reported that transfection of human osteosarcoma cell line (HOS) with
uPAR cDNA showed a 2-fold increase in the surface expression of uPAR
associated with 2-fold increase in receptor-bound uPA-mediated plasmin
generation. In contrasting experiments, antisense inhibition of the cell surface
expression of uPAR not only suppresses ERK/MAPK signalling activity but was
also associated with inhibition of adhesion, suppression of uPA secretion and
inhibition of pro-MMP-9 secretion (Ahmed et al., 2003a). In fact, proteomic
analysis

of

uPAR-antisense-clones

compared

to

wild-type

and

mock-

transfected control colon cancer cell line (HCT116) cells shows the loss of
approximately 200 proteins and quantitative differences in the expression of
141 other proteins (Ahmed et al., 2003b). Thus, evidence in the literature supports
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the notion that transfection of T-47D cells with uPAR cDNA may have affected
the secretion of uPA and expression of plasminogen receptors on the cell
surface along with that of cell-surface uPAR.
The low occupancy (44 %) of cell-surface uPAR on control untransfected
T-47D cells indicated that free uPAR was available for uPA binding prior to
transfection. The increase of cell-surface uPA on transfected T-47D cells is due
to concurrent upregulation of uPA expression and secretion in these cells,
which allowed more uPA to the increased cell-surface uPAR. Interestingly,
despite the increase of both cell-surface uPA and uPAR, overall uPAR occupancy
on transfected T-47D cells (~ 50 %) was not significantly different from that on
control T-47D cells. This was also reflected by the fact that there was a direct
correlation between the increase of cell-surface levels of uPAR and uPA, thus
the occupancy rates of uPAR on the cell-surface was not affected. In other
words, these cells appear to dynamically maintain a proportion of receptor
unoccupied despite transfection procedures. The significance of maintenance of
unoccupied receptors on these cells prior to and after transfection may be
related to the newly characterised functions of unoccupied uPAR. The clustering
of unoccupied uPAR has been implicated in cell signalling leading to changes in
adhesion and migration (Koshelnick et al., 1997; Sitrin et al., 2000; Gellert et
al., 2003; Sitrin et al., 2004) via association with lipid rafts or caveolae (Wei et
al., 1999) and integrins (Tarui et al., 2001). Since the binding of uPA restricts
the lateral mobility of uPAR (Myöhänen et al., 1993), reserving unoccupied
receptor may be a tactic used by cells to allow the movement of uPAR to focal
adhesion contact points where it may cluster and accumulate with caveolae
(Wei et al., 1999) and integrins before being occupied by uPA and being
restricted to these areas.
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While there was not a direct correlation, the increase in uPAR/uPA on
transfected T-47D cells corresponded to an increase in plasminogen binding
capacity. Furthermore, plasminogen binding was co-localised with cell-surface
uPA when analysed by confocal microscopy. On both MDA-MB-231 and uPARoverexpressing T-47D cells, uPA preferentially distributed to basal sections of
attached cells. This was in agreement with previous studies which documented
the high concentration of uPA/uPAR at focal adhesion sites (see review by
Andreasen et al., 1997). Areas of co-localisation of uPA and plasminogen were
confirmed on cell-surface of MDA-MB-231 cells as previously shown by
Andronicos

and

Ranson

(2001).

However,

the

overall

distribution

of

plasminogen was different on transfected T-47D cells compared to MDA-MB231 cells. MDA-MB-231 cells showed a broader diffuse staining for plasminogen
and not all co-localised with uPA (as per Andronicos and Ranson, 2001). The
large colocalisation of uPA and plasminogen on transfected T-47D cells in
addition to the increased plasminogen binding observed on control T-47D cells
when incubated with exogenous uPA suggests that uPA may act as a receptor
for plasminogen. In support of this suggestion, a novel non-active-site
interaction between uPA and plasminogen is necessary for the assembly and
efficiency of cell-surface plasminogen activation complexes (Ellis et al., 1999).
The inability to reduce the binding of glu-plasminogen when T-47D cells where
blocked with anti B-chain uPA monoclonal antibody confirmed that bound
plasminogen was independent of the active site of uPA. Similarly, this antibody
did not alter the co-localisation of glu-plasminogen and uPA detected by
confocal microscopy of MDA-MB-231 cells (Andronicos and Ranson, 2001). The
anti A-chain uPA monoclonal antibody also did not affect plasminogen binding
on transfected T-47D cells or MDA-MB-231 cells. This antibody is raised against
a different epitope in the A-chain of uPA deduced by Ellis et al. (1999) for the
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binding of glu-plasminogen, thus the possibility of uPA acting as a site for
plasminogen binding cannot be confidently excluded.
All together, the underlying reason for the co-localisation of gluplasminogen and uPA on the cell surface is to efficiently generate plasmin on
the cell surface (Andronicos and Ranson, 2001). However, other potential
receptors responsible for the co-localisation of plasminogen at close proximity to
cell-surface uPA are not known. Furthermore, comparison of transfected T-47D
cells to transfected MCF-7 cells complicates the scenario since both transfected
cell-lines displayed increased cell-surface uPAR and uPA, whereas only T-47D
cells showed increased plasminogen binding upon transfection with uPAR
cDNA. Similarly, while plasminogen binding increased on T-47D cells incubated
with exogenous uPA, plasminogen binding was not affected on MDA-MB-231
after the binding of exogenous uPA to these cells. These differences may reflect
cell line differences related to the expression of different plasminogen receptors.
In order to provide an explanation to these findings, two models are
proposed. First, intracellular signals initiated from increased uPAR and/or
increased uPA binding to uPAR may increase the expression of plasminogen
receptors on the cell surface. Intracellular signalling pathways initiated by
uPAR/uPA are indicated to regulate the proteolytic as well as the nonproteolytic functions of the urokinase plasminogen pathway such as cellular
adhesion,

chemotaxis,

cell

proliferation,

expression,

differentiation

and

endocytosis (see reviews by Conese and Blasi, 1995; Andreasen et al., 1997;
Chapman, 1997; Dear and Medcalf, 1998; Konakova et al., 1998; Preissner et
al., 2000; Blasi and Carmeliet, 2002). Increased plasmin generation, which
would require increased plasminogen binding, has been described for uPAR
cDNA transfected human osteosarcoma (HOS) cells (Kariko et al., 1993). In the
case of control untransfected T-47D cells incubated with exogenous uPA,
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intracellular signals are initiated simply due to the binding of uPA to
unoccupied cell-surface uPAR (Figure 27). Sufficient evidence exists to suggest
that intracellular signalling due to uPAR/uPA overexpression and/or the
addition of exogenous uPA was responsible for increased plasminogen binding
in T-47D cells. This appeared not to be the case for transfected MCF-7 cells
possibly due to inefficient increase in cell-surface uPAR/uPA.
The

second

proposed

model

which

may

explain

the

increased

plasminogen binding on uPAR/uPA overexpressing T-47D cells or uPAincubated control T-47D cells may relate to proteolytic activity on the cell
surface (Figure 27). The increased proteolytic activity of plasmin on the cellsurface may have caused the exposure of new lysine residues nearby and
resulted in increased plasminogen binding and the apparent co-localisation of
uPA and plasminogen on transfected T-47D cells. This was not observed on
MDA-MB-231 cells incubated with exogenous uPA since the cell-surface may
have been already maximally activated for plasminogen binding on these
invasive cells. In the case of transfected MCF-7 cells the small increase in cellsurface uPAR/uPA may have not substantially increased plasmin activity on the
cell-surface. Candidates receptors for plasminogen include actin, annexin II,
cytokeratin 8, α-enolase, megalin and tetranectin (reviewed by Félez, 1998;
Ranson and Andronicos, 2003). While only cytokeratin 8 and α-enolase display
a C-terminal lysine residue required for the lysine-dependent binding of gluplasminogen, the other plasminogen receptors may be considered as latent
receptors which require plasmin modification for glu-plasminogen binding
(Félez, 1998; Ranson and Andronicos, 2003). Thus, increased cell-surface uPA
on transfected T-47D cells and control T-47D cells incubated with exogenous
uPA as well as increased plasminogen receptors may result in increased
plasmin activity which may in turn activate latent plasminogen receptors.
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Finally, the overexpression of uPAR affected the morphology of
transfected T-47D cells where the cells adopted a less epithelial (round) shape
and more fibroblastic (elongated) shape, similar to MDA-MB-231 cells, in
comparison to control T-47D cells. This observation is supported by data
showing that, in contrast, antisense uPAR-transfected human glioma cell line
(SNB19) adopt larger and more round morphology, fail to form an organised
actin cytoskeleton and do not spread efficiently when plated over ECM
substrates in comparison to control cells (Chintala et al., 1997). Thus,
modulation of uPAR-expression appears to affect cell differentiation/expression
and morphology relating to the malignant phenotype of cancer cells.
In summary, transient overexpression of uPAR cDNA in T-47D cells
affected the level of cell-surface uPA and plasminogen binding. Transient uPARoverexpressing T-47D cells, as discussed in the next chapter were used to
assess PAI-2 binding in comparison to other breast cancer cell lines. uPARoverexpressing T-47D cells were also useful to elucidate some molecular details
regarding the effect of uPAR expression on invasiveness. Increased lysine
dependent plasminogen binding due to increased cell-surface uPA on uPARoverexpressing T-47D cells or control T-47D cells incubated with exogenous
uPA suggests a role for uPA/uPAR in plasminogen binding. Two models for this
effect were proposed, illustrated in Figure 27, which describe possible molecular
details for increased invasiveness due to uPAR overexpression however; future
work is required to provide definitive evidence for these conclusions or other
explanations.

uPAR

uPA

Plg receptor

Cell

Latent plg receptor

Nucleus

• Increasing cell-surface
uPAR/uPA by transfection
or
• Addition of uPA to occupy
the unoccupied uPAR

uPA proteolytic activity may activate latent
plasminogen receptors

uPAR/uPA mediated signal may induce
expression of plasminogen receptors on
the cell surface

Figure 27: Proposed model for increased plasminogen binding due to increased cell-surface uPA/uPAR
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Chapter 4: KINETIC ANALYSIS OF UPA:PAI-2 COMPLEX
FORMATION AND SUBSEQUENT INTERNALISATION BY
BREAST CARCINOMA CELL LINES

4.1. INTRODUCTION
Binding of uPA to its receptor significantly increases the rate of uPAmediated plasminogen activation in vitro (Ellis et al., 1991) and in vivo (Quax et
al., 1991b). The co-localisation of plasminogen with uPA at cell surfaces
provides a mechanism for accelerated plasminogen activation by cells
(Andronicos and Ranson, 2001). Receptor-bound plasmin is protected from
inactivation by circulating inhibitors (Hall et al., 1991) and thus promotes the
remodelling of the local extracellular environment by either directly degrading
basement membranes and extracellular matrix (ECM) or by activating prometalloproteases (Andreasen et al., 1997). Plasmin is also responsible for the
release of latent growth/angiogenic factors from ECM (Bass and Ellis, 2002;
Rakic et al., 2003).
The proteolytic activity of soluble and uPAR-bound uPA is efficiently
inhibited by PAI-1 and PAI-2 (see Section 1.4.D. for details, Cubellis et al., 1989;
Ellis et al., 1990; Pöllänen et al., 1990). The crystal structures and inhibitory
mechanism of both PAI-1 (Nar et al., 2000) and PAI-2 (Jankova et al., 2001;
Saunders et al., 2001) are well defined (see Section 1.4.D.1). Both act as classic
serpins and form SDS-stable 1:1 stoichiometric complexes with the catalytic site
on their target protease (Kruithof et al., 1995; Huntington et al., 2000; Nar et al.,
2000; Jankova et al., 2001; Saunders et al., 2001).
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Although the PAI-2 inhibitory mechanism is well characterised in vitro, to
date only indirect quantitative analyses of cell-bound uPA inhibition by PAI-2
have been made by monitoring plasminogen activation using a coupled
colorimetric assay (Ellis et al., 1990; McGowen et al., 2000). Using such an
assay, Ellis et al. (1990) derived the second order association rate constant
value of 3.3 x 105 M-1s-1 on U937 cells, thus were the first to describe the rapid
and efficient inhibition of cell surface uPAR-bound uPA by PAI-2. However,
insights into the serpin inhibitory mechanism gained since this study was
published (Kruithof et al., 1995; Jankova et al., 2001; Saunders et al., 2001)
cast some doubt on the parameters used to measure inhibition. Silverman
(1996) states that as serpins are ‘mechanism-based enzyme inactivators’, in
that they irreversibly inhibit their target protease by forming a covalent bond
with the protease (Huntington et al., 2000), the two principal parameters for
describing this class of inhibitors are the inactivation rate constant (kinact) and
the inactivation constant (KI). As PAI-2 has been shown to be a classic serpin
(Jankova et al., 2001; Saunders et al., 2001), kinact and KI are more appropriate
parameters for measuring inhibition by PAI-2. The irreversible formation of the
complex between PAI-2 and uPA reflects the complete inhibition of uPA activity.
Therefore, the level of PAI-2 binding to cells would provide a direct measure for
the inhibition of cell-surface uPA. While Estreicher et al. (1990) investigated the
kinetics of complex formation between receptor-bound uPA on the THP-1
monocytic cell line and PAI-2, this was a semi-quantitative and indirect analysis
of PAI-2 binding as

125I-uPA

was used as the means of detection. Thus, the

inactivation constants for PAI-2 inhibition of uPA (kinact and/or KI) have not been
previously reported.
There is also very little direct data regarding the fate of PAI-2 after
inactivation of uPAR-bound uPA. In contrast, PAI-1, either added to uPAR-
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bound uPA or as a preformed complex with uPA, has been definitively shown to
induce the rapid cellular internalisation and degradation of the complex. This
internalisation process requires uPAR and one or more of the members of the
low density lipoprotein receptor (LDLR) family of endocytosis receptors such as
α2-macroglobulin

receptor/low-density

lipoprotein

receptor-related

protein

(α2MR/LRP) (see reviews by Andreasen et al., 1997; Loskutoff et al., 1999).
Estreicher et al. (1990) reported that

125I-uPA:PAI-2

complexes are rapidly

cleared from the cell surface of THP-1 cells following the formation of a cellsurface bound 70 kDa degradation intermediate. The identity of the cleavage
site or product was not ascertained. Jensen et al. (1990) reported that PAI-2
mediated about 40 % degradation of uPAR-bound

125I-uPA

on human

choriocarcinoma cells. Both authors speculated that like PAI-1, PAI-2 mediates
the endocytosis of uPAR-bound uPA whereupon both uPA and PAI-2 are
degraded in lysosomes. However, neither study provided data supporting these
claims. Ragno et al. (1995), also using THP-1 cells, found that the 125I-uPA:PAI-2
complex is cleaved into a 70 kDa fragment (comprising the uPA B chain
complexed to PAI-2) as well as a 22 kDa fragment (mostly uPA A chain) after
binding to uPAR. These authors concluded that neither the 22 nor 70 kDa
fragments are internalised but rather that the 70 kDa fragment is released into
the cell medium while the 22 kDa fragment remains cell-surface bound. It
should be noted that a 70 kDa fragment (Saunders et al., 1998: See Figure 5) as
well as a 22 kDa fragment (Croucher et al., unpublished data) can also be
obtained in solution by incubating excess 55 kDa uPA with PAI-2. This suggests
that the intermediary formation of these fragments may not necessarily be a
step related to uPAR binding of uPA:PAI-2 but to an undefined cleavage step in
solution. Despite these apparent contradictions and lack of any direct evidence,
it has become accepted in the literature that PAI-2, unlike PAI-1 and other
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serpins, is not internalised after inhibiting uPAR-bound uPA on cells (Andreasen
et al., 1997; Andreasen et al., 2000; Schmitt et al., 2000).

4.1.A. RATIONALE AND AIMS
The inhibition kinetics of PAI-2 towards cell-surface uPA were measured
using coupled assays which utilised uPA-mediated plasmin generation as an
indicator of PAI-2 inhibition of uPA. The aim of this chapter was to develop
binding assays to measure uPA:PAI-2 complex formation on the cell surface which
would directly reflect PAI-2 inhibitory kinetics on the cell-surface. Due to the
controversial fate of cell-bound uPA:PAI-2 complexes, it was also the aim to
provide definitive evidence for the fate of these complexes in breast carcinoma
cell lines.

4.2. METHODS
4.2.A. PREPARATION OF 125I-PAI-2 FOR RADIOLIGAND BINDING STUDIES
Radio-iodination

of

PAI-2

was

performed

as

per

manufacturer’s

instructions (Pierce Chem. Co., IL, USA) and as previously described (Hang et
al., 1998). Briefly three iodo-beads were washed three times with 3 ml of
1 x PBS (pH 7.2) at room temperature and dried on Whatman #1 filter paper.
Washed beads were transferred to a reaction tube containing 0.5 milli-Curies
(mCi) of iodine-125 radioisotope (125I) diluted in a final 500 µl volume of 1 x PBS.
After 5 min incubation at room temperature, 50 µg of PAI-2 was added to the
reaction vessel, mixed gently and incubated 15 min at room temperature.
Radiolabelled PAI-2 was immediately separated from free

125I

by size

exclusion chromatography where PD-10 columns were equilibrated with 15 ml
of freshly prepared elution buffer [1 x PBS, 0.1 % w/v BSA, pH 7.4]. The
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radiolabelling reaction was allowed to pass through the column followed by two
0.2 ml aliquots of elution buffer. Ten to twelve 0.5 ml-fractions of the eluant
were collected during the continuous addition of elution buffer. Aliquots (10 µl)
from eluted fractions were counted using normalised‡ Cobra 5005R gamma (γ)counter (Packard Instruments Co., CT, USA). The fraction(s) corresponding to
the first high radioactivity peak were collected. This represented radiolabelled
PAI-2 (Figure 28) and was stored at 4oC in dark until further use for up to 14
days.
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Figure 28: Representative purification profile of 125I-PAI-2
Radiolabelling and purification of 125I-PAI-2 were performed as described earlier. The
radioactivity of 10 µl aliquots from the 0.5 ml fractions collected was measured and
plotted (Y-axis) against the elution volume required to obtain that fraction (X-axis). The
first peak (i.e. fraction 4) represents purified 125I-PAI-2 whereas the second peak
represents free 125I.

‡

See Appendix 1 (Section 7.1.) for normalisation procedure of the Cobra® γ-counter
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The percentage of free

125I

in the purified

125I-PAI-2

solution was

determined by instant thin layer chromatography (Section 2.2.B.5.). The purity
of

125I-PAI-2

was generally more than 95 % (97 ± 1 %, n = 4) indicating that the

majority of free

125I

was removed from 125I-PAI-2.

4.2.A.1. DETERMINATION OF SPECIFIC RADIOACTIVITY
The specific radioactivity of

125I-PAI-2

was determined using two

methods; autoradiography of SDS-PAGE fractionation and utilising the data
from PD-10 column purification (Bolton, 1977). This was done due to the
contaminating presence of BSA in the preparations as 0.1 % BSA (fraction V§)
was used in the PD-10 column purification.
In the first method, both

125I-PAI-2

and

125I-uPA:PAI-2

complexes were

fractionated on the same gel as PAI-2 standards of known protein amounts
(Figure 29 – A). Autoradiogram of this showed that all of the

125I-PAI-2

was

complexed with uPA, thus the 98 kDa band (Lane 2 Figure 29 – B) contains all
the

125I-PAI-2

added to the reaction. This indicated that some of the protein in

the 47 kDa band (Lane 1 Figure 29 – A) was due to the contaminating presence
of BSA which mostly fractionated at around this molecular weight (data not
shown). Since uPA:PAI-2 form 1:1 complexes, then 50 % of the protein in the 98
kDa band (Lane 2 Figure 29 – A) is due to PAI-2. The amount of

125I-PAI-2

in the

aliquot (10 µl) used was interpolated by comparison of the intensity of the 98
kDa band (Lane 2 Figure 29 – A) to the standard curve constructed for the
relationship between amounts of PAI-2 protein standards (Lanes 3 – 6 Figure 29
– A) and staining intensity (data not shown).

§

BSA was used in PD-10 purification in order to minimise the non-specific binding of
the small amounts of PAI-2 used to the column bed or plastic.
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Figure 29: Representative SDS-PAGE and autoradiogram of 125I-PAI-2
125I-uPA:PAI-2 complexes were generated as described in Section 2.2.B.4 except that a
molar excess of uPA was used. (A) Samples were fractionated by reducing 12 % SDSPAGE, (B) the gel was exposed to phosphor screen for 3 h and the screen was scanned,
then the gel was stained with Coomassie blue, destained and documented. Lane 1: 125IPAI-2, lane 2: 125I-uPA:PAI-2. Equivalent amount of 125I-PAI-2 (10 µl) was used for lanes
1 and 2. Lanes 3 – 6: PAI-2 standard solutions - 0.1, 0.4, 0.8 and 1.0 µg respectively.
The position and size of bands (in kDa) of the molecular weight marker are shown at the
right. SDS-PAGE and autoradiography produced the amount of 125I-uPA:PAI-2 complex
(98 kDa). This was converted to the amount of 125I-PAI-2 using molar equivalence since
1 mole of complex is equivalent to 1 mole of PAI-2.

The second method for determination of protein concentration utilised
the data from PD-10 column purification (Bolton, 1977). Briefly, the difference
between the total radioactivity used and the activity eluted as free

125I

was
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calculated to represent PAI-2-bound radioactivity (data not shown). The
radioactivity of the selected purified fraction over the total bound radioactivity
represented the percentage recovery of protein in the purified fraction (e.g. 6.3
% for preparation shown in Figure 28). The amount of PAI-2 in the purified
fractions was calculated by the percentage recovery and the total amount of
PAI-2 used (6.3 µg for preparation in Figure 28). The estimated protein
concentration of

125I-PAI-2

preparations was almost identical using the two

different methods and the average was used (Table III). Thus, specific
radioactivity (s.a.) could be calculated and this was based on the average
protein concentration derived using the above two methods, radioactivity in
each sample and the purity of

125I-PAI-2

preparations (Table III).

4.2.B. PREPARATION OF PAI-2-CY5 FOR INTERNALISATION STUDIES
PAI-2 was labelled with Cy5 fluorochromes as per manufacturer’s
instructions of the Cy5 mono-reactive dye pack (Amersham Biosciences,
Uppsala, Sweden). PAI-2-Cy5 was separated from free Cy5 by size-exclusion
chromatography (see Section 4.2.B.1.); however BSA was not included in the
equilibrium or elution buffer since large amounts of PAI-2 were used for the
conjugation reactions. Purified PAI-2-Cy5 was stored in the dark at 4oC until
further use. The protein concentration and the dye/protein ratio (D/P) for PAI2-Cy5 preparation were calculated as per manufacturer instructions**. PAI-2Cy5 retained the ability to form SDS-stable complexes with uPA (data not
shown).

**

D/P = [Cy5]/[PAI-2] = (A650 /

εCy5)/(A280 – (0.05 x A650)/ εPAI-2)

Concentration is in molar units, A: is the absorbance and
coefficient (M-1 cm-1)

ε

is the extinction
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Table III: Properties of the purified 125I-PAI-2 preparations
PAI-2
Concentration
(ng/µl)a

PAI-2
Concentration
(ng/µl)b

Radioactivity
(cpm/µl)

% Purity

Specific
radioactivity
(cpm/µg)

Specific
radioactivity
(cpm/nmole)

1

15

14

1.44 x 105

99.4%

1.28 x 107

6.01 x 108

2

1.5

1.6

5.03 x 104

96.3%

4.07 x 107

1.91 x 109

3

2.0

2.1

7.20 x 104

96.7%

4.35 x 107

2.05 x 109

125I-PAI-2

Preparation

PAI-2 concentration was determined by (a) SDS-PAGE and autoradiography method or (b) PD-10 column-based method. Radioactivity was determined
by counting the radioactivity of a known volume of 125I-PAI-2 solution. The specific radioactivity was calculated as the radioactivity concentration
(corrected to 80 % counting efficiency of detector) multiplied by the percentage purity (bound activity) and divided by the average protein concentration.
The specific activity was converted from units of cpm/µg to cpm/nmole using the molecular weight of PAI-2.
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4.2.C. RADIOLIGAND BINDING STUDIES USING 125I-PAI-2
The formation of complexes between

125I-PAI-2

and cell-surface uPA in

terms of PAI-2 binding reflects the inhibition of uPA activity and can be used to
analyse inhibitory kinetics of PAI-2 at the cell surface. Radioligand binding
studies were performed using

125I-PAI-2

of known concentration and specific

activity. Metastatic and non-metastatic breast carcinoma cell lines were
prepared and resuspended in binding buffer as described earlier (Section
2.2.A.1.).
Initial binding experiments were performed in order to estimate the time
required for saturation binding and establish a linear correlation between
binding and cell number. Cells were incubated at 4oC with

125I-PAI-2

(~ 5 x 105

cpm/ml) in the presence or absence of unlabelled PAI-2. Triplicate aliquots (200
µl) were removed at the specified time point and cells were processed for
radioactivity counting as described below. The relation between cell number and
binding of

125I-PAI-2

was established by the incubation of increasing cell

numbers at 4oC for the time required to reach saturation with 5 x 105 cpm/ml
of

125I-PAI-2

in the absence or presence of unlabelled PAI-2. The amount of

PAI-2 bound was plotted against the number of cells. Further binding
experiments were performed using the time required to reach saturation and
number of cells which falls in a linear correlation in the relationship between
the amounts of bound PAI-2.
Generally, after binding of

125I-PAI-2

to cells, cells were processed for

radioactivity counting and analysis as follows. Cells were washed using ice-cold
1 x PBS containing 1 mM CaCl2 and 1 mM MgCl2, lysed using 200 µl of 0.1 M
NaOH and counted using the γ-counter normalised for
binding of PAI-2 was measured as the binding of

125I

125I-PAI-2

counting. The total

in the absence of any
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inhibitors, whereas the non-specific binding was measured as the binding of
125I-PAI-2

to cells in the presence of 100-fold molar excess of unlabelled PAI-2.

The specific binding in all assays was calculated as the difference between the
total and non-specific binding. Binding was initially measured in units of
radioactivity relative to the number of cells used (i.e. cpm per million cells). This
binding was converted to be expressed in units of femtomole (fmole) per million
cells using the specific activity of

125I-PAI-2

used (cpm/mole). Data from all

binding experiments was analysed using the functions specified in the
radioligand binding analysis software, GraphPad® prism (v 3.03).

4.2.D. INTERNALISATION STUDIES USING PAI-2-CY5
PAI-2-Cy5 and confocal microscopy were used to detect the fate of PAI-2
on MDA-MB-231 and T-47D cells either detached or attached to cover slips. For
detached cells, cells were prepared as described earlier (Section 2.2.A.1.),
washed and resuspended in ice-cold phenol red-free binding buffer at 1 x 106
cells/ml. The cell solution was adjusted to 37oC and PAI-2-Cy5 was added at a
final concentration of 100 nM. Samples were removed at specified time points
and diluted 1:25 in ice-cold phenol red-free binding buffer in order to stop the
reaction. Samples were centrifuged at 652 x g for 3 min at 4oC and pellets were
washed with ice-cold PBS containing 1 mM CaCl2 and 1 mM MgCl2 and
analysed immediately by confocal microscopy (as described in Section 2.2.A.3.).
For attached cells, cells grown for 48 h on cover slips in 6-wells plates were
washed and activated with plasminogen (5 µg/ml in RPMI-1640 for 5 min at
RT). Cells were washed four times using PBS containing 1 mM CaCl2 and 1 mM
MgCl2, temperature was adjusted to 37oC and pre-warmed phenol red-free
binding buffer containing 100 nM PAI-2-Cy5 was added. At specified time
points, ice-cold phenol red-free binding buffer was added to dilute PAI-2-Cy5
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solution then the total volume was immediately removed. Cells were washed
gently 5 times with ice-cold 1 x PBS containing 1 mM CaCl2 and 1 mM MgCl2,
cover slip mounted on glass slide and analysed immediately by confocal
microscopy. In addition, internalisation was compared between cells before and
after blocking of uPA by pre-incubation of cells with 20 µg/ml anti-B-chain uPA
monoclonal antibody at 4oC. Cells pre-incubated with exogenous uPA (100 nM
at 4oC for 30 min) were also compared to control cells.
Endosomal and lysosomal markers conjugated with fluorochromes were
utilised in order to detect whether PAI-2-Cy5 localised into these organelles.
Cells were incubated for 20 min in ice-cold phenol red-free binding buffer
containing 100 nM of PAI-2-Cy5 and 50 µg/ml transferrin-Alexa488 (endosomal
marker Van Dam et al., 2002). Cells were washed with PBS containing 1 mM
CaCl2 and 1 mM MgCl2 at room temperature and then resuspended in 37oCprewarmed phenol red-free binding buffer containing 75 nM LysoTracker®
Yellow DND-68 (lysosomal marker). Samples were removed at specified time
points, washed with ice-cold PBS containing 1 mM CaCl2 and 1 mM MgCl2 and
analysed immediately by confocal microscopy.
In order to confirm lysosomal degradation of any internalised uPA:PAI-2
complexes, lysates of MDA-MB-231 cells pre-incubated with 100 nM PAI-2-Cy5
at 37oC for specified periods of time were fractionated by 12 % SDS-PAGE under
reducing conditions. The resulting gel was scanned using the red fluorescence
scanner then Coomassie blue stained (as described in Sections 2.2.B.2. and
2.2.B.3.) The acquired Cy5 fluoro-image was superimposed onto the Coomassie
blue stained gel and the molecular weight of the observed bands in the Cy5
scan was calculated using the standard molecular weight marker in the
Coomassie blue stained gel.
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4.2.E. EFFECT OF PAI-2 ON CELL-SURFACE UPA/UPAR LEVELS
The effect of PAI-2 binding to cell-surface uPA on uPA/uPAR was
analysed by flow cytometry. MDA-MB-231 cells pre-activated with plasminogen
were incubated in the absence or presence of 100 nM of PAI-2 in binding buffer
at 37oC. At specified time points, samples were removed, washed and then
subjected to indirect immunofluorescence detection of cell-surface uPA and
uPAR as described earlier (Section 2.2.A.2.). Anti human A-chain uPA
monoclonal antibody was used since PAI-2 inhibits uPA by interaction at the
uPA B-chain which may sterically hinder anti-B chain antibody access hence
inhibit detection by flow cytometry. In order to test dose-dependency of the
effect of PAI-2 on cell-surface uPA, this assay was performed using different
concentrations of PAI-2 (1, 10 and 100 nM).
The effect of PAI-2 on the total capacity of cells to bind uPA was assayed
by incubation of cells with 100 nM of PAI-2 at 37oC and samples were removed
at specified time points. The cells were adjusted to 4oC to inhibit any further
possible endocytosis then incubated in the absence (endogenous uPA) or
presence of 100 nM exogenous uPA (total maximal uPA) for 30 min on ice prior
to analysis of cell-surface uPA by flow cytometry. The difference between the
total maximal uPA and the endogenous uPA levels was used to represent the
binding of exogenous uPA (i.e. unoccupied uPAR) under the effect PAI-2
internalisation over time.
Finally, the effect of uPAR occupancy on the effect of PAI-2 on cellsurface uPA was assayed on cells pre-incubated with 100 nM of exogenous uPA
in binding buffer at 4oC (i.e. saturated cells) then incubated with 100 nM of PAI2 in binding buffer at 37oC. Samples were removed and washed and cell-surface
uPA level was measured by flow cytometry.
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4.3. RESULTS
4.3.A. QUANTIFICATION OF
UPAR-BOUND UPA

125I-PAI-2

BINDING

TO

CELL-SURFACE

4.3.A.1. JUSTIFICATION FOR PERFORMING BINDING EXPERIMENTS AT 4OC
The use of uPA colorimetric substrates was not suitable to assay cellsurface uPA activity since cell-viability was greatly reduced (> 90 % dead) within
few minutes of incubation (data not shown). To the best of my knowledge,
uPA:PAI-2 complex formation at 4oC over short periods of time has not been
shown previously. Since cell binding experiments with

125I-PAI-2

required

incubation at 4oC to prevent possible endocytosis, confirmation of complex
formation at 4oC was essential in order to reflect complete inhibition of uPA
activity. Incubation of molar excess of PAI-2 with uPA in fluid phase, to mimic
cell binding studies where saturating amount of PAI-2 would be added to cells,
showed that SDS-stable complexes between PAI-2 and uPA formed after 15 min
at 4oC (Figure 30). The conversion of the synthetic colorimetric uPA substrate,
Spectrozyme®-UK, was entirely inhibited when equimolar amounts of PAI-2 were
incubated for 15 min with uPA in solution at 4oC (data not shown). Thus,
complex formation between

125I-PAI-2

and cell-surface uPA at 4oC should occur

and would reflect the inhibition of uPA activity.
Initial binding experiments showed that complex formation on the
metastatic MDA-MB-231 cells reached equilibrium by 30 min of incubation at
4oC using 1.5 nM
total

125 I-PAI-2

125I-PAI-2

(data not shown). As only a small fraction of the

added was bound to cells, this indicated that PAI-2 ligand

was not depleted in the assay (Motulsky and Christopoulos, 2004). Using this
concentration of

125I-PAI-2

and 2 h incubation time, a linear correlation was

established between the amount of PAI-2 bound and cell concentration (1 – 5 x
106 cells/ml) (data not shown). Thus, subsequent experiments were performed
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using ~ 1.5 nM
Furthermore,

125I-PAI-2

125I-PAI-2

and 1 - 4 x 106 cells/ml and 1 – 2 h incubation.

binding assays did not affect cell viability as judged by

trypan blue staining compared to control cells (incubated in the absence of PAI2) performed on samples from each individual assay (data not shown).
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Figure 30: Formation of uPA:PAI-2 complexes at 4oC in fluid phase
A 4-fold molar excess of PAI-2 was incubated with uPA (containing both high [55 kDa]
and low [33 kDa] molecular weight forms) at 4oC. Equal aliquots were removed after
15 min (Lane 3), 30 min (Lane 4), 45 min (lane 5), 60 min (Lane 6) and 120 min (Lane
7) and fractionated by reducing 12 % SDS-PAGE. PAI-2 alone (4 µg, Lane 2), uPA alone
(1 µg, Lane 1) and 4-fold molar excess PAI-2 incubated with uPA for 120 min at 37oC
(Lane 8) were also fractionated as controls.

A series of

125I-PAI-2

binding experiments confirmed that PAI-2 binding

capacity is directly related to the amount of cell-surface uPA which indicate that
125I-PAI-2

binding to the cell-surface was reflective of uPA inhibition and that

uPA is the only specific cell-surface protease inhibited by PAI-2 on human
breast carcinoma cell lines. First, the specific

125I-PAI-2

binding on high uPA

expressing MDA-MB-231 cells was significantly higher (~ 10-fold) than that on
low uPA-expressing MCF-7 and T-47D cells (p < 0.05 n =3, Figure 31).
Furthermore, for each cell line PAI-2 binding was significantly enhanced by
plasminogen pre-treatment (to activate any receptor-bound pro-uPA) (Figure
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31). These data also indicated that a proportion of the total endogenous cell

Specific 125I-PAI-2 Binding
(fmoles per million cells)

surface uPA was in the pro-uPA form.
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Figure 31: 125I-PAI-2 binding to metastatic and non-metastatic breast cancer cells
MDA-MB-231, MCF-7 and T-47D cells were incubated in the absence (clear bars) or
presence (filled bars) of 5 µg/ml plasminogen at room temperature. Cells were washed
and incubated with 1.5 nM 125I-PAI-2 at 4oC for 2 h in the absence (total) or presence
(non-specific) of 150 nM of unlabelled PAI-2. Specific binding was calculated and data
presented are the mean ± SEM (n = 3). One asterisk denotes significant difference in
PAI-2 binding to the same cell line under different treatment, whereas two asterisks
denote significant difference between different cell lines subjected to the same treatment
(p < 0.05).

Secondly, when cell-surface uPA was either pre-blocked using a
neutralizing monoclonal antibody, or a uPA specific active-site alkylating agent
(EGR-CMK) or acid-stripped prior to

125I-PAI-2

incubation, the total

125I-PAI-2

binding to MDA-MB-231 cells was reduced to the same levels obtained in the
presence of excess unlabelled PAI-2 (i.e. non-specific binding, approximately
25% of total binding) (Figure 32). These data indicate that all of the specific
binding of PAI-2 to these cells can be attributed to cell surface uPAR-bound uPA
and that there may be some non-specific binding sites for PAI-2. Similar results
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were obtained using HCT116 colorectal (Hang et al., 1998) and PC-3 prostate
(Al-Ejeh et al., 2004) carcinoma cells. This indicates that these treatments
sufficiently decreased binding to non-specific binding levels and indicate that
uPA is the only specific target for PAI-2 on breast, colorectal and prostate
carcinoma cells. When surface-stripped cells were then incubated with
exogenous uPA prior to

125I-PAI-2

incubation, total

125I-PAI-2

binding was

enhanced by 2.3-fold compared to control cells (Figure 32). These data also

Total 125I-PAI-2 Binding
(fmoles per million cells)

suggest the presence of unoccupied uPAR sites on non-treated cells.
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Figure 32: 125I-PAI-2 binding to MDA-MB-231 cells under different treatments
MDA-MB-231 cells pre-activated with plasminogen were incubated in the absence
(control) or presence of anti-B-chain uPA (10 µg/ml of the #394 monoclonal antibody) or
the active-site alkylating agent (EGR-CMK, 0.5 mM) for 30 min at 4oC. Other cells were
incubated for 5 min in acid wash solution (acid strip: 100 mM NaCl, 50 mM glycine, pH
2.8, Stoppelli et al., 1986). All cells were diluted 1:10 in binding buffer to neutralise the
incubation condition and washed with PBS. Stripped cells were incubated in the
absence of presence of 100 nM uPA for 30 min at 4oC and then washed. Treated cells
were incubated with 1.5 nM 125I-PAI-2 for 2 h at 4oC whereas control cells were similarly
incubated with 125I-PAI-2, however in the absence (control) or presence of 150 nM
unlabelled PAI-2 (excess unlabelled). Cells were washed and lysed for radioactivity
counting. Asterisks denote significant differences in amounts of PAI-2 bound compared
to control MDA-MB-231 cells (p < 0.05, n = 3).
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Cell-surface endogenous uPA levels were significantly enhanced (2-fold,
Figure 33 – A) on uPAR overexpressing T-47D cells (2-fold increase in uPAR,
data not shown) compared to controls (i.e. untreated or mock-transfected cells,
as described in Section 3.3.B.1). Concomitantly, a significant increase in PAI-2
binding capacity was also observed on uPAR-transfected T-47D cells compared
to control T-47D cells (p < 0.05 n = 3, Figure 33 – B).
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Figure 33: Specific binding of 125I-PAI-2 to control and transiently uPARoverexpressing T-47D cells
T-47D cells were transiently transfected with pcDNA3/uPAR+ plasmid as per optimised
method (Section 3.3.A.). (A) Control and transfected T-47D cells (T-47D/uPAR+) were
assayed for uPA expression by flow cytometry using the #394 anti-uPA monoclonal
antibody. Data are presented as the mean fluorescence intensity (MFI) ± SEM (n =3). (B)
Control and transfected T-47D cells were incubated with 1.5 nM 125I-PAI-2 in the
absence or presence of 150 nM of unlabelled PAI-2. The specific binding was calculated
and data presented are the mean ± SEM (n = 3). Asterisks denote significant differences
between control and transfected T-47D cells (p < 0.05). Transfected cells showed 2-fold
increase in cell-surface uPAR (data not shown).
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Finally,

when

simultaneous

assays

for

125I-PAI-2

binding

and

immunofluorescent detection of uPA were performed, a linear correlation was
observed between PAI-2 binding capacity and cell-surface uPA levels on the
various cancer cell lines (Figure 34). This was expected since PAI-2 complexes to
uPA at 1:1 molar stoichiometric ratio.
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Figure 34: Correlation between cell-surface uPA and 125I-PAI-2 binding
The specific 125I-PAI-2 binding on cultured breast cancer cells was plotted against the
cell-surface uPA simultaneously assayed for the same cell line. Data are presented as
mean ± SEM (n = 3) for PAI-2 binding and MFI ± SEM (n = 3) for cell-surface uPA level.
The r2 for the linear correlation was 0.99 and the data did not deviate from the fitted line
as judged by runs test (degrees of freedom = 28). Asterisks mark significant differences
in cell-surface uPA and PAI-2 binding level compared between the different cell lines
used. There was no significant difference between MCF-7 and T-47D cells for cellsurface uPA or PAI-2 binding level.
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4.3.A.2. PAI-2 INHIBITION PARAMETERS AT THE CELL SURFACE
Saturation assays showed that PAI-2 bound in a saturable and specific
manner to MDA-MB-231 cells (representative saturation curve shown in Figure
35). As expected, saturation binding best fitted a single-binding site model since
PAI-2 inhibits uPA by forming an irreversible 1:1 stoichiometric covalent
complex with the protease. The maximal amount of PAI-2 complexed with uPA
and the concentration PAI-2 required for half-inactivation†† (inhibition constant,
KI) of uPA on the surface MDA-MB-231 cells were calculated by the fitted model
from three separate experiments and summarised in Table IV. The average
maximal binding was calculated to be 5.0 ± 0.2 fmoles of

125I-PAI-2

per million

cells and the average KI was 81 ± 9 pM.
Maximal binding of PAI-2 was significantly different between one of the
assays compared to the other two assays (5.9 ± 0.2 compared to 4.6 ± 0.1 and
4.5 ± 0.1 fmoles per million cells, p < 0.05). In assay 1, cells were cultured for 72
h compared to 48 h for assays 2 and 3. This is explained by the fact that cellsurface uPA levels are higher after 72 h in culture without passage compared to
48 h and that PAI-2 binding capacity is directly correlated to cell-surface uPA
(Figure 34). Nevertheless, the KI was not significantly different between the three
assays (p > 0.05), indicating that inhibition was mechanism-dependent rather
than uPA-level dependent. As further proof to the independency of KI from cellsurface uPA levels, saturation analysis of the non-metastatic, low cell-surface
uPA expressing T-47D cells which bind less PAI-2 (Section 4.3.A.1) also
produced a similar KI to that reported for MDA-MB-231 cells (83 ± 3 pM, Figure
36).

††

KI = concentration of PAI-2 required to reach half the maximal amount of PAI-2
complexed with cell-surface uPA. Since complex formation is reflective of inhibition
then KI = the concentration of PAI-2 required to inhibit half of cell-surface uPA
(Silverman, 1996).
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Figure 35: Saturation binding of 125I-PAI-2 to MDA-MB-231 cells at 4oC
125I-PAI-2

was measured in the absence (▼, total binding) or presence (●, non-specific
binding) of a 100-fold molar excess of unlabeled PAI-2 at each concentration. Specific
binding () was calculated by the subtraction of non-specific binding from the total
binding. Data was fitted best to a one binding site hyperbolic model (r2 = 0.97) from
which the concentration of 125I-PAI-2 required to achieve half-maximal binding (KI) as
well as the maximal binding was calculated. Irreversible binding of 125I-PAI-2 directly
reflects the inactivation of uPAR-bound uPA. Each data point represents the mean ±
standard error of the mean (SEM, n = 3).

Table IV: Inhibition parameters of 125I-PAI-2 binding to MDA-MB-231 cells

Saturation
Assay

KI
(pM)

Maximal Binding
(fmoles/million cells)

1

81 ± 4

5.9 ± 0.2*

2

83 ± 6

4.6 ± 0.1

3

79 ± 5

4.5 ± 0.1

Mean ±
SEM

81 ± 9

5.0 ± 0.2

Saturation assays were performed using three different preparations of 125I-PAI-2. Data
were fitted to one-binding site hyperbolic function as per Figure 35. None of the data
deviated from the fitted model (r2 = 0.93 – 0.97) as judged by the runs test performed by
GraphPad® (degrees of freedom = 18 – 21). The average KI and average maximal binding
and their respective SEM from the three experiments are shown. Asterisk denote
significant difference of maximal binding in assay 1 compared to assay 2 and 3 (p <
0.05, n = 20).
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Figure 36: Saturation binding of 125I-PAI-2 to T-47D cells at 4oC
T-47D cells (2 x 106 cells/ml) pre-incubated with 5 µg/ml plasminogen (at room
temperature for 5 min) were incubated in triplicate with increasing concentration of 125IPAI-2 in the absence or presence of 100-fold molar excess of unlabelled PAI-2. After 2 h
incubation, cells washed with PBS and lysed for activity counting. The specific binding
was calculated and data presented are the mean ± SEM. Data was fitted to one-binding
site hyperbolic curve (r2 = 0.95) and did not deviate from the fitted model as judged by
the runs test (degrees of freedom = 17).

The kinetics of formation of

125I-PAI-2

complexes with cell-surface uPA

was assayed at both 4oC and 37oC (Figure 37). The rate of complex formation
was reflective of the rate of inhibition (kinact) of cell-surface uPA and was
calculated to be 0.32 ± 0.03 and 0.48 ± 0.04 min-1 at 4oC and 37oC, respectively.
Based on the equation which describes the kinetics of mechanism-based
enzyme inactivators‡‡ the time required to reach half inhibition (t1/2) was

‡‡ t1/2 =

In 2 + In 2•KI Where t1/2 is the time for half inactivation, [I] concentration of
kinact
kinact•[I] the inactivator, KI is the inactivation constant ([I] required for
half inactivation) and kinact is the rate of inactivation. The
term inhibition is used here instead of inactivation to
avoid confusion as PAI-2 is described as uPA inhibitor
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calculated to be 2.3 ± 0.1 and 1.5 ± 0.1 min at 4oC and 37oC, respectively. These
differences in kinact/t1/2 inhibition at 4oC compared to 37oC indicated that
inhibition of cell-surface uPA was faster at 37oC than that at 4oC. The maximal
amount of bound

125I-PAI-2

were not significantly different between cells

incubated at 4oC and 37oC, indicating that the total amount of complexes

Specific 125I-PAI-2 Binding
(fmoles per million cells)

formed was temperature independent.
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Figure 37: Kinetics of

125

I-PAI-2 association to MDA-MB-231 cells

MDA-MB-231 cells (1 x 106 cells/ml) pre-activated with plasminogen were incubated
with 1.5 nM of 125I-PAI-2 in the absence or presence of 150 nM unlabelled PAI-2 at 4oC
(○) and 37oC (▲). At the specified time points aliquots were removed for radioactivity
counting. The specific binding of 125I-PAI-2 (fmoles/106 million cells) was calculated and
data presented are the mean ± SEM (n = 3). Data was fitted to one-phase exponential
association function (r2 > 0.96) and the curves did not deviate from the model. Only the
rate of complex was found to be significantly different (p < 0.05).
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4.3.B. THE FATE OF CELL-BOUND PAI-2
As shown in Figure 37, maximal PAI-2 binding to MDA-MB-231 cells
occurs within 15 min at 4oC. As incubation at 4oC prevents any endocytosis
that might occur, the majority of bound PAI-2 should be at the cell surface. This
was confirmed using PAI-2-Cy5 as the ligand for analysis of PAI-2 binding by
confocal microscopy (Figure 38). That binding was uPA-dependent was further
confirmed by pre-blocking cells with anti-B-chain uPA monoclonal antibody
(Figure 38). Pre-incubation of cells with exogenous 100 nM uPA, which
saturates all cell-surface uPAR (Stillfried G., manuscript in preparation), lead to
an increase in cell-surface associated PAI-2-Cy5 (Figure 38).
Confocal microscopy analysis of MDA-MB-231 cells incubated with PAI2-Cy5 at 37oC showed that PAI-2 was mainly localised in intracellular vesicles
after 15 min (Figure 39 - B). Internalisation of PAI-2-Cy5 at 37oC was specific
and selective since incubation of cells with BSA-Cy5 did not show any cellassociated fluorescence (Figure 39 – C). Indeed, pre-blocking of cell-surface uPA
on MDA-MB-231 cells with the anti-B chain uPA (#394) monoclonal antibody
not only inhibited the binding of PAI-2 (see Figure 38) but also the
internalisation of PAI-2-Cy5 (Figure 40). In contrast, when cells were preincubated with exogenous uPA in order to saturate cell-surface uPAR there was
a significant increase in PAI-2-Cy5 detected in the cytoplasm (Figure 40). This
suggests that PAI-2 not only binds in a uPAR-bound uPA-dependent manner
(see Figure 38) but is also internalised via a uPA-dependent pathway.

Control

Isotype

Anti-uPA

Exogenous uPA

I

II

III

IV

V

VI

VII

VIII

IX

X

XI

XII

Transmission

PAI-2-Cy5

Overlay

Figure 38: Binding of PAI-2-Cy5 to MDA-MB-231 cells at 4oC
MDA-MB-231 cells (1 x 106 cells) pre-activated with plasminogen were incubated in the absence (control: I, V, and IX) or presence of 20
µg/ml mouse IgG1 (isotype: II, VI and X), 20 µg/ml anti-B-chain uPA (#394) monoclonal antibody (anti-uPA: III, VII and XI), or 100 nM
of exogenous uPA for 30 min at 4oC (exogenous uPA: IV, VIII, and XII). Cells were washed and incubated with 5 µg/ml of PAI-2-Cy5 at
4oC for 15 min then washed with PBS and analysed immediately by confocal microscopy. Samples were analysed using the same
settings for photomultiplier voltage and pinhole (2.8) except for cells incubated with exogenous uPA where the pinhole was reduced to
half pinhole value (1.4) of other treatments due to the high intensity of the signal. Only a representative image is shown for each
treatment selected from > 10 images obtained from assays (> 2) repeated independently. The scale bars in all transmission images (I –
IV) and overlays of PAI-2-Cy5 signal with the transmission images (IX – XII) represent 10 µm and cell viability was higher than 95 % in
all samples as determined by trypan blue stain.
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Figure 39: Internalisation of PAI-2-Cy5 by MDA-MB-231 cells at 37oC
MDA-MB-231 cells (1 x 106 cells/ml) pre-activated with plasminogen were incubated
with 5 µg/ml of PAI-2-Cy5 at 37oC for (A) 0 min or (B) 15 min. (C) Cells pre-activated
with plasminogen were also incubated with 5 µg/ml BSA-Cy5 at 37oC for 15 min.
Aliquots were removed, washed with ice-cold PBS and analysed immediately by confocal
microscopy. This assay was repeated twice using different cultures of cells and only a
representative image is shown from > 10 images obtained in each assay. The scale bars
in all transmission images represent 5 µm and cell viability was higher than 95 % in all
samples as detected by trypan blue stain.
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Figure 40: Effect of uPA modulation on the internalisation of PAI-2-Cy5
MDA-MB-231 cells (1 x 106 cells) pre-activated with plasminogen were incubated in
the absence (control) or presence of 20 µg/ml anti-B-chain uPA (#394) monoclonal
antibody (anti-uPA) or 100 nM of exogenous uPA for 30 min at 4oC (exogenous uPA).
Cells were washed and incubated 5 µg/ml of PAI-2-Cy5 for 15 min at 37oC. Samples
were washed with ice-cold PBS and analysed immediately by confocal microscopy.
Samples were analysed using the same settings for photomultiplier voltage and pinhole
except for cells incubated with exogenous uPA where the pinhole was reduced to half
the value for pinhole of other treatments due to the high intensity of the signal. The
scale bars in all transmission images represent 5 µm and cell viability was higher than
95 % in all samples as detected by trypan blue stain. Samples shown are from two
representative experiments (n > 10 experiments).
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4.3.B.1. COMPARTMENTATION AND DEGRADATION OF INTERNALISED PAI-2
Transferrin-Alexa488 (endosomal marker) and LysoTracker® Yellow DND68 (lysosomal marker) were used for the visualisation of these compartments in
T-47D and MDA-MB-231 cells incubated with PAI-2-Cy5. Co-localisation of the
endosomal and lysosomal markers after 15 min at 37oC showed three different
areas of compartmentation in T-47D cells (Figure 41- A). There were areas
where only endosomal marker was observed and areas where only lysosomal
marker

was

observed,

explained

by

early

endosomes

and

lysosomes,

respectively. Finally, endosomes co-localised with lysosomes at some areas of
the cytoplasm of these cells, suggesting the fusion of late endosomes and
lysosomes at these areas. In the case of MDA-MB-231 cells, transferrin-Alexa488
always co-localised with LysoTracker® Yellow DND-68 after 15 min at 37oC
(Figure 41 – B). Since differentiation between the these two markers was
possible in the case of T-47D cells, the co-localisation of transferrin and
LysoTracker® in MDA-MB-231 cells may be due to inability of these cells to
shuttle transferrin-Alexa488 from endosomes to the cell exterior which is a
requirement for detecting early endosomes (Van Dam et al., 2002). Thus, colocalisation of internalised PAI-2-Cy5 with transferrin-Alexa488 in MDA-MB-231
was not informative as endosomal compartmentation was not clear.
As shown in Figure 41 – A, T-47D cells did not bind or internalise
detectable amounts of PAI-2-Cy5 when analysed by confocal microscopy
although PAI-2 binding was measured using

125I-PAI-2

on these cells (see Figure

36). This may be due to lower detection limit of fluorescent confocal microscopy
compared to radio-detection methods in addition to the fact that T-47D cells
express very little of uPA on the cell-surface. While a large proportion of
internalised PAI-2-Cy5 co-localised with the lysosomal marker by 15 min of
incubation at 37oC, a small amount of intracellular PAI-2-Cy5 was not localised
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in lysosomes (Figure 41 – B). This non-lysosomal intracellular PAI-2-Cy5 at 15
min incubation was presumably in endosomes as after 45 min incubation all
PAI-2-Cy5 localised in lysosomes (Figure 41 – C). The presumed endosomal and
the evident lysosomal compartmentation of internalised PAI-2-Cy5 indicated the
endocytosis of bound PAI-2 on metastatic MDA-MB-231 cells. As little PAI-2
bound to and is hence internalised by the non-metastatic low uPA-expressing T47D cells, this further confirmed the uPAR-bound uPA-dependent pathway of
PAI-2 internalisation.
Lysates of MDA-MB-231 cells incubated with PAI-2-Cy5 showed the
presence of degradation fragments with a molecular weight less than 37 kDa
the intensities of which increased over time (Lanes 3 - 5 Figure 42). The
intensity of these degradation fragments was significantly lower for lysates
prepared from MDA-MB-231 cells pre-treated with anti-B chain uPA monoclonal
antibody before incubation with PAI-2-Cy5 (lane 2 in Figure 42). Thus, the
presence of uPA:PAI-2 fluorescent degradation products further confirmed the
localisation of internalised PAI-2-Cy5 in lysosomes.
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Figure 41: Compartmentation of internalised PAI-2-Cy5
Cells incubated with PAI-2-Cy5 and transferrin-Alexa488 for 20 min at 4oC were washed and incubated at 37oC with LysoTracker® Yellow
DND-68. Cells were then washed at the specified times and analysed by confocal microscopy obtaining images sequentially using detectors
for Cy5, Alexa488 and LysoTracker® fluorescence. (A) T-47D cells after 15 min incubation at 37oC, (B) MDA-MB-231 cells after 15 min
incubation at 37oC and (C) MDA-MB-231 cells after 45 min incubation at 37oC. For (A) 6 panels are shown, which are Transferrin-Alexa488
(green), LysoTracker® (blue), PAI-2-Cy5 (red), Transferrin-Alexa488/LysoTracker® overlay, transmission image and TransferrinAlexa488/LysoTracker®/PAI-2-Cy5 overlay superimposed on the transmission image (scale bars represents 10 µm). For each (B) and (C), 6
panels are shown, which are Transferrin-Alexa488 (green), LysoTracker® (blue), PAI-2-Cy5 (red), Transferrin-Alexa488/PAI-2-Cy5 overlay,
LysoTracker®/PAI-2-Cy5 overlay and Transferrin-Alexa488/LysoTracker®/PAI-2-Cy5 overlay superimposed on the transmission image
(scale bars represents 10 µm). Co-localisation of Transferrin-Alexa488 and PAI-2-Cy5 appears in yellow/orange, co-localisation of
LysoTracker® and PAI-2-Cy5 appears in pink, co-localisation of Transferrin-Alexa488 and LysoTracker® appears in cyan and the colocalisation of Transferrin-Alexa488/LysoTracker®/PAI-2-Cy5 appears in white. Cell viability was higher then 95 % for all cells and only
representative samples are shown.
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Figure 42: Degradation of internalised PAI-2-Cy5
MDA-MB-231 cells pre-incubated with plasminogen were incubated with PAI-2-Cy5 at
37oC for 5 (Lane 3), 10 (lane 4) and 15 (lane 5) min prior to washing and lysing in
reducing sample buffer and fractionation by 12 % SDS-PAGE. MDA-MB-231 cells preincubated with plasminogen were pre-blocked with 10 µg/ml anti-B chain uPA
monoclonal antibody for 30 min at 4oC prior to incubation with PAI-2-Cy5 for 15 min at
37oC (Lane 2) and PAI-2-Cy5 (0.33 µg, 7.5 fmoles) (Lane 1) were also fractionated as
controls. (A) The SDS-PAGE was stained in Coomassie blue stain, destained and
documented after (B) being scanned using the red fluorescence detector of the Storm®
scanner. The Coomassie blue stained gel was superimposed on the fluorescence scan
and the molecular weight marker bands (kDa) were marked on the scan.
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4.3.C. FURTHER

INSIGHTS
ENDOCYTOSIS

INTO

THE

MECHANISM

OF

PAI-2

4.3.C.1. CLEARANCE OF CELL-SURFACE UPA
At 37oC in the absence of PAI-2, endogenous cell-surface uPA levels on
MDA-MB-231 cells slowly decreased over the observation period (~10 % loss by
60 min), indicating slow endogenous uPA clearance from the cell surface (Figure
43). A similarly slow turnover of cell-associated exogenous uPA has been shown
for monocytic cells that do not produce any detectable PAIs (THP-1 cells)
(Estreicher et al., 1990). Since (1) endogenous cell surface PAIs are also not
detectable on breast carcinoma cells used in this study (Gillian Stillfried,
personal communications), (2) PAI-2 is internalised via a uPA/uPAR dependent
pathway; and (3) PAIs affect cell-associated uPA clearance via uPAR endocytosis
(Cubellis et al., 1990; Estreicher et al., 1990; Jensen et al., 1990), then
exogenous PAI-2 should influence uPA disappearance. Indeed, the addition of
100 nM PAI-2 significantly accelerated the loss of cell surface endogenous uPA
(Figure 43). This effect was most apparent within the first 10 min (t1/2 = 1.14 ±
0.06 min in the presence of 100 nM PAI-2 vs. t1/2 = 787 ± 37 min in the absence
of PAI-2) and was dose-dependent (t1/2 = 1.52 ± 0.06 and 3.07 ± 0.04 min in the
presence of 10 and 1 nM PAI-2, respectively). The rate of PAI-2 mediated uPA
loss from the cell surface was appreciably slower after 10 min in the presence of
PAI-2 and, by 60 min in the presence of 100 nM PAI-2, approximately 30 % of
the total cell-surface endogenous uPA disappeared from the cell surface (Figure
43). This apparent stabilisation of cell-surface uPA levels at approximately 70 80 % of initial cell-surface levels, even in the presence of high PAI-2
concentrations (i.e. 100 nM), appears to be at odds with the uPA-dependent
endocytosis of the majority of cell-bound PAI-2 (refer to Figure 41). This
suggested additional complex concurrent processes during endocytosis of the
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uPA:PAI-2 complex involving uPAR occupancy levels, potential uPAR recycling
and uPA secretion, which must lead to replenishment of cell-surface uPA,
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resulting in the apparent stabilisation of relatively high uPA levels.
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Figure 43: PAI-2-mediated clearance of cell-surface uPA
MDA-MB-231 cells pre-treated with plasminogen were incubated in the absence (●) or
presence of 1 (■), 10 (▲) or 100 (▼) nM of PAI-2 at 37oC. Samples were removed at the
specified time points, washed and analysed by flow cytometry for cell-surface uPA. Only
fluorescence associated with viable cells was used and the data are displayed as the
percentage of MFI over the maximal MFI observed at time zero (absence of PAI-2). Data
points, % MFI ± SEM (n ≥ 3), were fitted to one-phase exponential decay curve and did
not deviate from the fitted model as judged by runs test (degrees of freedom > 18).

4.3.C.2. EFFECT OF PAI-2 ON CELL-SURFACE UPAR
The effect of uPAR/uPA:PAI-2 complex formation and endocytosis on
potential uPAR recycling and occupancy levels was assessed using two different
methods. Firstly, endogenous levels of cell surface uPAR were directly measured
by immunofluorescence and flow cytometry. During the first 10 min of
incubation with PAI-2 the total cell-surface uPAR level decreased rapidly to ~
40% of the maximal uPAR levels (i.e. at zero min in the presence of PAI-2)

145

(Figure 44). Between 10 and 15 min after incubation with PAI-2, uPAR cellsurface levels were restored to 86 % of the maximal level.
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Figure 44: PAI-2-mediated clearance of cell-surface uPAR
MDA-MB-231 cells pre-treated with plasminogen were incubated with 100 nM of PAI-2
at 37oC. At the specified time points cell-surface uPAR was measured using the #3934
antibody by flow cytometry. Only fluorescence associated with viable cells was used and
the data are displayed as percentage of MFI over the maximal MFI observed at time zero
(% MFI ± SEM, n = 3).

This result indicated that some uPAR recycling must take place. Given
that not all uPAR disappeared from the cell surface, this further indicates that
only a proportion of uPAR is occupied with endogenous uPA on this cell (refer to
Figure 32). Thus, it appears that the effect of PAI-2 incubation is to cause
internalisation of existing occupied uPAR and presumably recycling of
unoccupied receptor to the cell surface. As suggested above, any uPA secretion
that may occur as a result of complex endocytosis could bind to unoccupied
uPAR (either pre-existing or recycled). Thus, the difference between the amount
of endogenous uPA and the total amount of uPA the cells could potentially bind
to the cell surface (i.e. measured after the addition of exogenous uPA) gives an
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indication of the amount of unoccupied uPAR at any time after incubation with
PAI-2. In agreement with previous experiments (refer to Figure 43), the
endogenous cell-surface uPA level decreased by 30 % by 10 min of incubation
with 100 nM PAI-2, after which time it stabilised at this level (Figure 45 – A).
Total uPA levels (endogenous uPA plus bound exogenous uPA) decreased to 65
% by 10 min after incubation with PAI-2. However, unlike the endogenous uPA
levels, total uPA levels were restored to 90 % of the maximal levels (i.e. at zero
min in the presence of PAI-2) between 10 and 30 min after incubation with
PAI-2 (Figure 45 – B). Unoccupied uPAR was then calculated and represented
graphically, and found to initially decrease by 40 % in the first 10 min after
incubation with PAI-2 (Figure 45 – C). By 30 min after incubation with PAI-2,
unoccupied uPAR levels increased to 130 % of that at time zero of incubation
with PAI-2.
Assuming that unoccupied uPAR remains on the cell surface, the data
suggests that while the majority of cell-surface uPAR/uPA:PAI-2 is internalised,
cells may replenish cell-surface uPA from intracellular reservoir resulting in the
decrease of unoccupied cell-surface uPAR and an overall stabilisation of cell
surface uPA levels. After the first 10 min of internalisation, uPAR recycling may
result in the observed restoration of cell-surface uPAR and the marked increase
in unoccupied cell-surface uPAR between 10 and 30 min. Indeed, when
unoccupied cell-surface uPAR was saturated with uPA by incubation with
exogenous uPA prior to incubation with PAI-2, the clearance of cell-surface uPA
was slower but greater percentage was cleared in comparison to previous uPA
clearance data. As shown in Figure 46, cell-surface uPA continued to decrease
rapidly after 10 min of incubation with PAI-2 (t1/2 = 9.1 ± 0.4 min). Stabilisation
of cell-surface uPA occurred between 30 and 60 min where unoccupied uPAR
would have been made available by recycling in order to bind secreted uPA.
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Figure 45: Total cell-surface uPA capacity and endogenous cell-surface uPA
during PAI-2 endocytosis
MDA-MB-231 cells pre-treated with plasminogen were incubated with 100 nM of PAI-2
at 37oC. At the specified time points samples were removed and processed as follows.
(A) Cells were analysed for cell-surface uPA by flow cytometry (i.e. endogenous cellsurface uPA). (B) Cells were incubated with 100 nM exogenous uPA for 30 min at 4oC
then analysed for cell-surface uPA by flow cytometry (i.e. total cell-surface uPA
capacity).(C) The difference between B and A was calculated to represent the binding of
exogenous uPA (i.e. unoccupied cell-surface uPAR). Only fluorescence associated with
viable cells was used and the data are displayed as absolute MFI units ± SEM (n = 3).
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Figure 46: The effect of uPAR saturation on PAI-2-mediated clearance of
cell-surface uPA
MDA-MB-231 cells pre-treated with plasminogen were incubated with exogenous uPA
(30 min at 4oC), washed then incubated with 100 nM of PAI-2 at 37oC. Samples were
removed at the specified time points, washed and analysed by flow cytometry for cellsurface uPA. Only fluorescence associated with viable cells was used and the data are
displayed as the percentage of MFI over the maximal MFI observed at time zero (absence
of PAI-2). The MFI for cells incubated with exogenous uPA was 2-fold higher than
normal cells indicating 50 % of cell-surface uPAR was unoccupied (data not shown).
Data points, % MFI ± SEM (n ≥ 3), were fitted to one-phase exponential decay curve and
did not deviate from the fitted model as judged by runs test (degrees of freedom > 18).

4.4. DISCUSSION
The results presented in this chapter describe the irreversible inhibitory
kinetics and fate of PAI-2 bound to the surface of human carcinoma cells and
provides definitive evidence of uPAR-bound uPA mediated endocytosis of PAI-2.
In order to investigate the cellular fate of PAI-2, it was essential to quantify the
irreversible binding of PAI-2 to cell-surface uPAR-bound uPA and perform
internalisation assays under saturating conditions. PAI-2 is known to be an
efficient inhibitor of uPA activity (Ellis et al., 1990) and can form 1:1 SDS-stable
complexes with

125I-uPA

on the cell surface (Estreicher et al., 1990). Therefore,

149

the amount of PAI-2 bound to cells and the concentration of PAI-2 required to
saturate uPAR-bound uPA are directly reflective of the irreversible inhibition
constant KI. The very low KI value described here confirms the efficient and
potent inhibition of cell surface uPAR-bound uPA by PAI-2 and falls in the range
of the most potent antiviral drugs. For example, anti-HIV cyclic urea drugs,
which are also mechanism-based protease inactivators, have KI values in the
range of 18 - 88 pM (De Lucca et al., 1998). The kinact value measured for PAI-2
is in the range of typical reported values (0.001 – 1 min-1) and describes a
relatively rapid inhibitory mechanism (Silverman, 1996).
That uPAR-bound uPA is the only specific site for PAI-2 binding on
human carcinoma cells is supported by the following evidence. Firstly, the onebinding site model best fitted the specific PAI-2 binding data thus indicating the
presence of a single population of high-specificity target for PAI-2. Secondly, the
specific binding of PAI-2 to cells on which the uPA active site was either
specifically blocked or inactivated was completely inhibited. Thirdly, a linear
correlation exists between cell-surface uPA levels and the PAI-2 binding
capacity. Given that uPA was the only determinant for

125I-PAI-2

binding to

breast cancer cells, the inhibition parameters derived in this study represents
specific targeting of cell surface uPA by PAI-2. It should be noted, however, that
a small proportion of the total binding could not be competed by excess PAI-2
(refer to Figure 32), suggesting the presence of non-specific, uPA-independent
PAI-2 binding moiety/ies. The nature of this interaction has yet to be
characterised.
The uPA-dependent binding of PAI-2 was also illustrated using PAI-2-Cy5
by confocal microscopy. At 4oC, PAI-2-Cy5 was localised at the cell-surface of
MDA-MB-231 cells however, rapid and specific internalisation of PAI-2-Cy5 was
observed when cells were incubated at 37oC. The rate of internalisation was

150

determined using a novel assay (developed by David Croucher, University of
Wollongong) utilising the Alexa488/Alexa488 quenching antibody system and the
human prostate carcinoma PC-3 cells (Al-Ejeh et al., 2004) and MDA-MB-231
cells (Unpublished manuscript by Amy Wyatt, School of Biological Sciences,
University of Wollongong, 2003). Maximal PAI-2 internalisation by these cells
was achieved over a similar time frame (within ~ 15 - 20 minutes) at 37oC to
that described for

125I-uPA:PAI-1

complex in murine LB6 clone 19 cells via the

uPA/uPAR-mediated pathway (Nykjær et al., 1997). Internalised PAI-2 was
localised in lysosomes with MDA-MB-231 cells and in both endosomes and
lysosomes within the metastatic prostate cancer cells, PC-3 (Al-Ejeh et al.,
2004). These results clearly illustrate that PAI-2 was localised in endosomes
and lysosomes where PAI-2 (and presumably uPA) is degraded.
The internalisation process of PAI-2 appeared similar to that described
for all other serpin:uPA complexes, whereupon the latter is degraded within
lysosomes while uPAR is recycled back to the cell surface (Andreasen et al.,
1997; Nykjær et al., 1997; Nykjær and Willnow, 2002; Strickland et al., 2002).
Given that PAI-2 forms a stable irreversible complex with receptor-bound uPA
and that PAI-2 internalisation occurs via the uPAR/uPA pathway as other
serpin:uPA complexes, then PAI-2 should initiate the internalisation of uPA.
Evidence for the PAI-2-mediated internalisation of cell-surface uPA was
observed by the loss or clearance of uPA from the cell surface upon inhibition by
PAI-2. In the absence of added PAI-2 the disappearance of cell surface uPARbound uPA levels was slow. The addition of PAI-2 initially greatly accelerated
this process. Similar clearance characteristics were described for bound
exogenous radiolabelled uPA in the absence and presence of PAI-2 using
monocytic cells with low endogenous PAIs (Estreicher et al., 1990). The
internalisation of the majority of uPA-occupied cell-surface uPAR within the first
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10 min was in agreement with the internalisation of PAI-2. The reappearance of
uPAR on the cell-surface after 10 min was in agreement with the previously
reported recycling of uPAR after the internalisation of serpin:uPA complexes
(Nykjær et al., 1997). Thus, results from this study are largely in agreement with
previously published reports of uPA:PAI-1 internalisation. However, PAI-2mediated clearance of uPA from the cell-surface stabilised at 20 - 30 % of the
total uPA after the initial rapid clearance. This result seemed at odds since the
majority of bound PAI-2 was internalised within 40 min incubation at 37oC
whereas there was only an apparent 20 - 30 % decrease in cell-surface uPA
during this time frame. The low uPA clearance in the presence of PAI-2 may be
explained by concomitant cell surface uPA replenishment since the cells used in
this study continuously express cell bound uPAR and secrete pro-uPA (Ranson
et al., 1998; Andronicos and Ranson, 2001). If the initial internalisation of
inhibited uPA is concomitantly counterbalanced by the secretion of pro-uPA,
some of which ligands unoccupied uPAR originally present on the cells and/or
recycled uPAR; then it is possible that secreted pro-uPA replenishes a
proportion of these receptors. This suggestion was tested by assaying the
binding of exogenous uPA to MDA-MB-231 cells incubated with PAI-2. The
decreased binding of exogenous uPA overtime during uPAR/uPA:PAI-2
internalisation indicated that unoccupied uPAR was being masked from
exogenous uPA. This provides preliminary evidence for the replenishment of
cell-surface uPA during uPAR/uPA:PAI-2 internalisation. Thus, while the
majority

of

uPAR/uPA:PAI-2

were

internalised

causing

the

observed

internalisation of the majority of PAI-2 and uPAR within the first 10 min of
incubation, secreted uPA liganded to previously unoccupied uPAR resulting in
the observed decrease of unoccupied cell-surface uPAR levels and the
stabilisation of uPA clearance. This was supported by the effect of uPAR-
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saturation with uPA prior to the addition of PAI-2 where a larger decrease in cellsurface uPA (~ 60 %) was observed and stabilisation occurring between 30 and
60 min of internalisation where uPAR would be recycled to the cell surface and
secreted uPA may ligand to these newly presented unoccupied receptors. The
addition of PAI-2 to THP-1 cells preloaded with exogenous uPA resulted in
similar effects on the rate of uPA disappearance with 30 – 40 % of the total cellassociated uPA also lost by 60 min at 37oC (Estreicher et al., 1990). While ~ 60
% exogenous radioactive uPA:PAI-1 complex is lost from the cell surface of U937
monocytic (Cubellis et al., 1990) or trophoblastic cells (Jensen et al., 1990) by
60 min, a similar biphasic pattern was also apparent. The higher percentage
loss using PAI-1 may either reflect slightly different mechanisms between PAI-1
and PAI-2 and/or different cell types and/or methods of analysis.
Given the wide involvement of the LDLR family members in processes of
endocytosis including that of uPA:PAI-1 (Nykjær and Willnow, 2002; Strickland
et al., 2002), it is not surprising to find that this family is at least partially
responsible for endocytosis of uPA:PAI-2 complexes (as indicated by RAP
inhibition experiments performed by Croucher D. in Al-Ejeh et al., 2004). (RAP:
receptor associated protein, inhibitor of LDLR endocytosis). Certain LDLR family
members when associated with uPAR complexed with uPA:PAI-1 sustain the
cell-signalling pathways that are activated via uPAR, resulting in enhanced uPA
and uPAR levels among other effects (Nykjær and Willnow, 2002; Strickland et
al., 2002). Thus, it is also conceivable that in the presence of PAI-2, LDLRmediated signalling pathways would be activated and may also enhance the
secretion of intracellular pro-uPA stores. This effect may take up to 10 min at
37oC thus accounting for the biphasic effect of PAI-2 on uPA clearance (i.e.
rapid then slow clearance) observed. Assuming that a proportion of the newly
liganded uPA stays in the pro-enzyme form despite the presence of any residual
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cell bound plasmin, then only the two-chain uPA would be internalised by the
PAI-2 still present in the cell environment.
Along with published data (Al-Ejeh et al., 2004), the results presented in
this chapter allow the proposal of a model for the internalisation of PAI-2 (Figure
47). In this model, PAI-2 forms complexes with uPAR-bound uPA where uPAR
occupancy is generally less than 70 %. The internalisation of uPA:PAI-2
complexes occurs shortly after complex formation and endocytosis of
uPAR/uPA:PAI-2 is mediated by a member of the low-density lipoprotein
receptor (LDLR) gene family. During the internalisation of the majority of
uPAR/uPA:PAI-2 complexes formed on the cell surface, a signal (possibly
mediated by LDLR) initiates the secretion of uPA from an intracellular reservoir.
The cell-surface is replenished with uPA, which leads to increased occupancy of
uPAR. The uPA:PAI-2 complex is degraded in the lysosomes while uPAR
reappears on the cell surface possibly via recycling along with the LDLR, as
previously documented (Nykjær et al., 1997).
It is noteworthy that as in the case of T-47D cells (see Chapter 3),
MDA-MB-231 cells showed preferential maintenance of partially unoccupied
uPAR levels on the cell surface despite the continual secretion of uPA by these
cells. As discussed in Chapter 3, it is possible that unoccupied uPAR may be
essential for other uPAR-related functions such as uPA-independent signalling
(Gellert et al., 2003) or cell-attachment to ECM via interaction of uPAR clusters
with integrins and matrix proteins (Wei et al., 1999; Ossowski and AguirreGhiso, 2000; Wei et al., 2001).
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Figure 47: Mechanism proposal for the internalisation of uPAR/uPA:PAI-2 complexes
For simplicity plasminogen receptors are not shown.
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In summary, this study, as published by Al-Ejeh et al. (2004), provides
the first conclusive evidence for the internalisation of PAI-2 by human
carcinoma cells, which represents an advance in the understanding of the
regulation of cell-surface plasminogen activation. Together with the fact that
PAI-2 binding capacity and internalisation is uPA-dependent, these results
clearly indicate that PAI-2 would not only preferentially target uPA-expressing
tumour cells by very efficiently and irreversibly inhibiting uPA, but would also
efficiently

deliver

attached

cytotoxins

to

the

intracellular

space.

The

endosomal/lysosomal localisation of PAI-2 further promotes the utility of αemitting radionuclide-PAI-2 constructs (or any other PAI-2-cytotoxin construct)
as a uPA-targeted anti-tumour drug (Kruithof et al., 1995; Hang et al., 1998; Li
et al., 2002; Ranson et al., 2002; Allen et al., 2003). Furthermore, the
quantification of PAI-2 binding capacity in terms of KI values is important for
determining PAI-2 concentrations required for delivering sufficient amounts of
cytotoxins to the target cell.
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Chapter 5: OPTIMISATION OF RADIOLABELLING OF PAI-2
WITH THERAPEUTIC RADIOISOTOPES

5.1. INTRODUCTION
The clinical significance of uPA as a marker of metastatic cancers has
been established for several human cancers and the elevated levels of uPA in
malignant tumours compared to normal tissue is commonly discussed as a
therapeutic target (Duffy, 1993b; Duffy, 1996; Andreasen et al., 1997; Schmitt
et al., 1997; Brunner et al., 1999; Duffy et al., 1999; Gershtein and
Kushlinskii, 1999; Look and Foekens, 1999; Mazar et al., 1999). As illustrated
in Table I (Chapter 1), there is conclusive evidence indicating the prognostic
significance of uPA in various human cancers and, in the case of breast cancer,
level-1 of evidence exists for this prognostic significance (Duffy, 2004).
Identification of such a strong marker allows the development of therapy tactics
which exploit the ability to target uPA.
Modulation of uPA expression and the use of antagonist of the
uPA/uPAR binding have shown success in regulating cancer metastasis and
invasion (see Section 1.7.). In the case of transfection methods, the therapeutic
potential of such strategy in humans is limited due to the requirement of cancer
cell-specific gene delivery methods. Thus antagonists of the uPA/uPAR binding
seem more feasible for clinical applications. Although such pharmaceuticals
may be administered to inhibit tumour growth, migration or differentiation,
tactics such as cytotoxins or toxic radiation for the killing and clearance of
tumour cells present more valuable curative advantages.
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Radionuclides have been long used for medical applications. α-emitters
emit high energy (6 - 9 MeV) over a short distance (40 to 80 µm) (Waldmann,
1991; Behr et al., 1998; Behr et al., 1999; Chatal and Hoefnagel, 1999; Griffiths
et al., 1999), thus this energy is mainly deposited in the targeted cells and very
few nuclear hits are required to kill these cells (Lloyd et al., 1979; Kassis et al.,
1986). Monoclonal antibodies radiolabelled with α–emitting radionuclides (e.g.
213Bismuth

and

211Astatine)

are

starting

to

show

promise

in

radio-

immunotherapy (Couturier et al., 1999; Nikula et al., 1999; McDevitt et al.,
2000; Zalutsky and Vaidyanathan, 2000; McDevitt et al., 2001; Jurcic et al.,
2002).
Several biological and biochemical characteristics of PAI-2 advocate the
possible utilisation of this serpin as a cancer radiotherapeutic agent. Biological
characteristics that favour PAI-2 for targeting uPA include: (1) PAI-2 inhibits
uPA-mediated invasion of cancer cells in vitro (Kirchheimer and Remold, 1989;
Brückner et al., 1992; Stahl and Mueller, 1994); (2) Exogenously added
recombinant PAI-2 inhibits cancer invasion and metastasis in vivo (Baker et al.,
1990a; Shinkfield et al., 1992; Montgomery et al., 1993; Reiter et al., 1993;
Billström et al., 1994; Evans and Lin, 1995) and (3) PAI-2 preferentially
accumulates in cancer tissue compared to normal tissue in tumour-bearing
mice compared to mice without tumours (Hang et al., 1998). Taken together,
and despite the presence of PAI-1 in malignant tumours, it is apparent that uPA
is accessible to exogenously administered PAI-2 in several tumour types in vivo.
Biochemical characteristics which favour the use of PAI-2 for cancer therapy
include, the specific and efficient inhibition of uPAR-bound uPA while reserving
thrombosis as suggested by the low second order inhibition rate constant
towards tPA and protection of fibrin-bound tPA from inhibition by PAI-2
(Kruithof et al., 1995). Secondly, PAI-2 is very stable in vitro (Ranson et al.,
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2002), unlike PAI-1 which is subject to oxidation (Baker et al., 1990b), implying
that PAI-2 can be easily modified for radiolabelling. These characteristics of PAI2 in addition to the recent documentation of the internalisation of uPA:PAI-2
complex (Al-Ejeh et al., 2004) encourage the use of PAI-2 for radiotherapy of
human cancers.
Previous studies describe the conjugation of PAI-2 to the metal chelator,
cDTPA, followed by radiolabelling of PAI-2-DTTA product with the α-emitter,
213Bismuth.

In these ‘proof-of-principle’ studies, the resulting adduct (PAI-2-

DTTA-213Bismuth) shows preferential targeting of metastatic breast cancer cells
in

vitro

(Ranson

et

al.,

2002)

and

targets

tumour

xenografts

and

micrometastates in vivo (Li et al., 2002; Allen et al., 2003). The efficient
cytotoxicity of PAI-2-DTTA-213Bismuth is explained by the efficient binding and
rapid internalisation of uPA:PAI-2 complexes after their formation on the cell
surface (Chapter 4, Al-Ejeh et al., 2004). Bismuth-213 (213Bi) is efficiently eluted
from Actinium-225 (225Ac) column (Li et al., 2002; Ranson et al., 2002). Due to
213Bi

being eluted from the

225Ac

column with 0.075 M HI, pH fluctuations were

observed that affected the solubility PAI-2-DTTA.

5.1.A. RATIONALE AND AIMS
The aim of this chapter was to further characterise PAI-2-DTTA.
Furthermore, mainly due to the short half-life of

213Bi

(45 min), a quick,

efficient, reproducible and reliable method for radiolabelling of PAI-2-DTTA with
213Bi

needed to be developed for this alpha therapy tactic to be accessible. Thus,

another aim of this chapter was to test buffers which prevent PAI-2-DTTA
precipitation and optimisation of radiolabelling with

213Bi.
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5.2. METHODS
5.2.A. CONJUGATION OF PAI-2 TO CDTPA
Generally, PAI-2 was reacted with a 50-fold molar excess of the metal
chelators as described by Ranson et al. (2002). In a final 450 µl volume of 1 x
PBS (pH 7.2), 31 µl of freshly prepared anhydrous 25 mg/ml cDTPA in DMSO
was reacted with 2 mg of PAI-2 at RT for 1 h with vigorous shaking. Conjugation
was stopped using 50 µl 1 M Tris-HCl (pH 7.2) (10 % v/v final concentration).
PAI-2-DTTA was separated from free chelator moieties (cDTPA) using 30-kDa
cut-off microconcentrators. Briefly, reactions were placed in the top chamber of
30 kDa cut-off microconcentrator units and centrifuged at 7430 x g for 3 - 5
min. The retained volume was washed three times by centrifugation with 500 µl
of 1 x PBS (pH 7.2). The washes were discarded and the final retained volume
was removed to a fresh tube. The microconcentrator filter was washed (no
centrifugation) using 1 x PBS (pH 7.2) and the washes were added to the fresh
tube and stored at 4oC.
The BioRad® DC protein concentration assay kit was used to determine
the concentration of conjugated PAI-2 against standard BSA and/or PAI-2
solutions (see Section 2.2.B.1.). The activity of PAI-2-DTTA conjugates was
compared to unconjugated PAI-2 using gel shift and the Spectrozyme-UK®
assays as described in Section 2.2.B.4.

5.2.B. ELECTROSPRAY IONISATION MASS SPECTROSCOPY
For electrospray ionisation mass spectroscopy (ESI-MS) of PAI-2 and
PAI-2-DTTA, samples were washed five times by centrifugation at 7430 x g for 3
- 5 min with milliQ water using 30 kDa cut-off microconcentrators. The retained
washed samples were finally prepared in milliQ water and diluted 1:1 in 50 %
methanol: 10 % acetic acid (v/v) solution at a final protein concentrations in the
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range of 1 - 10 µM. Samples were injected in the Q-TOF mass spectrometer
(Department of Chemistry, University of Wollongong) and analysed using a 30
volts cone and 5000 resolution power. Data collected were analysed using the
software provided with the mass spectrometry instrument.

5.2.C. RADIOLABELLING OF PAI-2-DTTA WITH 213BISMUTH
5.2.C.1. MAINTENANCE OF 225ACTINIUM COLUMN
The total amount of

225Ac

(Oak Ridge National Laboratory, United States

Department of Energy, USA) was dissolved in 300 µl of 0.1 M HNO3 and the
solution was loaded onto resin (AG® 50W-X4, provided in column Oak Ridge
National Laboratory, United States Department of Energy, USA) pre-equilibrated
with 1 ml 0.1 M HNO3. The column was washed with 250 µl of dH2O. When not
in use, the

225Ac

column was stored in 0.1 M HNO3 and washed with 1 ml of

dH2O prior to use. The

225Ac

column was stripped and reloaded on a weekly

basis. Stripping was performed by washing 3 times with 250 µl of 8 M HNO3 in
a fume hood. Washes were collected in a 20 ml glass vial, 15 µl of H2O2 was
added and content was evaporated on a hot plate until dryness. The evaporation
step was repeated by adding 25 µl of 8 M HNO3 and 5 µl of H2O2. The final
remaining volume was loaded onto a fresh resin as described above.
5.2.C.2. OPTIMISATION OF LABELLING PAI-2-DTTA WITH 213BI (α-PAI-2)
213Bi

was eluted in a final solution containing 0.075 M HI and 1 x PBS as

previously described (Ranson et al., 2002). The pH of the elution solution (0.075
M HI; 1 x PBS) only was measured using pH strips (0 - 14 pH range). In
addition, the pH was measured for elution solution titrated with three different
solutions - 1 M sodium hydroxide, 3 M Sodium acetate (pH 5.5) and 1.5 M citric
acid (citrate, pH 5.5). The effect of control and titrated elution solution on the
solubility of various concentrations of PAI-2-DTTA was assessed as follows.
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After the addition of PAI-2-DTTA, these solutions were centrifuged at 7430 x g
for 2 min in order to pellet any precipitated PAI-2-DTTA. Pellet formation was
assessed in these solutions in comparison to incubations containing the elution
solutions or PAI-2-DTTA alone.
The radioactivity of elutions was measured (in µCi) using the AtomLab
200 dose calibrator (regularly calibrated using a Caesium source) before and
after pH adjustment. ITLC was performed before and after pH-adjustment as
described earlier (Section 4.3.A.2.) and the strip sections were counted using a
normalised γ-counter for

213Bi

counting (15 – 350 keV window). Generally,

PAI-2-DTTA was added to the pH-adjusted elution and ITLC was performed
using 1 µl samples in selected mobile phases (specified for each experiment in
Figure legends).
The radiolabelling of PAI-2-DTTA with
to PAI-2-DTTA concentration,

213Bi

213Bi

was investigated with respect

concentration and time. All reactions were

conducted in a final 150 µl volume and for 10 min at RT (unless specified
otherwise) and stopped with 5 µl of 0.5 M EDTA. For all assays, ITLC performed
using

213Bi

alone incubated identically to radiolabelling reactions was used as a

control. For the effect of protein concentration, increased concentrations of
PAI-2-DTTA were incubated with a set concentration of
213Bi

213Bi

(200 µCi/ml) and

incorporation was determined by ITLC. The effect of increasing

213Bi

concentration on the radiolabelling reaction was assayed using a set
concentration of PAI-2-DTTA (100 µg/ml) and incorporation was measured. In
order to determine the effect of reactants’ concentrations on the radiolabelling
reaction, equal amounts of PAI-2-DTTA and

213Bi

(maintained at µg: µCi ratio of

1:1) were incubated in different final volumes and incorporation was assayed
using ITLC. The time course experiments were conducted using 30 µg PAI-2DTTA and 30 µCi

213

Bi in a final 150 µl volume and ITLC was performed at
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specified time points. The zero time point was obtained by the addition of 30 µCi
213Bi

to PAI-2-DTTA solution containing 5 µl of 0.5 M EDTA and the sample was

used immediately for ITLC.

5.2.D. STABILITY OF α-PAI-2
213Bi-labelled

PAI-2-DTTA (α-PAI-2) was prepared at different specific

radioactivities (µCi/µg). Under identical radiolabelling conditions, PAI-2 (not
conjugated to cDTPA) was incubated with

213Bi.

Protein concentration in all

samples was 100 µg/ml and 20 µl aliquots from each reaction were incubated in
triplicate with 0, 0.09, 0.9 or 9 µg of hydrolysed DTPA in a final 110 µl volume of
RPMI-1640 containing 5 % FCS. Reactions were incubated at 37oC for 45 min
and ITLC was performed in order to assess the stability of incorporated

213Bi

in

the presence of excess free DTPA and FCS.

5.2.E. INTEGRITY OF α-PAI-2
Optimally radiolabelled PAI-2-DTTA was assessed for structural integrity
and uPA binding ability using SDS-PAGE (as described in Section 2.2.B.4.)
followed by autoradiograph. α-PAI-2 prepared at different specific radioactivities
(µCi/µg) was incubated in the presence or absence of uPA at 37oC for 45 min.
Samples were fractionated by reducing 12 % SDS-PAGE (Section 2.2.B.2.) and
autoradiography was performed as described in Section 2.2.B.3.

5.3. RESULTS
5.3.A. CONJUGATION OF CDTPA TO PAI-2
cDTPA was conjugated to PAI-2 in several different reactions and the
protein was efficiently recovered (> 90 % recovery). The ability of PAI-2-DTTA to
form SDS-stable complexes with uPA was identical to that of free untreated
PAI-2 (Figure 48). PAI-2 (47 kDa) formed complexes of 80 and 98 kDa with low-
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and high-molecular weight uPA subunits (33 kDa, 55 kDa), respectively.
Similarly, PAI-2-DTTA (lane 4) formed stable complexes with similar sizes when
incubated with uPA (Figure 48).

Mr (kDa)
209
124

1

80.0
49.1
34.8

2

3

4

5
98 kDa complex
80 kDa complex
55 kDa HMW - uPA
47 kDa
33 kDa LMW - uPA

28.9

20.6
7.1
Figure 48: PAI-2-DTTA forms SDS-stable complexes with uPA
PAI-2 and PAI-2-DTTA (2 and 1 µg, respectively) were incubated in a final 20 µl volume
of PBS in the presence or absence of uPA (1 µg) (low and high molecular weight subunits
33 and 55 kDa respectively) at 37oC for 90 min. At the end of the incubation, samples
were fractioned using 12 % reducing SDS-PAGE. Sizes of the molecular weight marker
bands in kDa are displayed on the left; lane 1: uPA; lane 2: PAI-2; lane 3: PAI-2
incubated with uPA; lane 4: PAI-2-DTTA; lane 5: PAI-2-DTTA incubated with uPA.
Similar data were obtained for the other PAI-2-DTTA conjugates prepared and for PAI-2DTTA conjugates when analysed 6 months after preparation.

Incubation of PAI-2 conjugates at 1:1 molar ratio with uPA completely
inhibited uPA enzyme activity (Figure 49). A dose-dependent decrease in the
inhibition of uPA activity was seen as the ratio of PAI-2 to uPA was decreased.
There were no significant differences between the inhibitory activity of PAI-2DTTA and PAI-2 (Figure 49).
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Molar ratio of PAI-2-DTTA to uPA
Figure 49: PAI-2-DTTA inhibits uPA enzymatic activity
Active uPA (20 IU, ~ 0.33 µg) was incubated with equimolar amount of unconjugated
PAI-2 (clear bars) and PAI-2-DTTA conjugate (filled bars). In addition conjugates were
incubated at 0.5:1 and 0.1:1 molar ratio of PAI-2:uPA. BSA (negative control) was also
incubated with uPA (no effect on activity, data not shown). uPA activity was measured
using Spectrozyme®-UK assay (see Section 2.2.B.4). Data presented are the mean ±
standard error of the mean (SEM, n = 6 replicates). Similar data were obtained for the
other PAI-2-DTTA conjugates prepared.

When analysed by electrospray ionisation mass spectroscopy, the
spectrum of free PAI-2 showed a single band with a molecular weight of 46844.8
± 0.7 Da (data not shown). In comparison, spectra of PAI-2-DTTA conjugates
displayed at least 2 additional peaks with higher molecular weights than that of
free PAI-2 (Figure 50). The difference between these high molecular weight
peaks and the PAI-2 peak was always a whole multiple of 429 Da (Figure 50 inset). These increments corresponded to one partially hydrolysed cDTPA ion
(373.35 Da) with a chelated iron atom (Fe 55.85 Da). The source of iron was
expected to be from the stainless steel bar that the samples face before being
sprayed in the electro-field (Mr Larry Hicks, personal communications). Thus,
the mass spectroscopy data demonstrated that the PAI-2-DTTA preparations
contain a mixture of several PAI-2-DTTA moieties. The percentage of free PAI-2
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in all PAI-2-DTTA preparations was less than 10 %. Mass spectroscopy analysis
performed immediately or up to 5 months after the preparation of PAI-2-DTTA
(stored in dark at 4oC) produced identical spectra for the same samples,

MW Difference (Da)

3

Relative intensity

2
4

Thousands

indicating that PAI-2-DTTA was relatively stable (data not shown).

2.5
2.0

r2 = 1

1.5
1.0
0.5
0.0
1

1

2

3

4

5

Peak Number

PAI-2

5

Molecular mass (Da)
Figure 50: Electrospray mass spectroscopy of PAI-2-DTTA
Samples were washed, adjusted to obtain approximately 1-10 µM final concentration
and analysed by Q-TOF ESI-mass spectrometer at 30 volts cone and 5000-resolution
power. Spectrum of PAI-2 only showed one peak (data not shown). The spectrum shown
is from one PAI-2-DTTA preparation and the numbers displayed on the peaks represent
the mass in Da. Similar spectra were obtained for other PAI-2-DTTA conjugates;
however the spectra varied in the number of peaks observed (data not shown). Inset:
The difference between the PAI-2 peak and each PAI-2-DTTA peak observed in spectra
(labelled as 1-5) was plotted against the peak number. Each increase in the molecular
weight represented an increase by the exact molecular weight of hydrolysed cDTPA
molecule with a chelated iron atom.
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The number of cDTPA molecules conjugated to PAI-2 in different
conjugation experiments varied although the same batch of PAI-2 was used.
This variation was also observed between different batches of PAI-2. The
number of cDTPA molecules conjugated to PAI-2 varied between different
batches and within different reactions using the same batch of PAI-2. The
minimum number of conjugated cDTPA molecules was 2, the maximum was 5
and the average was 3 - 4 molecules (n = 15, data not shown).

5.3.B. PREPARATION OF 213BI ELUTION SOLUTION FOR RADIOLABELLING
The solution used for eluting

213Bi

from the

225Ac

column, 0.075 M HI/1 x

PBS, had a pH of 0.5. PAI-2-DTTA precipitated when added to this solution at a
concentration of 0.19 – 1.1 mg/ml, possibly due to the low pH. The elution
solution could be titrated using 1 M sodium hydroxide, 6 M sodium acetate pH
5.5 or 1 M citrate pH 5.5 (Figure 51). Adjustment of pH of elution solution to pH
5 – 6 was essential since radiolabelling with

213Bi

is optimal at this pH (McDevitt

et al., 1999) and PAI-2-DTTA is expected to be soluble at this pH as the pI of
PAI-2 is 5.5 (Kruithof et al., 1995).
Sodium hydroxide showed a steep titration curve at around pH 5 - 6,
thus pH adjustment of the

213Bi-elution

solution required gradual careful

addition of sodium hydroxide. Although successful radiolabelling of PAI-2-DTTA
with

213Bi

was possible using this system (data not shown), the use of 1 M

sodium hydroxide was aborted due to the time lost during pH adjustment and
irreproducibility of this method because of the pH leap. Titration of the elution
solution using a final concentration of sodium acetate between 0.2 - 0.6 M
showed that a buffering region existed where the pH ranged between 4 and 5.5.
Nevertheless, precipitation of PAI-2-DTTA was observed when added at different
protein concentrations (0.2 – 1 mg/ml) to elution solution adjusted with various
concentrations of sodium acetate (0.1 - 0.6 M) (data now shown).
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Figure 51: Titration of the 213Bi elution solution
Elution solution (0.075 M HI/1 x PBS) was titrated with (A) 1 M sodium hydroxide, (B) 6
M sodium acetate, pH 5.5 or (C) 1 M citrate buffer, pH 5.5. The pH of the solution was
measured and plotted against the final concentration (mM) of the titration buffer in the
final total volume.

168

5.3.B.1. LABELLING OF PAI-2-DTTA WITH 213BI USING CITRATE BUFFER
Incubation of PAI-2-DTTA at 1 mg/ml with elution solution adjusted with
0.09 – 0.13 M citrate showed that protein precipitation decreased as the final
molar concentration of citrate increased (Table V – A). PAI-2-DTTA precipitation
was not observed when the elution solution was buffered using 0.13 M citrate
(final solution pH 5.5 – 6). Incubation of various concentrations of PAI-2-DTTA
in elution solutions adjusted with 0.13 M final concentration of citrate buffer
did not result in precipitation of the protein (Table V – B). Omission of PBS from
the elution solution resulted in PAI-2-DTTA precipitation (pH 5.5, data not
shown), the reason for this precipitation was not clear.

Table V: Effect of citrate buffered elution on PAI-2-DTTA precipitation

A
Elution solution
0.075 M HI and 1
x PBS

Final [citrate] [PAI-2-DTTA]
(M)
(mg/ml)
0.09
0.10
0.11
0.12
0.13

1
1
1
1
1

pH

Precipitation

3.5 - 4
4 - 4.5
4.5 - 5
5 – 5.5
5.5 - 6

Most (+++)
Less (++)
Less (+)
Least (-)
No precipitation

B
Elution solution
0.075 M HI and 1 x
PBS

Final [citrate] [PAI-2-DTTA]
(M)
(mg/ml)
0.13
0.13
0.13
0.13

0.58
0.73
1.16
1.93

pH

Precipitation

5.5 - 6
5.5 - 6
5.5 - 6
5.5 - 6

No
No
No
No

(A) Elution solution was titrated with 1 M citrate buffer (pH 5.5); PAI-2-DTTA was added
at 1 mg/ml and precipitation was assessed. (B) PAI-2-DTTA was incubated at different
concentrations in elution solution buffered using 1 M citrate buffer (pH 5.5) at 0.13 M
final concentration. The pH of the final solution was measured and protein precipitation
was assessed.
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The studies performed with citrate-buffered elution solution above did
not contain
of

213Bi

213Bi

radionuclide. Nevertheless, as shown in Table VI, the presence

at various concentrations did not affect the pH of the citrate-buffered

solution. ITLC performed using 1 µl of citrate-buffered

213Bi

elution showed that

using 0.1 M citrate buffer as the mobile phase, 99 % of radiation moved to the
solvent front (Table VII - A). As other buffers showed that significant level of
radiation remained at the origin, these could not be used for assessing the
percentage incorporation of

213Bi

using ITLC. No precipitation of protein was

observed when PAI-2-DTTA was incubated with buffered

213Bi

HI/1 x PBS/0.13 M citrate) for 15 min. The incorporation of
213Bi

solution (0.075 M

213Bi

when buffered

solution was incubated with PAI-2-DTTA at 1 µCi:1 µg ratio was 93 and

93.7 % at 1 and 5 min, respectively (Table VII – B).

Table VI: The effect of 213Bi on the pH of citrate-buffered elution solution
213

0.075 M
HI (µl)

Bi in
0.075 M HI
(µl)

10 x
PBS
(µl)

1M
citrate
(µl)

Final
volume
(µl)

[213Bi]
(µCi/µl)

pH

100
75
50
25
0

0
25
50
75
100

13
13
13
13
13

17
17
17
17
17

130
130
130
130
130

0
0.12
0.24
0.36
0.48

5.5-6
5.5-6
5.5-6
5.5-6
5.5-6

was eluted using 250 µl of 0.15 M HI followed by 250 µl of dH2O. Different volumes
of 213Bi elution were mixed with different volumes of 0.075 M HI in a final volume of 100
µl. The pH was adjusted using 10 x PBS and 1 M citric acid solution (pH 5.5) and the pH
of the final 130 µl volume was measured.
213Bi
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Table VII: Effect of different solvents on separation of free and
PAI-2-DTTA-incorporated 213Bi by ITLC

A: Mobility of free 213Bi
ITLC buffer

Radioactivity at origin

0.5 M acetate

58 %

0.1 M citrate

1%

1 x PBS

33 %

dH2O

20 %

B: Mobility of PAI-2-DTTA-213Bi
Reaction

213

Bi incorporation

1 min

93.0 %

5 min

93.7 %

(A) 2 µl of buffered 213Bi (0.075 M HI/1 x PBS/0.13 M citrate, pH 5.5 – 6) was spotted
onto ITLC strips and chromatography was performed using the specified mobile phases.
Radioactivity at the origin was calculated as the percentage of radioactivity at origin over
the radioactivity at both the origin and solvent front. (B) ITLC was performed using 0.1
M citrate (pH 5.5) solution as the mobile phase at 1 and 5 min from the incubation of
PAI-2-DTTA with buffered 213Bi at 1 µg: 1 µCi ratio at RT. The percentage of activity at
the origin (% origin/[origin + solvent front]) was calculated as a measure of 213Bi
incorporation.

5.3.C. OPTIMISATION OF RADIOLABELLING OF PAI-2-DTTA WITH
(α-PAI-2)
Using the citrate buffering system for preparing a suitable
solution, the radiolabelling of PAI-2-DTTA with

213Bi

213BI

213Bi-elution

was optimised in terms of

protein/radioactivity concentrations and time. High percentage incorporation of
213Bi

(> 90 %) was obtained when PAI-2-DTTA was incubated with 213Bi to give

specific radioactivity less than 10 µCi/µg (Figure 52 – A and B). In addition to
the effect of the

213Bi:

PAI-2-DTTA ratio,

affected by the final concentrations of

213Bi

percentage incorporation was also

213Bi

and PAI-2-DTTA even when both

reactants were maintained at 1 µCi: 1 µg ratio (Figure 52 – C).

213
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Figure 52: Radiolabelling optimisation of PAI-2-DTTA with 213Bi
(A) Buffered 213Bi solution (200 µCi/ml) was incubated with increasing concentrations of
PAI-2-DTTA for 10 min at room temperature. 213Bi incorporation was assessed by ITLC
using 0.1 M citrate (pH 5.5) as mobile phase. (B) 100 µg/ml PAI-2-DTTA was incubated
with increasing concentrations of buffered 213Bi and incorporation was assessed. (C)
PAI-2-DTTA (7.25 µg) and buffered 213Bi (7.25 µCi) were incubated in different final
volumes for 10 min. Data presented in Figure are the mean incorporation percentages ±
SEM (n = 3). Note: the percentage 213Bi incorporation is the percentage of 213Bi
incorporated into PAI-2-DTTA over the total 213Bi added.
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At high final concentrations (200 µCi and 200 µg per ml), the
radiolabelling of PAI-2-DTTA with

213Bi

was rapid and reached maximal within

the first 5 min of incubation (Figure 53). The incorporation of

213Bi

into PAI-2-

DTTA was solely due to the DTTA moiety as PAI-2 failed to incorporate any
in comparison to PAI-2-DTTA (Figure 54 – A). Incorporated
chelated since only 15 and 16 % of

213Bi

213Bi

213Bi

was strongly

was stripped from PAI-2-DTTA-213Bi

prepared at 1 and 5 µCi/µg, respectively, when challenged with excess amount
(80 µg/ml) of free DTPA (Figure 54 – B).
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Figure 53: Kinetics of the PAI-2-DTTA 213Bi-labelling reaction
PAI-2-DTTA (200 µg/ml) and buffered 213Bi (200 µCi/ml) were incubated at room
temperature and at the specified time points the reaction was stopped by the addition of
EDTA (20 mM final concentration). 213Bi incorporation was assessed using ITLC and
data presented are the mean ± SEM (n = 3).
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Figure 54: Specificity and stability of the 213Bi-labelling reaction
(A) PAI-2-DTTA or PAI-2 were incubated for 10 min at RT with buffered 213Bi at 1 or 5
µCi/µg in the same final volume. 213Bi incorporation was assessed and data presented
are the mean incorporation ± SEM (n = 3). (B) PAI-2-DTTA labelled with buffered 213Bi at
1 (clear bars) and 5 (filled bars) µCi/µg were incubated at 37oC for 45 min in RPMI-1640
+ 5 % FCS containing increasing concentrations of hydrolysed cDTPA (DTPA). 213Bi
incorporation was assessed and data presented are the mean ± SEM (n = 3). There was
no significant differences in the percentage of 213Bi remaining with the protein between
the 1 and 5 µCi/µg α-PAI-2 preparations after challenge with all DTPA concentrations (p
> 0.05, n = 3). However, challenge of both specific radioactivities with 80 µg/ml DTPA
caused a small but significant loss of 213Bi label from the protein compared to
unchallenged controls ( , p < 0.05, n = 3).
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5.3.D. INTEGRITY OF α-PAI-2
α-PAI-2 prepared at specific radioactivities decreased the structural and
functional integrity of PAI-2. The intensity of the band corresponding to PAI-2
(47 kDa) detected by SDS-PAGE decreased as the specific radioactivity of α-PAI2 increased from 0.1 to 10 µCi/µg (Figure 55 – A). In agreement,
autoradiography (Figure 55 – B) showed an increase in the intensity of possible
radioactive degradation products at the bottom of the gel with increasing
specific radioactivities of α-PAI-2. The intensity of the 47 kDa band in the
autoradiogram increased with higher specific radioactivity of α-PAI-2 which
reflects higher incorporation of 213Bi (lanes 2, 4, 6 and 8 in Figure 55 – B).
The ability of α-PAI-2 to from SDS-stable complexes with uPA was also
affected by its specific radioactivity. α-PAI-2 prepared at 0.1 and 1 µCi/µg
efficiently formed complexes with uPA as bands for free α-PAI-2 were not evident
(lanes 3 and 5 compared with lanes 2 and 4, respectively, Figure 55 – B). In
contrast, for the 5 and 10 µCi/µg α-PAI-2, large amounts of free α-PAI-2 were
evident even after incubation with excess uPA (lanes 7 and 9 compared with
lanes 6 and 8, respectively, Figure 55 – B). This indicated that although a
fraction of 5 and 10 µCi/µg α-PAI-2 remained intact, only a fraction of this
intact α-PAI-2 at these specific radioactivities were able to form SDS-stable
complexes with uPA.
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Figure 55: α-PAI-2 integrity and uPA-binding ability
PAI-2-DTTA was radiolabelled with buffered 213Bi to produce α-PAI-2 at specific
radioactivities of 0.1, 1, 5 and 10 µCi/µg. The protein concentration for all incubations
was identical and the same volume from each specific radioactivity was incubated at
37oC for 60 min in the absence or presence of excess uPA containing high (55 kDa) and
low (33 kDa) molecular weight uPA. Aliquots containing the same protein amounts were
fractionated by 12 % reducing SDS-PAGE. (A) The SDS-PAGE gel was stained in
Coomassie blue stain solution, destained and documented after (B) exposure to
phosphor screen for 3 h and scanning using the Storm® scanner. Lane 1: molecular
weight marker. Lane 2: 0.1 µCi/µg α-PAI-2; lane 3: 0.1 µCi/µg α-PAI-2 + uPA; lane 4: 1
µCi/µg α-PAI-2; lane 5: 1 µCi/µg α-PAI-2 + uPA; lane 6: 5 µCi/µg α-PAI-2; lane 7: 5
µCi/µg α-PAI-2 + uPA; lane 8: 10 µCi/µg α-PAI-2; lane 9: 10 µCi/µg α-PAI-2 + uPA and
lane 10: uPA.
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5.3.E. CYTOTOXICITY OF α-PAI-2
5.3.E.1. CYTOTOXICITY OF BUFFER-EXCHANGED α-PAI-2
α-PAI-2 prepared at 1, 5 and 10 µCi/µg specific radioactivities were
efficiently buffer exchanged from the labelling buffer into RPMI-1640 + 5 % FCS
using 30 kDa cut-off microconcentrators (90 % of the initial activity recovered,
data not shown). α-PAI-2 under these conditions showed slight cytotoxicity to
MDA-MB-231 cells (Figure 56 - A). At 3 µCi/100 µl dose of 1, 5 and 10
µCi/µg α-PAI-2, the percentage of surviving cells compared to control cells was
79.4 ± 0.5, 80.2 ± 0.2 and 83.6 ± 2.4 %, respectively. The cytotoxicity was not
significantly different using the different specific activities of α-PAI-2 (p > 0.05, n
= 3). In a separate experiment, treatment of the MDA-MB-231 cells with bufferexchanged 1 µCi/µg α-PAI-2 significantly decreased cell survival to 75.4 ± 1.3 %
(p < 0.05, n = 5, Figure 56 - B). The survival of the non-invasive breast cancer
cells, T-47D cells, was not significantly affected by the addition of this dose of
washed α-PAI-2 (p > 0.05, n = 5). This suggested that the cytotoxicity of α-PAI-2
observed on MDA-MB-231 cells was due to high cell-surface uPA levels on these
cells compared to T-47D cells. Despite the success of this assay, the cytotoxicity
level of buffer-exchanged α-PAI-2 was lower than that previously reported by
Ranson et al. (2002). This may be explained by difference in the radiolabelling
procedure (Ranson et al., 2002). Higher doses of α-PAI-2 (> 3 µCi/100 µl) were
not possible due to the dilution of radioactivity during buffer exchange
technique, thus alternative procedures were investigated (Section 5.4.E.2.).
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Figure 56: Cytotoxicity of buffer-exchanged α-PAI-2
(A) MDA-MB-231 cells cultured for 48 h were detached and incubated with 5 µg/ml
plasminogen for 5 min at room temperature. Cells (2 x 104) were washed and incubated
overnight in triplicate 100 µl volumes of RPMI-1640 + 5 % FCS in the absence or
presence of specified doses of buffer-exchanged α-PAI-2 prepared at 1 (clear bars), 5
(light grey) and 10 (dark grey) µCi/µg. Cells were washed and incubated with 100 µl of
phenol-free binding buffer containing 5 % FCS and 20 µl of MTS/PMS substrate. The
absorbance of the product (at 495 nm) was measured after 3 h incubation at 37oC,
blanked against absorbance of solution in the absence of cells and cell survival was
calculated as the percentage of absorbance of α-PAI-2-treated cells against control cells.
(B) MDA-MB-231 cells (clear bars) and T-47D cells (filed bars) were subjected to
treatment with 3 µCi/100 µl dose of 1 µCi/µg α-PAI-2 as described for A and cell
survival was calculated (mean percentage survival ± SEM, n = 5). Asterisk denotes
significant difference between control and treated MD-MB-231 cells (p < 0.05). The
treatment of T-47D cells did not significantly affect cell survival compared to control
T-47D cells (p > 0.05, n = 5).

178

5.3.E.2. CYTOTOXICITY OF NON-BUFFER-EXCHANGED α-PAI-2
In order to avoid the time lost during the purification of α-PAI-2 due to
the short half-life of

213Bi

and to prevent the dilution caused by the purification

procedure, non-buffer-exchanged α-PAI-2 preparations were investigated for use
in cytotoxicity assays. Control experiments showed that the percentage of
surviving cells decreased with increasing concentrations of buffered elution
solution (0.075 M HI, 1 x PBS, 0.2 M citrate, pH 5.5 - 6) added to culture media
in comparison to cells incubated with culture media only (Figure 57 - A). In
contrast to the cytotoxic effect of the elution solution, increased cell proliferation
was observed with increasing concentrations of unlabelled PAI-2-DTTA added to
culture media (Figure 57 - B). Thus, in order to account for these confounding
effects, control treatments were included in cytotoxicity assays which were
identical to the α-PAI-2 treatments except for the absence of

213Bi.

In comparison to the control solutions described above, cytotoxicity of
non-buffer-exchanged α-PAI-2 preparations on MDA-MB-231 cells depended on
both the specific radioactivity and the dose of α-PAI-2 added. At all specific
radioactivities, there was a dose-dependent, significant decrease in MDA-MB231 cell-survival (Figure 58 – A). In comparison to MDA-MB-231 cells, T-47D
cells resisted treatment with low doses (1 and 2 µCi/100 µl) at all specific
radioactivities (p < 0.05, n = 3) (Figure 58 – B). The use of high doses (4 and 8
µCi) of all specific radioactivities did not show significant difference between the
survival of T-47D and MDA-MB-231 cells (p > 0.05, n = 3). This indicated that
high doses of α-PAI-2 sufficiently targeted both cell lines. The highest specific
radioactivity of α-PAI-2 (10 µCi/µg) had the least cytotoxic effect on both MDAMB-231 and T-47D cells. For example using 1 µCi/µg α-PAI-2, cells survival at
each dose used significantly decreased compared to that using 5 or 10 µCi/µg
α-PAI-2 (Figure 58 – A and B). This was in agreement with decreased integrity
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and uPA-binding ability of α-PAI-2 with increasing specific radioactivity (refer to
Figure 55).
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Figure 57: Effect of elution solution and PAI-2-DTTA on cell survival
(A) MDA-MB-231 cells were incubated overnight in RPMI-1640 + 5 % FCS in the
absence or presence of buffered elution solution (0.075 M HI/1 x PBS/0.2 M citrate, pH
6). Cell survival was measured after overnight incubation in comparison to control
treatment (RPMI-1640 + 5 % FCS only) and the mean ± SEM (n = 3) was plotted against
the concentration of buffered elution solution in the 100 µl volume (v/v %). (B) MDAMB-231 cells were incubated with increasing concentrations of unlabelled PAI-2-DTTA.
Cell survival was compared to control cells and plotted against the concentration of PAI2-DTTA (expressed as µg/100 µl) and the data shown are the mean + SEM (n =3).
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Figure 58: Optimised cytotoxicity of α-PAI-2 on MDA-MB-231 and T-47D cells
(A) MDA-MB-231 and (B) T-47D cells, cultured for 48 h, were detached and treated with
the specified doses of α-PAI-2 prepared at 1 (■), 5 (●) and 10 (▲) µCi/µg. For each dose
of the different specific radioactivities, the corresponding control treatment involved the
addition of the same volume of buffered elution solution and the same amount of
protein in the form of unlabelled PAI-2-DTTA. Survival was determined after overnight
treatment compared to these controls and data presented are the mean ± SEM (n = 3).
(A) Survival plots of MDA-MB-231 cells were fitted to one-phase exponential decay
model. (B) Survival plots of T-47D cells were fitted to sigmoidal dose-response model.
The sigmoidal shape indicated that T-47D cells were resistant to low doses of α-PAI-2;
however toxicity was achieved at high doses. Models were selected according to the best
fit and none of the data deviated from the fitted model as judged by runs test performed
by GraphPad® software. The dotted lines represent the toxic dose (Do, 37 % survival).
Data presented are representative from two independent assays.
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5.3.E.3. PROLIFERATIVE CAPACITY OF CELLS SURVIVNG α-PAI-2 EXPOSURE
After overnight treatment with 4 and 8 µCi/100 µl doses of 1 µCi/µg
α-PAI-2, 62 ± 0.6 and 70 ± 0.9 % of the total cell population compared to control
cells did not survive, respectively (Figure 59 – A and B). Whether the remaining,
presumably not targeted, cells were healthy and able to proliferate was checked
by examining cell survival 48 h after treatment with 1 µCi/µg α-PAI-2. Using
both 4 and 8 µCi/100 µl doses of 1 µCi/µg α-PAI-2 the cell numbers were
significantly recovered (to 92.1 ± 3.2 and 54.1 ± 1.5 % compared to controls,
respectively) after 48 h compared to the overnight time point (Figure 59 – A and
B). This indicated that the surviving remaining cells after overnight treatment
with 1 µCi/µg α-PAI-2 retained their ability to proliferate. Cells treated with 4
and 8 µCi/100 µl doses of 5 and 10 µCi/µg α-PAI-2 showed less than 50 %
recovery between overnight and at 48 h (Figure 59 – A and B). Thus, although
5 and 10 µCi/µg α-PAI-2 were less cytotoxic than 1 µCi/µg α-PAI-2 after
overnight incubation (Figure 59, clear bars), these higher specific radioactivity
preparations appeared to decrease the proliferative capacity of the remaining
cells that survived after overnight treatment during 48 h incubation after
treatment (Figure 59, filled bars). This suggests that since treatment with
1 µCi/µg α-PAI-2 appeared not to affect the proliferation of surviving cells then
1 µCi/µg α-PAI-2 caused minimal co-lateral cytotoxicity. That is surviving cells
(untargeted) were not affected by 1 µCi/µg α-PAI-2 in the media, therefore
proliferated normally.
5.3.E.4. EFFECT OF CELL ATTACHMENT ON α-PAI-2 CYTOTOXICITY
Attached MDA-MB-231 cells, treated identically to detached cells, were
less sensitive to the cytotoxicity of α-PAI-2. Nevertheless, cell survival depended
on the dose and specific radioactivity of α-PAI-2 (Figure 60 – A). This indicated
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that attachment of MDA-MB-231 cells did not affect the targeting mechanism of
α-PAI-2; however, only a fraction of the administered dose may have targeted
these cells. In agreement, higher levels of PAI-2-Cy5 bound to detached MDAMB-231 cells compared to attached cells (Figure 60 - B). This binding was
similarly inhibited by blocking the B-chain of uPA (data not shown). Thus, the
effect of cell attachment on the binding of PAI-2-Cy5 and the cytotoxicity of
α-PAI-2 may be due to the unavailability of uPAR-bound uPA which is involved
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Figure 59: Recovery of α-PAI-2-treated MDA-MB-231 cells at 48 hour post treatment
MDA-MB-231 cells cultured for 48 h were detached and treated with (A) 4 µCi/100 µl
and (B) 8 µCi/100 µl doses of α-PAI-2 prepared at 1, 5 and 10 µCi/µg as described for
Figure 58. For each dose of the different specific radioactivities, control treatments
involved the addition of the same volume of buffered elution solution and unlabelled
PAI-2-DTTA. The percentage of surviving cells compared to control treatments was
determined after overnight incubation (clear bars) and 48 h past the treatment (filled
bars). Data presented are the mean ± SEM (n = 3). The number of cells in control
treatments was approximately doubled between the overnight time point and the 48 h
time point (data not shown).
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Figure 60: Effect of cell-attachment on ability of PAI-2 to access cell-surface uPA
(A) Attached MDA-MB-231 cells (2 x 104 cells) cultured for 48 h were activated with plasminogen and treated with the specified doses of α-PAI-2
prepared at 1 (■), 5 (●) and 10 (▲) µCi/µg. Survival was determined compared to control treatments as described for Figure 58 and data presented are
the mean ± SEM (n = 3). (B) Detached (left column) and attached (right column) MDA-MB-231 cells pre-activated with plasminogen were incubated with
PAI-2-Cy5 for 5 min at 37oC, cells were washed and then analysed by confocal microscopy. Top row are the transmission images and the scale bars
represent 10 µm. Bottom row are the Cy5 scan of the transmission images. One representative sample (n = 6) is shown for each treatment and preincubation of cells with anti-B-chain uPA monoclonal antibody (#394) completely inhibited PAI-2-Cy5 binding (data not shown).
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5.4. DISCUSSION
The results of this chapter describe the successful efficient radiolabelling
procedure of PAI-2-DTTA with the α-emitter radioisotope,

213Bi.

It was confirmed

that conjugation of PAI-2 to the metal chelator, cDTPA, did not affect the
binding ability or the inhibitory effect of PAI-2 towards uPA (see also Ranson et
al., 2002). Mass spectroscopy confirmed the addition of a variable number of
DTTA moieties to PAI-2 in the PAI-2-DTTA preparations. Ranson et al. (2002)
also showed that conjugation with cDTPA did not affect PAI-2 function and their
preparation contained a mixture of modified PAI-2 containing 1 – 4 DTTA
molecules per PAI-2 molecule. Further investigation in this chapter showed that
there was always a mixture of different stoichiometric ratios of PAI-2 to DTTA
(i.e. PAI-2-DTTA, PAI-2-[DTTA]2 … PAI-2-[DTTA]n) which varied between different
reactions and within replicates of the same reaction. This variation may be due
to complex reaction kinetics. These complicated reaction kinetics are beyond the
scope of this study; however, they may be related to reaction conditions and
sterical hindrance on the surface of PAI-2 despite the fact that only limited sites
on the surface of PAI-2 are available for reaction. Thus, although the average
number of DTTA molecules conjugated to PAI-2 was calculated as 3 - 4
molecules (n = 15), it is recommended that mass spectroscopy should be
performed for each preparation due to the variation observed.
Previous radiolabelling of PAI-2-DTTA with

213Bi

showed that the

percentage of incorporated radioactivity was greater than 90 % (Ranson et al.,
2002). However, α-PAI-2 needed to be purified from free

213Bi

using size

exclusion chromatography of the radiolabelling reaction which is a timeconsuming process. Although Ranson et al. (2002) demonstrated the uPAdependent cytotoxicity of their α-PAI-2 preparation, more efficient, rapid and
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reproducible radiolabelling protocol was needed considering the short-life of
213Bi

and for potential clinical applications. The radiolabelling reaction of PAI-2-

DTTA with

213Bi

was first optimised in terms of the buffer used for this reaction.

PAI-2-DTTA was readily precipitated when added to the solution used to elute
213Bi

due to the very low pH of this solution (pH 0 – 1). Although sodium acetate

was described to neutralise the elution solution (Ranson et al., 2002), it was
found that PAI-2-DTTA precipitated even when the elution solution was
adjusted to pH 5.5 using sodium acetate. The reason for the unreported
precipitation in the α-PAI-2 prepared by Ranson et al. (2002) may be due to the
very low protein concentrations used in their study (5 – 10 µg in a 550 µl typical
elution volume). Furthermore, considering that the average activity eluted in
550 µl volume is higher than 500 µCi, the previous labelling involved the
addition of 100 µCi of

213

Bi per 1 µg of PAI-2-DTTA (Ranson et al., 2002). The

authors described the preparation of 15 – 20 µCi/µg of α-PAI-2 after PD-10
column purification, indicating that only 10 – 15 % of added

213Bi

incorporated

inefficient

thus

necessitating

further

purification.

This

was

radiolabelling (Ranson et al., 2002) and the precipitation of PAI-2-DTTA reported
in this thesis when using sodium acetate as buffering system suggested that
alternative methods were required to optimise the radiolabelling of PAI-2-DTTA.
The use of citric acid buffer (pH 5.5) showed that protein precipitation by
the elution solution was prevented by the presence of 0.13 – 0.2 M final
concentration of citrate. Initial radiolabelling reactions under citrate buffering
system described an efficient incorporation of

213Bi

(> 90 %) which was

confidently assessed using 0.1 M citrate (pH 5.5) as the mobile phase for ITLC.
Using these conditions for pH adjustment and ITLC, the radiolabelling of PAI-2DTTA with

213Bi

was optimised with respect to the ratio of radioactivity to

protein, concentration of reactants and time. A standard operating procedure
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(SOP) for pre-clinical analyses was developed for the radiolabelling reaction
where

213Bi

is eluted using 250 µl of freshly prepared 0.15 M HI and 250 µl of

dH2O into reaction tube containing 85 µl of 1.5 M citrate (pH 5.5) and 65 µl of
10 x PBS (pH 7.2) then PAI-2-DTTA is added and incubated for 5 – 10 min.
Using the developed SOP, PAI-2-DTTA was radiolabelled with
different specific activities and

213Bi

213Bi

at

incorporation was shown to be specific and

stable. There was a loss in the integrity and uPA-binding ability with increasing
specific radioactivity of α-PAI-2 preparations. In agreement, higher specific
radioactivity (5 and 10 µCi/µg) preparations of α-PAI-2 were less cytotoxic
towards MDA-MB-231 and T-47D cells compared to lower specific radioactivity
(1 µCi/µg) preparation. T-47D cells tolerated low doses (< 4 µCi/100 µl) of
1 µCi/µg α-PAI-2 compared to MDA-MB-231 cells. This indicated that cytotoxic
effect of 1 µCi/µg α-PAI-2 was uPA-dependent at doses less than 4 µCi/100µl.
However, doses higher than 4 µCi/100 µl of 1 µCi/µg α-PAI-2 efficiently reduced
the survival of suspension cultures of both high and low uPA expressing
MDA-MB-231 and T-47D cells, respectively. Cells significantly recovered when
incubated for 48 h after treatment with all doses of 1 µCi/µg α-PAI-2. On the
other hand, cells treated with 5 and 10 µCi/µg α-PAI-2 did not recover as
efficiently at 48 h incubation after treatment. This suggested that although 5
and 10 µCi/µg α-PAI-2 showed less cytotoxic effect than 1 µCi/µg α-PAI-2, these
high specific radioactivity preparations may have caused co-lateral damage to
untargeted cells and affected their proliferation ability. Finally, attached
MDA-MB-231 cells tolerated the same doses of α-PAI-2 (1, 2, 4 and 8 µCi/100
µl) at the different specific radioactivities (1, 5 and 10 µCi/µg) delivered to
suspension MDA-MB-231 cells. This increased tolerance maybe explained by
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less binding of PAI-2 to these cells when attached compared to when in
suspension.
The results of this chapter are important for the preparation and
assessment of the use of α-PAI-2 in pre-clinical in vivo trials. Based on these
results, the 1 µCi/µg α-PAI-2 preparation was suggested for use for pre-clinical
trials since: (1) this preparation did not affect the structural integrity of PAI-2 or
its uPA binding ability, (2)

213Bi

incorporation was highly stable, (3) the uPA-

dependent cytotoxic effect of α-PAI-2 was highest on both detached and
attached cells and (4) the 1 µCi/µg α-PAI-2 preparation appeared to cause the
least co-lateral damage.
In conclusion, this chapter described the efficient conjugation of cDTPA
to PAI-2 and methods required for characterisation of the final product of this
reaction. Furthermore, the preparation of PAI-2-DTTA and its radiolabelling
with

213Bi

was optimised into a standard operating procedure, which was

adopted for the preparation of

213Bi-PAI-2

for pre-clinical trials of radiotherapy

using mouse models of human tumours (Stutchbury et al., manuscripts in
preparation). These pre-clinical trials showed that mice tolerated buffered

213Bi

elution and that 1 µCi/µg α-PAI-2 effectively reduced tumour growth and
conferred a survival advantage (Stutchbury et al., manuscript in preparation).
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Chapter 6: CONCLUSIONS AND FUTURE WORK
The kinetics of the inhibition of cell-surface uPA on breast cancer cells by
PAI-2 were directly described using appropriate parameters (KI and kinact) in this
thesis as compared to the previous indirectly assayed second order rate
constant (Ellis et al., 1990). uPA was identified as the major specific target for
PAI-2 on the cell surface. The inhibition parameters measured in this thesis
characterise PAI-2 as a very specific potent inhibitor of uPAR-bound uPA on the
cell surface. Inhibition of cell-surface uPA by PAI-2 is rapidly followed by the
endocytosis of PAI-2, uPA as well as uPAR which seems to mimic the previously
reported internalisation of cell surface uPA/uPAR induced by other serpins
(Andreasen et al., 1997). Data also indicate that uPAR may be recycled to the
cell surface which is in agreement with previous findings using other serpins
(Nykjær et al., 1997). Members of the LDLR family are involved in part in the
internalisation of PAI-2 (Al-Ejeh et al., 2004). Despite these similarities between
PAI-2 induced internalisation of uPAR/uPA:PAI-2 complexes and other
uPAR/uPA:serpin complexes, data suggests that the mechanism of PAI-2
internalisation may be novel in terms of endocytosis mediators (Croucher D.,
personal communications). During the internalisation of uPAR/uPA:PAI-2, uPA
may be replenished on the cell surface in the pro-enzyme form. These results
lead to an entire new PhD project (undertaken by Croucher D., Dr. M. Ranson
Laboratory, University of Wollongong) to provide definitive evidence for the
suggested replenishment of cell-surface uPA and the recycling of uPAR as well
as deducing the complete mechanism of uPAR/uPA:PAI-2 internalisation.
The

evident

internalisation

and

the

perinuclear

localisation

of

internalised PAI-2 provide a definitive biological rationale for the targeted alpha
therapy being developed using this serpin (Li et al., 2002; Ranson et al., 2002;
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Allen et al., 2003). The standard operating procedures for the preparation and
characterisation of α-PAI-2 described in this thesis were adopted by Dr Marie
Ranson and collaborators (University of Wollongong, Australia) in pre-clinical
development of α-PAI-2 for treatment of breast and prostate cancer. Given
further time and resources, separation of the different PAI-2-DTTA moieties in
the conjugation reactions by high-pressure liquid chromatography would have
been advantages for at least two reasons. First, such separation would result in
a more uniform solution of PAI-2-DTTA for clinical use. Secondly, as tryptic
digest and peptide mass finger printing using mass spectroscopy resulted in
very complex spectra (data not shown), separation of different PAI-2-DTTA
moieties before fingerprinting may simplify these results. This may be employed
in order to deduce the sites of cDTPA conjugation to PAI-2 and completely
characterise this promising cancer targeting vehicle.
Finally, transfection of the non-invasive breast cancer T-47D cells with
uPAR cDNA was also useful for the PAI-2 binding studies. Furthermore, the
overexpression of uPAR in the non-invasive T-47D cells caused an interesting
modulation of other components of the urokinase-type plasminogen activation
cascade. Using this technique, initial and preliminary explanations were
provided for elucidating links between the upregulation of uPAR expression and
the adoption of metastatic phenotype. Although such a link has been described
previously (e.g. Ranson et al., 1998), the findings in this thesis gave deeper
insights into the adoption of the malignant phenotype by cancer cells and raised
new questions which may be the subject for future research. The possibility that
the non-active site epitope on uPA suggested by Ellis et al. (1999) can act as a
receptor for plasminogen binding may be evaluated by developing antibodies to
this epitope. This would provide an explanation for increased plasminogen
binding

when

increasing

cell-surface

uPA

and

the

co-localisation

of
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uPA/plasminogen

on

T-47D

cells.

Furthermore,

the

possible

effect

of

uPAR/uPA-transient overexpression on the expression of plasminogen receptors
may be characterised by proteomic comparison between control and transfected
T-47D cells. The ability to knock out the expression of uPAR in the invasive
MDA-MB-231 cells would provide useful material for comparison with uPARoverexpressing

T-47D

cells,

however,

consistent

preparation

of

uPAR-

downregulated MDA-MB-231 cells in this study failed. Further work is required
to prepare uPAR--MDA-MB-231 cells and new techniques such as small
interfering RNA (siRNA) transfection technology would be recommended. siRNAtransfection is showing more success than cDNA transfection methods in
silencing the expression of cellular components (Caplen and Mousses, 2003). In
addition, the possibility that increased cell-surface plasmin activity by the
addition of exogenous uPA or transient overexpression of uPAR/uPA may
activate latent plasminogen receptors needs to be tested. It is well known that
increased cell-surface uPAR/uPA leads to an increase in plasmin-dependent
proteolysis and invasion both in vitro and in vivo and that plasmin generation is
mediated by the proteolytic activity of uPA on receptor-bound plasminogen (see
review by Andreasen et al., 1997). However, it is not clear whether this involves
modulation of plasminogen receptors on the cell surface. Altogether, the future
work suggested above may be incorporated into a PhD project aimed at
understanding the molecular details of the increased plasminogen binding due
increased of cell-surface uPAR/uPA.
In conclusion, this thesis described the direct inhibition parameters of
cell-surface uPA by PAI-2 and the internalisation of PAI-2:uPA complexes
formed on the cell-surface. This published study (Al-Ejeh et al., 2004) also
provided a biological rationale for the use of PAI-2 as uPA-based anti-cancer
therapy, one of which is the use of cytotoxic alpha radiation. Alpha-PAI-2
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preparation was successfully optimised according to standard operating
procedures and these procedures showed success in trials of radiotherapy using
mouse models of human tumours (Stutchbury et al., manuscripts in
preparation). Finally, in addition to their use in elucidating the binding of PAI-2,
transiently uPAR-overexpressing cells provided preliminary insights into the
relationship between metastatic phenotype and plasminogen binding (used in
part in Stillfried G. et al., manuscript in preparation) and may be expanded to a
new PhD thesis.
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Chapter 7: APPENDICES

7.1. APPENDIX 1: NORMALISATION OF GAMMA-COUNTER
The radionuclide (2.5 µCi) was dissolved in 1 ml of PBS and 200 µl
aliquots were transferred to 5 γ-counter tubes (0.5 µCi in 200 µl per tube).
Tubes were placed in normalisation rack at positions 1, 5, 9, 13 and 17 to
normalise the 5 detectors of the Cobra 5005R γ-counter using specified
normalisation window for each radionuclide. Machine was normalised for
‘position 2’ which was ideal for counting 0.2 ml – 0.5 ml samples. The ChiSquare test produced after normalisation was used to judge whether detectors
were normalised efficiently (Chi Square 99 % confidence range = 7.63 – 36.19).
In the case where detectors were out of this range, normalisation was repeated
and in some cases only the efficiently normalised detectors were selected for
counting.

7.2. APPENDIX

2:

QUANTIFICATION

AND

PURITY

OF

DNA

PREPARATIONS
Agarose gel electrophoresis of plasmid DNA against known amounts
molecular weight marker allowed the quantification of the amounts of DNA
present in the sample. The amount of each band in the molecular weight
marker, Figure 61, was calculated using the ratio of the band size to the size of
λDNA (85500 bp) multiplied by the amount of marker used (180 ng). The
amount of DNA in bands, for example lane 1 and 2 Figure 61, was calculated
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based on the standard curve constructed for the relationship between staining
intensity and the amount from the molecular weight marker. The amount of
DNA in the original sample was calculated based on the amount measured in
the loaded volume and considering the dilution factors. For the example shown,
the average amount of DNA was 263 ng in the 10 µl loaded. Thus, the amount
in the 25 µl total volume was 657.5 ng which was acquired using 0.5 µl of
plasmid solution. The concentration of the original plasmid solution calculated
using this method (1.32 µg/µl) was compared to value obtained by
spectrophotometric method (Table VIII). The concentration of DNA in plasmid
solution was calculated from the absorbance at 260 nm and found to be 1.38
µg/µl. The average concentration (1.35 ± 0.03 µg/µl) from the two methods was
used to represent the concentration of plasmid solution. The ratio of the
absorbance at 260 nm to that at 280 nm (2.0) indicated that the preparation
was of high purity and very small amounts of protein was present in the
sample.

Table VIII: Quantification and purity of plasmid DNA

Measurement

Value

A260
A280
A260/A280
DNA concentration
Concentration of stock
preparation

0.138
0.069
2
6.9 µg/ml
1.38 µg/µl

Plasmid was diluted 1:200 in dH2O and the absorbance
at 260 and 280 nm was measured using dH2O as blank.
DNA concentration was measured given that 0.1
absorbance ≡ 50 µg/ml (Maniatis et al., 1989). The
concentration of the stock was then measured by
multiplication with the dilution factor (200). The purity of
DNA sample was measured as the ratio of
A260nm/A280nm (Maniatis et al., 1989).
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A

B

C

Figure 61: Quantification of DNA preparation
(A)
(0.5 µl) was diluted in a final 20 µl dH2O and mixed 5 µl of 5 x DNA
loading dye. Lane 1 and 2: 10 µl of pcDNA3/uPAR- solution and lane 3: 5 µl of 37 ng/µl
of λDNA/Hind III marker. Electrophoresis was performed using 1.2 % agarose gel at 70
volts for 1 h and gel was stained in ethidium bromide solution, washed and
documented. (B) Analysis of the gel image using GelProTM Analyzer software. (C)
Quantification of the size and amount of bands observed in lanes 1 and 2 using
standard curves constructed from the molecular weight marker (lane 3). The molecular
weight of the bands (mol.w.) is in base pairs unit and the amount is in ng.
pcDNA3/uPAR-

7.3. APPENDIX 3: UPA ACTIVITY STANDARD CURVE
The inhibition of uPA activity due incubation of PAI-2 was assayed using
a colorimetric assay which utilised synthetic substrate for uPA, Spectrozyme®UK. The kinetics of substrate conversion to the coloured product was assayed at
405 nm for uPA pre-incubated with PAI-2 and compared to standard curve for
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the relationship between the activity units of uPA (IU) and the rate of substrate
conversion. The standard curve was constructed using serial 1:2 dilutions of 20
IU of uPA incubated with 2 mM of Spectrozyme®-UK. The change in absorbance
at 405 nm over time was plotted against the activity units (Figure 62) and the
linear correlation was used to interpolate the activity of uPA retained after
incubation with PAI-2.

50

Rate of substrate
conversion

45
40

R2 = 0.9957

35
30
25
20
15
10
5
0
0

5

10

Amount of uPA (IU)

15

20

Figure 62: Standard curve for the rate of substrate conversion and uPA
concentration
See method in Section 2.2.B.4. The rate of substrate conversion (change in absorbance
overtime) was plotted against the concentration of uPA and a linear correlation (r2 =
0.996) was fitted to the data (mean ± SEM, n = 3).
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7.4. APPENDIX 4: BUFFERS AND SOLUTIONS
Agarose gel
1.2 % w/v agarose
dissolved in 1 x Tris-Borate-EDTA (TBE) buffer
Binding buffer (Hank’s buffered saline solution)
9.5 g/l Hank’s powder
1 mM HEPES
0.1 % w/v bovine serum albumin (BSA)
1 mM CaCl2
1 mM MgCl2
pH 7.4
Filtered with 0.22 µm filters

* Phenol red-free binding buffer was prepared identically however using phenol
red-free Hank’s powder
Coomassie blue stain
0.1 % w/v Brilliant Blue R250
40 % v/v methanol
10 % v/v glacial acetic acid
Coomassie blue destain
40 % methanol
10% glacial acetic acid
60 % water
Culture media
10.4 g/l of RPMI-1640 powder (contains 2 mM glutamine)
2 g/l sodium bicarbonate
adjusted to pH 7.2
Filter-sterilised using 0.22 µm sterile filters units
DNA precipitation buffer
1.5 M sodium acetate pH 8
250 mM EDTA
DNA sample buffer [5 x concentration]
30 % glycerol
0.125 % w/v xylene cyanol
0.125 % w/v bromophenol blue
Elution solution for

213Bi

250 µl of 0.15 M HI followed by 250 µl of H2O (0.075 M HI)
Eluted into tube containing 50 µl of 10 x PBS (final 1 x PBS concentration)
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Elution buffer for PD-10 columns
1 x PBS
0.1 % w/v BSA
pH 7.4
0.1 % gelatine buffer
0.1 g gelatine
150 mM NaCl
20 mM Tris-HCl
In 100 ml of dH2O and adjusted to pH 8.4
Luria Broth (LB)
10 g/l trypton
5 g/l yeast extract
10 g/l NaCl
Mounting buffer
1 x PBS containing 10 % v/v glycerol
5 x non-reducing sample buffer
60 mM Tris-HCl
2 % w/v SDS
10 % v/v glycerol
0.01 % w/v bromophenol blue

*

5 x reducing sample buffer prepared as for non-reducing sample buffer but
including 5 % w/v 2-β-mercaptoethanol
1 x Phosphate buffered saline (PBS)

8 g/l NaCl
0.2 g/l KCl
1.44 g/l Na2HPO4
0.24 g/l KH2PO4
pH adjusted to 7.4
Filtered with 0.22 µm filters
(10 x PBS was prepared by adding 10 x the concentrations above).
* Note: When 1 x PBS was used with cells (e.g. washing), MgCl2 and CaCl2 were
added each at 1 mM final concentration.
1 x running buffer for SDS-PAGE
3.03 g/l Tris-HCl
14.4 g/l glycine
1 g/l SDS
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SDS-PAGE gels
Resolving gel
12 % v/v of liquid 40 % acrylamide
0.1 % w/v SDS
375 mM Tris-HCl pH 8.8
0.1 % v/v TEMED
0.05 % w/v ammonium persulphate (APS)
Stacking gel
4 % v/v of liquid 40 % acrylamide
0.1 % w/v SDS
126 mM Tris-HCl pH 6.8
0.1 % v/v TEMED
0.05 % w/v APS
SOC medium
Sterile solution containing:
2 % w/v Bactotryptone
0.5 % w/v yeast extract
10 mM NaCl
2.5 mM KCl
20 mM MgCl2
10 mM MgSO4
20 mM Glucose
TBE buffer
10 x buffer prepared at:
108 g/l Tris-HCl
55 g/l boric acid
40 mM EDTA pH 8.0
diluted 1 in 10 for use at 1 x concentration
TE buffer
10 mM Tris-HCl, pH 7.4
1 mM EDTA
Z-agar plates
Sterile 1.5 % w/v agar in LB poured and set on Petri plates
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